• Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22: 655-664 (1987).

• Aaseth J, Flaten TP, Andersen O. Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics. Scand. J. Gastroenterol. 42: 673-681 (2007). *

• Abbasciano V, Trevisani L, Di Todaro F, Guglielmini C, Marzola A, Sartori S, Salemi A. Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. An early case. Recenti Prog. Med. 97: 28-31 (2006).

• Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47: 949-957 (2008). *

• Abdel Fattah S, Abdel KhaliK K, el-Shawarby L, Abdel Fattah S, el Shimi S, Soliman M, Hassan H. Some immunological aspects of chronic liver diseases in Egyptian children. J. Egypt. Soc. Parasitol. 21: 343-355 (1991).

• Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 20: 127-130 (1995).

• Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50: 1818-1826 (2009). *

• Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 36: 1393-1399 (2002). *

• Abe K, Saito H, Takahashi A, Rai T, Takiguchi J, Kanno Y, Monoe K, Ohira H. A case of acute hepatitis associated with Basedow's disease. Nippon Shokakibyo Gakkai Zasshi 104: 52-56 (2007).

• Abraham C, Hart J, Locke SM, Baker AL. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 172-176 (2008). *

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin. Liver Dis.11: 25-35 (2007).

• Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 51: 1867-1873 (2005). *

• Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39: 909-914 (2004). *

• Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 99: 1316-1320 (2004). *

• Adams PC. Role of genetic testing and liver biopsy in the diagnosis of hemochromatosis. Curr. Gastroenterol. Rep. 1: 27-29 (1999).

• Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am. J. Gastroenterol. 96: 567-569 (2001). *

• Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J. Hepatol. 48: 1000-1007 (2008). *

• Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 99: 1160-1174 (2004). *

• Ahmad J, Slivka A. Hepatobiliary disease in inflammatory bowel disease. Gastroenterol. Clin. North Am. 31: 329-345 (2002).

• Ahmad M, Afzal S, Roshan E, Mubarik A, Bano S, Khan SA, Hashmi SN. Usefulness of needle biopsy in the diagnosis of paediatric liver disorders. J. Pak. Med. Assoc. 55: 24-28 (2005).

• Ahmad M, Riley TR 3rd. Can one predict when ultrasound will be useful with percutaneous liver biopsy? Am. J. Gastroenterol. 96: 547-549 (2001). *

• Aithal GP. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998 (2007). *

• Aitola P, Matikainen M, Mattila J, Tomminen T, Hiltunen KM. Chronic inflammatory changes in the pouch mucosa are associated with cholangitis found on peroperative liver biopsy specimens at restorative proctocolectomy for ulcerative colitis. Scand. J. Gastroenterol. 33: 289-293 (1998). *

• Aitola P, Mattila J, Matikainen M. Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma. Int. J. Colorectal Dis. 15: 167-171 (2000). *

• Aitola P, Miettinen A, Mattila A, Matikainen M, Soppi E. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J. Clin. Pathol. 48: 645-647 (1995). *

• Aitola PT, Soppi ET, Halonen PJ, Laine ST, Matikainen MJ. The effect of proctocolectomy on serum antibody levels against cow's milk proteins in patients with chronic ulcerative colitis, with special reference to liver changes. Scand. J. Gastroenterol. 29: 646-650 (1994).

• Aizawa K, Kawaguchi S, Doi M, Mizuno W, Uragami K, Oka T, Miyamoto H, Itoh H, Nishioka S. A case of primary intrahepatic sclerosing cholangitis (PISC) complicated with atypical biliary epithelial proliferation. Intern. Med. 31: 114-121 (1992). *

• Akcam M, Artan R, Yilmaz A, Cig H, Aksoy NH. Abdominal tuberculosis in adolescents. Difficulties in diagnosis. Saudi Med. J. 26: 122-126 (2005).

• Akin K, Beyler AR, Kaya M, Erden E. The importance of iron and copper accumulation in the pathogenesis of non-alcoholic steatohepatitis. Turk. J. Gastroenterol. 14: 228-233 (2003). *

• Akiyama Y, Suzuki T, Tanaka M, Fujimaki T, Asaoka T, Kobayashi K, Ohno S, Imai F, Matuo H. Primary biliary cirrhosis (PBC)-CREST overlap syndrome complicated with Sjogren's syndrome. Ryumachi 37: 42-47 (1997).

• Akutsu N, Sakamoto H, Nakagaki T, Sato H, Matsui T, Kobayashi T, Takamura T, Noto H, Katsuramaki T, Hirata K, Imai K, Shinomura Y. A case of alveolar hydatid disease of the liver for which progression was seen on CT images. Nippon Shokakibyo Gakkai Zasshi 104: 1625-1631 (2007).

• Al Sofayan MS, Ibrahim A, Helmy A, Al Saghier MI, Al Sebayel MI, Abozied MM. Nuclear imaging of the liver: is there a diagnostic role of HIDA in posttransplantation? Transplant. Proc. 41: 201-207 (2009). *

• Al-Osaimi AM, Berg CL. Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature. Am. J. Gastroenterol. 97: S85 (2002). *

• Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 41: 668-670 (2005). *

• Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 17: 977-986 (2003). *

• Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic Milutinovic A, Kovacevic N, Krstic S, Popovic D. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J. Gastroenterol. 15: 591-594 (2009). *

• Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J. Hepatol. 48: 300-307 (2008).

• Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, Izaola O, Sagrado MG, Conde R, Gonzalez JM. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig. Dis. Sci. 53: 1088-1092 (2008). *

• Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, Gores GJ, Odin JA. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J. Autoimmun. 27: 232-241 (2006).

• Almasio PL. HALT-C in the final analysis: a molehill out of a mountain. J. Hepatol. 50: 1280-1282 (2009).

• Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxi A. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment. Pharmacol. Ther. 14: 1645-1652 (2000). *

• Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 128-133 (1994).

• Altman RP, Chandra R, Lilly JR. Ongoing cirrhosis after successful porticoenterostomy in infants with biliary atresia. J. Pediatr. Surg. 10: 685-691 (1975).

• Altuntas B, Kansu A, Girgin N. Hepatic damage in gluten sensitive enteropathy. Acta Paediatr. Jpn. 40: 597-599 (1998).

• Alustiza JM, Artetxe J, Castiella A, Agirre C, Emparanza JI, Otazua P, Garcia-Bengoechea M, Barrio J, Mujica F, Recondo JA. MR quantification of hepatic iron concentration. Radiology 230: 479-484 (2004). *

• Amakasu H, Kanno A, Abe M. Multiple myeloma occurring in early stage primary biliary cirrhosis. Tohoku J. Exp. Med. 169: 197-203 (1993).

• Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5: 30-33 (2006). *

• Amarapurkar AD, Kher A, Agrawal R, Meenakshi B, Kandalkar BM, Deshpande JR. A rare cause of steatohepatitis. Trop. Gastroenterol. 25: 176-177 (2004).

• Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop. Gastroenterol. 25: 130-134 (2004).

• Amarapurkar DN, Patel ND, Amarapurkar AD. Hepatic sarcoidosis. Indian J. Gastroenterol. 22: 98-100 (2003).

• Ament AE, Haaga JR, Wiedenmann SD, Barkmeier JD, Morrison SC. Primary sclerosing cholangitis: CT findings. J. Comput. Assist. Tomogr. 7: 795-800 (1983).

• Amer R, Bamonte G, Forrester JV. Resolution of juvenile idiopathic arthritis-associated uveitis after development of common variable immunodeficiency. Eur. J. Ophthalmol. 17: 666-668 (2007).

• American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 123: 1364-1366 (2002). *

• Anagnostopoulos G, Sakorafas GH, Grigoriadis K, Margantinis G, Kostopoulos P, Tsiakos S, Arvanitidis D. Hepatitis caused by occupational chronic exposure to trichloroethylene. Acta Gastroenterol. Belg. 67: 355-357 (2004).

• Anagnostopoulos GK, Margantinis G, Tsiakos S, Kostopoulos P, Grigoriadis K, Arvanitidis D. Postinfantile giant-cell hepatitis associated with ulcerative colitis and autoimmune hepatitis. J. Gastroenterol. Hepatol. 21: 1863-1864 (2006). *

• Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur. J. Gastroenterol. Hepatol. Oct 31 [Epub ahead of print] (2009).

• Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M, Fernandez MC, Pelaez G, Rodrigo L, Duran JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yague T, Salmeron J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44: 1581-1588 (2006). *

• Angelin B, Ewerth S, Einarsson K. Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels. J. Lipid Res. 24: 461-468 (1983). *

• Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).

• Angulo P. Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19 (2003). *

• Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J. Hepatol. 41: 943-949 (2004). *

• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362 (1999). *

• Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17: 186S-190S (2002). *

• Angulo P, MacCarty RL, Sylvestre PB, Jorgensen RA, Wiesner RH, LaRusso NA, Lindor KD. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 47: 157-161 (2002). *

• Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405 (2008). *

• Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: emerging insights and their implications for management. Gut 56: 1009-1018 (2007). *

• Apostolov E, Al-Soud WA, Nilsson I, Kornilovska I, Usenko V, Lyzogubov V, Gaydar Y, Wadstrom T, Ljungh A. Helicobacter pylori and other Helicobacter species in gallbladder and liver of patients with chronic cholecystitis detected by immunological and molecular methods. Scand. J. Gastroenterol. 40: 96-102 (2005).

• Arakawa Y, Amaki S, Miyakawa H, Sakai T, Gotou I, Tanaka N, Moriyama M, Iwasaki A, Sugitani M, Arakawa Y. PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J. Gastroenterol. 39: 490-495 (2004). *

• Arslan N, Mavi A, Kalkan S, Aydin A, Ortac R, Buyukgebiz B, Durak H. Findings of hepatobiliary scintigraphy and liver biopsy in Maroteaux-Lamy syndrome presenting as neonatal cholestasis. Pediatr. Int. 48: 498-500 (2006). *

• Asanuma T, Ono M, Kubota K, Hirose A, Hayashi Y, Saibara T, Inanami O, Ogawa Y, Enzan H, Onishi S, Kuwabara M, Oben JA. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut Nov 16 [Epub ahead of print] (2009).

• Ashamiss F, Wierzbicki Z, Chrzanowska A, Scibior D, Pacholczyk M, Kosieradzki M, Lagiewska B, Porembska Z, Rowinski W. Clinical significance of arginase after liver transplantation. Ann. Transplant. 9: 58-60 (2004).

• Askar E, Ramadori G, Mihm S. Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection. World J. Gastroenterol. 15: 3884-3890 (2009). *

• Aspirot A, Su W, Flageole H, Puligandla PS, Shaw K, Laberge JM. Cholestasis associated with small bowel atresia: do we always need to investigate? J. Pediatr. Surg. 42: 873-877 (2007).

• Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 83: 1571-1576 (2007).

• Avril A, Pichard V, Bralet MP, Ferry N. Mature hepatocytes are the source of small hepatocyte-like progenitor cells in the retrorsine model of liver injury. J. Hepatol. 41: 737-743 (2004). *

• Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. World J. Gastroenterol. 13: 2693-2696 (2007). *

• Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410 (2007). *

• Babb RR. Chronic liver disease. The scope of causes and treatments. Postgrad. Med. 91: 89-96 (1992).

• Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 120: 718-725 (2001). *

• Bae SH, Kim JS, Kim DH. Deflazacort for type-1 autoimmune hepatitis in a Korean girl. J. Korean Med. Sci. 21: 758-760 (2006). *

• Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol. 3: 27 (2003). *

• Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18: 1392-1398 (1993).

• Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 98: 1567-1571 (1990).

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Ballardini G, Bianchi FB, Mirakian R, Fallani M, Pisi E, Bottazzo GF. HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin. Exp. Immunol. 70: 35-46 (1987). *

• Bandyopadhyay SK, Bandyopadhyay R, Dutta A. Primary amyloidosis presenting as intrahepatic cholestasis. Indian J. Pathol. Microbiol. 49: 557-559 (2006).

• Barbatis C, Grases P, Shepherd HA, Chapman RW, Trowell J, Jewell DP, McGee JO. Histological features of sclerosing cholangitis in patients with chronic ulcerative colitis. J. Clin. Pathol. 38: 778-783 (1985). *

• Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J. Clin. Pathol. 40: 879-884 (1987). *

• Baric I, Fumic K, Glenn B, Cuk M, Schulze A, Finkelstein JD, James SJ, Mejaski-Bosnjak V, Pazanin L, Pogribny IP, Rados M, Sarnavka V, Scukanec-Spoljar M, Allen RH, Stabler S, Uzelac L, Vugrek O, Wagner C, Zeisel S, Mudd SH. S-Adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc. Natl. Acad. Sci. U.S.A. 101: 4234-4239 (2004). *

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Barreales M, Perez-Carreras M, Meizoso T, Garrido M, Masedo A, Colina F, Solis JA. Epstein-Barr virus infection and cholestatic hepatitis. An. Med. Interna. 23: 483-486 (2006).

• Barrio J, Castiella A, Lobo C, Indart A, Lopez P, Garcia-Bengoechea M, Cosme A, Arenas JI. Cholestatic acute hepatitis induced by amoxycillin-clavulanic acid combination. Role of ursodeoxycholic acid in drug-induced cholestasis. Rev. Esp. Enferm. Dig. 90: 523-526 (1998).

• Barta SK, Yahalom J, Shia J, Hamlin PA. Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. Clin. Lymphoma Myeloma 7: 77-82 (2006).

• Barth C, Bosse A, Andus T. Severe acute cholestatic hepatitis by infiltration of monoclonal plasma cells in multiple myeloma. Z. Gastroenterol. 43: 1129-1132 (2005).

• Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am. J. Gastroenterol. 95: 2936-2939 (2000). *

• Bassendine MF, Dewar PJ, James OF. HLA-DR antigens in primary biliary cirrhosis: lack of association. Gut 26: 625-628 (1985). *

• Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, Abroon J, O'Brien CB, Senior JR. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 88: 691-700 (1993).

• Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch. Intern. Med. 163: 615-620 (2003). *

• Bayraktar Y, Arslan S, Saglam F, Uzunalimoglu B, Kayhan B. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients? Hepatogastroenterology 45: 2064-2072 (1998).

• Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behcet's disease. Am. J. Gastroenterol. 92: 858-862 (1997).

• Becker P, Maurer B, Schirmacher P, Waldherr R, Parlesak A, Bode C, Seitz HK. Vitamin A-induced cholestatic hepatitis: a case report. Z. Gastroenterol. 45: 1063-1066 (2007).

• Beddy P, Lyburn I, Geoghegan T, Buckley O, Buckley A, Torreggiani W. Outpatient liver biopsy: a prospective evaluation of 500 cases. Gut 56: 307 (2007). *

• Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J. Hepatol. 50: 1-3 (2009). *

• Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307 (2006). *

• Bell H, Berg JP, Undlien DE, Distante S, Raknerud N, Heier HE, Try K, Thomassen Y, Haug E, Raha-Chowdhury R, Thorsby E. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects. Scand. J. Gastroenterol. 35: 1301-1307 (2000). *

• Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 51: 111-120 (2010).

• Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 18: 10-15 (1993).

• Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 117: 1234-1237 (1999). *

• Berasain C, Betes M, Panizo A, Ruiz J, Herrero JI, Civeira MP, Prieto J. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 47: 429-435 (2000). *

• Berbegal J, Morera J, Andrada E, Navarro V, Lluch V, Lopez-Benito I. Syndrome of allopurinol hypersensitivity. Report of a new case and review of the Spanish literature. Med. Clin. (Barc.) 102: 178-180 (1994).

• Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, van de Kerkhof PC, Drenth JP. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int. 27: 639-645 (2007). *

• Berends MA, van Oijen MG, Snoek J, van de Kerkhof PC, Drenth JP, Han van Krieken J, de Jong EM. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch. Dermatol. 143: 1515-1519 (2007). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Bergman J, Schjott J. Hepatitis caused by Lotus-f3? Basic Clin. Pharmacol. Toxicol. 104: 414-416 (2009). *

• Bernstine H, Mor E, Ben Ari Z, Belinki A, Hardoff R. Scintigraphic patterns of veno-occlusive disease in liver transplantation. Clin. Nucl. Med. 29: 292-295 (2004).

• Berry PA, Cross TJ, Thein SL, Portmann BC, Wendon JA, Karani JB, Heneghan MA, Bomford A. Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment. Clin. Gastroenterol. Hepatol. 5: 1469-1476 (2007).

• Berry PA, Smith-Laing G. Hepatitis A vaccine associated with autoimmune hepatitis. World J. Gastroenterol. 13: 2238-2239 (2007). *

• Bianchi FB, Muratori L. Primary and secondary autoimmunity in hepatology. Ann. Ital. Med. Int. 15: 56-62 (2000).

• Bianchi L. Liver biopsy in elevated liver functions tests? An old question revisited. J. Hepatol. 35: 290-294 (2001). *

• Bianchi L. Liver biopsy interpretation in hepatitis. Part II: Histopathology and classification of acute and chronic viral hepatitis/differential diagnosis. Pathol. Res. Pract. 178: 180-213 (1983).

• Bianchi L, Terracciano LM. Giant cell hepatitis in adults. Schweiz. Rundsch. Med. Prax. 83: 1237-1241 (1994).

• Biasi D, Caramasch P, Carletto A, Casaril M, Colombari R, Zeminian S, Bambara LM. Sjogren's syndrome associated with autoimmune hepatitis. A case report. Clin. Rheumatol. 16: 409-412 (1997).

• Biecker E, Stieger M, Zimmermann A, Reichen J. Autoimmune hepatitis, cryoglobulinaemia and untreated coeliac disease: a case report. Eur. J. Gastroenterol. Hepatol. 15: 423-427 (2003).

• Bismuth M, Aguilar-Martinez P, Michel H. Hereditary haemochromatosis. Presse. Med. 32: 1716-1723 (2003).

• Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology 127: 1847-1849 (2004). *

• Bissinger AL, Oettle H, Jahn G, Neuhaus P, Sinzger C. Cytomegalovirus infection after orthotopic liver transplantation is restricted by a pre-existing antiviral immune response of the recipient. J. Med. Virol. 73: 45-53 (2004). *

• Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 39: 961-968 (2004). *

• Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue is not a specific symptom in patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 17: 351-357 (2005).

• Blanc JF, Bioulac-Sage P, Balabaud C, Desmouliere A. Investigation of liver fibrosis in clinical practice. Hepatol. Res. 32: 1-8 (2005).

• Bloch DB, Yu JH, Yang WH, Graeme-Cook F, Lindor KD, Viswanathan A, Bloch KD, Nakajima A. The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J. Rheumatol. 32: 477-483 (2005).

• Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J. Hepatol. 50: 592-603 (2009). *

• Blomme BA, Van Steenkiste C, Vanhuysse J, Colle I, Callewaert N, Van Vlierberghe H. The impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and men. Am. J. Physiol. Gastrointest. Liver Physiol. Jan 7 [Epub ahead of print] (2010). *

• Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 36: 604-609 (1995). *

• Bloom S, Heryet A, Fleming K, Chapman RW. Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis. Gut 34: 977-983 (1993). *

• Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82: 310-317 (1975).

• Boberg KM, Brosstad F, Egeland T, Egge T, Schrumpf E. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb. Haemost. 81: 378-381 (1999).

• Boberg KM, Schrumpf E, Fausa O, Elgjo K, Kolmannskog F, Haaland T, Holter E. Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified as small-duct primary sclerosing cholangitis. Scand. J. Gastroenterol. 29: 744-752 (1994).

• Bodenheimer HC Jr, Schaffner F, Sternlieb I, Klion FM, Vernace S, Pezzullo J. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5: 1139-1142 (1985).

• Bogdanos D, Vergani D, Mieli-Vergani G. Overlap syndromes from pediatrics to adulthood. J. Gastroenterol. Hepatol. 19: S284-S286 (2004). *

• Boki KA, Dourakis SP. Polymyositis associated with primary biliary cirrhosis. Clin. Rheumatol. 14: 375-378 (1995).

• Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin. Liver Dis.11: 17-23 (2007).

• Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int. 26: 566-571 (2006). *

• Borgaonkar MR, Morgan DG. Primary biliary cirrhosis and type II autoimmune polyglandular syndrome. Can. J. Gastroenterol. 13: 767-770 (1999). *

• Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann. Hepatol. 8: 26-31 (2009).

• Bottero J, Lacombe K, Guechot J, Serfaty L, Miailhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J. Hepatol. 50: 1074-1083 (2009).

• Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N, Rousselet MC, Konate A, Amrani N, de Ledinghen V, Cales P. The combination of a blood test and fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 29: 1507-1515 (2009). *

• Bouyahia O, Boukthir S, Mrad SM, El Ghrabi AS. Diagnosis of hyper transaminasemia in childhood. Tunis. Med. 86: 722-727 (2008).

• Boykinova OB, Stoilova YD, Tsvetkova TZ, Baltadjiev IG. Epidemiological, immunological and clinical characteristics of acute hepatitis C. Folia Med. (Plovdiv.) 51: 61-69 (2009).

• Bozkaya H, Bektas M, Metin O, Erkan O, Ibrahimoglu D, Dalva K, Akbiyik F, Gurel S, Bozdayi AM, Akay C, Yurdaydin C, Aslan O, Uzunalimoglu O. Screening for hemochromatosis in Turkey. Dig. Dis. Sci. 49: 444-449 (2004). *

• Braden GL, Warzynski MJ, Golightly M, Ballow M. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin. Immunol. Immunopathol. 70: 145-151 (1994).

• Braganza JM. The role of the liver in exocrine pancreatic disease. Int. J. Pancreatol. 3 Suppl. 1: S19-42 (1988).

• Braier J, Ciocca M, Latella A, de Davila MG, Drajer M, Imventarza O. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med. Pediatr. Oncol. 38: 178-182 (2002). *

• Brailski Kh, Damianov B. Primary biliary cirrhosis. Vutr. Boles. 22: 27-37 (1983).

• Brandsaeter B, Schrumpf E, Clausen OP, Abildgaard A, Hafsahl G, Bjoro K. Recurrent sclerosing cholangitis or ischemic bile duct lesions - a diagnostic challenge? Liver Transpl. 10: 1073-1074 (2004). *

• Braun M, Fraser GM, Kunin M, Salamon F, Kaspa RT. Mesalamine-induced granulomatous hepatitis. Am. J. Gastroenterol. 94: 1973-1974 (1999). *

• Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 344: 495-500 (2001). *

• Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. "State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J. Surg. 33: 797-803 (2009). *

• Brensilver HL, Kaplan MM. Significance of elevated liver alkaline phosphatase in serum. Gastroenterology 68: 1556-1562 (1975).

• Brinson RR, Curtis WD, Schuman BM, Mills LR. Recovery from hepatic vein thrombosis (Budd-Chiari syndrome) complicating ulcerative colitis. Dig. Dis. Sci. 33: 1615-1620 (1988).

• Broome U, Scheynius A, Hultcrantz R. Induced expression of heat-shock protein on biliary epithelium in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 18: 298-303 (1993).

• Bruguera M, Llach J, Rodes J. Nonsyndromic paucity of intrahepatic bile ducts in infancy and idiopathic ductopenia in adulthood: the same syndrome? Hepatology 15: 830-834 (1992).

• Brunerova L, Bartakova H, Jankovska M, Cieslarova B, Hulek P, Kozak T, Andel M. The Budd-Chiari syndrome in a patient with primary thrombocythemia treated with interferon alfa and transjugular portosystemic shunt. Cas. Lek. Cesk. 143: 198-201 (2004).

• Brunt EM. Pathology of hepatic iron overload. Semin. Liver Dis. 25: 392-401 (2005).

• Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 21: 3-16 (2001).

• Brunt EM, Di Bisceglie AM. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum. Pathol. 35: 509-512 (2004).

• Brunt EM, Tiniakos DG. Metabolic storage diseases: amyloidosis. Clin. Liver Dis. 8: 915-930, x (2004).

• Buckley SE, DiPalma JA. Recognizing primary biliary cirrhosis and primary sclerosing cholangitis. Am. Fam. Physician 53: 195-200 (1996).

• Bugeac N, Pacht A, Mandel H, Iancu T, Tamir A, Srugo I, Shaoul R. The significance of isolated elevation of serum aminotransferases in infants and young children. Arch. Dis. Child. 92: 1109-1112 (2007).

• Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am. J. Gastroenterol. 98: 1155-1158 (2003). *

• Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am. J. Surg. Pathol. 19: 699-708 (1995).

• Buster EH, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol. 20: 68-72 (2008).

• Cabanillas M, Perez-Perez L, Sanchez-Aguilar D, Toribio J. Generalized pustular psoriasis and cytolytic hepatitis associated with neutrophilic cholangitis. Actas. Dermosifiliogr. 97: 330-333 (2006).

• Cabibi D, Tarantino G, Barbaria F, Campione M, Craxi A, Di Marco V. Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. Dig. Liver Dis. Jan 6 [Epub ahead of print] (2010).

• Caca K, Ferenci P, Kuhn HJ, Polli C, Willgerodt H, Kunath B, Hermann W, Mossner J, Berr F. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J. Hepatol. 35: 575-581 (2001). *

• Caldwell SH, de Freitas LA, Park SH, Moreno ML, Redick JA, Davis CA, Sisson BJ, Patrie JT, Cotrim H, Argo CK, Al-Osaimi A. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 49: 1888-1895 (2009).

• Caldwell SH, Leung PS, Spivey JR, Prindiville T, de Medina M, Saicheur T, Rowley M, Reddy KR, Coppel R, Jeffers LJ, et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 16: 899-905 (1992).

• Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J, Ducluzeaux PH, Lunel F. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J. Hepatol. 50: 165-173 (2009). *

• Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11: 12-15 (1990).

• Camara B, Kamar N, Bonafe JL, Danjoux M, Suc B, Rostaing L. Syphilis hepatitis and liver transplantation. Med. Mal. Infect. 37: 121-123 (2007).

• Camara B, Kamar N, Bonafe JL, Danjoux M, Suc B, Rostaing L. Syphilis-related hepatitis in a liver transplant patient. Exp. Clin. Transplant. 5: 724-726 (2007).

• Campbell WL, Sheng R, Zajko AB, Abu-Elmagd K, Demetris AJ. Intrahepatic biliary strictures after liver transplantation. Radiology 191: 735-740 (1994). *

• Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47: 1916-1923 (2008). *

• Cangemi JR, Wiesner RH, Beaver SJ, Ludwig J, MacCarty RL, Dozois RR, Zinsmeister AR, LaRusso NF. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96: 790-794 (1989).

• Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J. Rheumatol. 35: 421-424 (2008).

• Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 44: 446-457 (2006). *

• Caponcelli E, Knisely AS, Davenport M. Cystic biliary atresia: an etiologic and prognostic subgroup. J. Pediatr. Surg. 43: 1619-1624 (2008).

• Cappell MS. Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am. J. Gastroenterol. 86: 1-15 (1991).

• Capron JP, Sevenet F, Quenum C, Doutrellot C, Capron-Chivrac D, Delamarre J. Massive hepatic steatosis disclosing adult celiac disease. Study of a case and review of the literature. Gastroenterol. Clin. Biol. 7: 256-260 (1983).

• Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin. Rheumatol. 28: 1001-1003 (2009).

• Carneiro SC, Cassia FF, Lamy F, Chagas VL, Ramos-E-Silva M. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. J. Eur. Acad. Dermatol. Venereol. 22: 25-29 (2008). *

• Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, Forns X, Jimenez W, Navasa M. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 138: 147-158.e1 (2010). *

• Carrion JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 51: 23-34 (2010).

• Cars O, Stenram U, Stromberg A. Alpha-1-antitrypsin deficiency, mitochondrial antibodies and possible primary biliary cirrhosis. A case report and family study. Ups. J. Med. Sci. 80: 93-98 (1975).

• Casanas R, Scharfetter H, Altes A, Remacha A, Sarda P, Sierra J, Merwa R, Hollaus K, Rosell J. Measurement of liver iron overload by magnetic induction using a planar gradiometer: preliminary human results. Physiol. Meas. 25: 315-323 (2004). *

• Castro J, Amigo L, Miquel JF, Galman C, Crovari F, Raddatz A, Zanlungo S, Jalil R, Rudling M, Nervi F. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45: 1261-1266 (2007). *

• Cathebras PJ, Mosnier JF, Gouilloud S, Bouchou K, Rousset H. Hepatic granulomatosis in a patient with Graves' disease. Eur. J. Gastroenterol. Hepatol. 7: 905-908 (1995).

• Cayon A, Crespo J, Guerra AR, Pons-Romero F. Gene expression in obese patients with non-alcoholic steatohepatitis. Rev. Esp. Enferm. Dig. 100: 212-218 (2008).

• Chamouard P, Walter P, Baumann R, Poupon R. Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol. Clin. Biol. 29: 1286-1288 (2005).

• Chamuleau RA, Diekman MJ, Bos PJ, Smitt JH, Bosma A, Schellekens PT. Reappearance of vanished bile ducts. Hepatogastroenterology 39: 523-524 (1992).

• Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558 (2005). *

• Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM. Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. BMC Med. Genomics 2: 51 (2009). *

• Chapman RW. To perform or not to perform liver biopsy: an alternative view. Gut 52: 1227 (2003). *

• Chapman RW. To perform or not to perform liver biopsy - that is the question. Gut 51: 9-10 (2002). *

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 127: 1356-1371 (2004). *

• Chavhan GB, Roberts E, Moineddin R, Babyn PS, Manson DE. Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography. Pediatr. Radiol. 38: 868-873 (2008).

• Chazouilleres O, Wendum D. Diseases of the intrahepatic bile duct: diagnosis and treatments. Gastroenterol. Clin. Biol. 27: 307-318 (2003).

• Chedid A, Mendenhall CL, Moritz TE. The antigenic heterogeneity of the bile duct epithelium in alcoholic liver disease. VA Cooperative Study Group 275. Arch. Pathol. Lab. Med. 123: 411-414 (1999). *

• Chen CJ, Yang HI, Iloeje UH; The REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49: S72-S84 (2009).

• Chen J, Ahmad J. Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use. J. Gen. Intern. Med. 23: 1914-1916 (2008). *

• Chen L, Borozan I, Milkiewicz P, Sun J, Meng X, Coltescu C, Edwards AM, Ostrowski MA, Guindi M, Heathcote EJ, McGilvray ID. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int. 28: 997-1010 (2008). *

• Chen WD, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 3: CD004036 (2004). *

• Chhetri D, Gupta R, Duseja A, Dhiman RK, Chawla Y, Das A. Benign recurrent intrahepatic cholestasis (BRIC) in an adult. Trop. Gastroenterol. 28: 186-187 (2007).

• Chiba T, Goto S, Yokosuka O, Imazeki F, Tanaka M, Fukai K, Takahashi Y, Tsujimura H, Saisho H. Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol. 16: 225-228 (2004).

• Chien RN, Sheen IS, Chen TJ, Liaw YF. A clinicopathological study in primary biliary cirrhosis. J. Formos. Med. Assoc. 91 Suppl. 2: S117-S121 (1992).

• Cho JY, Suh KS, Lee HW, Cho EH, Yang SH, Cho YB, Yi NJ, Kim MA, Jang JJ, Lee KU. Hypoattenuation in unenhanced CT reflects histological graft dysfunction and predicts 1-year mortality after living donor liver transplantation. Liver Transpl. 12: 1403-1411 (2006). *

• Cho JY, Suh KS, Lee HW, Cho EH, Yang SH, Cho YB, Yi NJ, Kim MA, Jang JJ, Lee KU. Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl. Int. 19: 807-813 (2006). *

• Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW. Acute drug-induced hepatitis caused by albendazole. J. Korean Med. Sci. 23: 903-905 (2008).

• Cholongitas E, Burroughs AK. Is it difficult to obtain an optimal liver biopsy specimen? Hepatology 51: 355-356 (2010). *

• Cholongitas E, Quaglia A, Samonakis D, Mela M, Patch D, Dhillon AP, Fanshawe TR, Burroughs AK. Transjugular liver biopsy in patients with diffuse liver disease: comparison of three cores with one or two cores for accurate histological interpretation. Liver Int. 27: 646-653 (2007). *

• Cholongitas E, Quaglia A, Samonakis D, Senzolo M, Triantos C, Patch D, Leandro G, Dhillon A, Burroughs AK. Transjugular liver biopsy: how good it is for accurate histological interpretation? Gut 55: 1789-1794 (2006). *

• Chou JW, Yu CJ, Chuang PH, Lai HC, Hsu CH, Cheng KS, Peng CY, Chiang IP. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann. Pharmacother. 42: 1887-1892 (2008).

• Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterol. 5: 27 (2005). *

• Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin. Liver Dis. 24: 349-362 (2004).

• Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C, Kopanakis S, Giamarellou H. Cholestatic liver injury after glimepiride therapy. J. Hepatol. 42: 944-946 (2005). *

• Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, Oh E, Gretch D, Williams J, McMahon B. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J. Viral Hepat. 13: 652-658 (2006). *

• Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, Dumlu S, Turet S. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur. J. Gastroenterol. Hepatol. 20: 33-36 (2008).

• Classen M, Gotze H, Richter HJ, Bender S. Primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 6: 197-202 (1987).

• Cobbold JF, Morin S, Taylor-Robinson SD. Transient elastography for the assessment of chronic liver disease: ready for the clinic? World J. Gastroenterol. 13: 4791-4797 (2007). *

• Cobbold JF, Patel JH, Goldin RD, North BV, Crossey MM, Fitzpatrick J, Wylezinska M, Thomas HC, Cox IJ, Taylor-Robinson SD. Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. J. Hepatol. 52: 16-24 (2010).

• Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment. Pharmacol. Ther. 30: 3-13 (2009). *

• Cojocariu C, Trifan A, Stanciu C. Hereditary hemochromatosis. Rev. Med. Chir. Soc. Med. Nat. Iasi. 111: 584-592 (2007).

• Coleman WB, Best DH. Cellular responses in experimental liver injury: possible cellular origins of regenerative stem-like progenitor cells. Hepatology 41: 1173-1176 (2005). *

• Collardeau-Frachon S, Bouvier R, Le Gall C, Rivet C, Cabet F, Bellon G, Lachaux A, Scoazec JY. Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases. Virchows Arch. 451: 57-64 (2007). *

• Colombo C, Apostolo MG, Assaisso M, Roman B, Bottani P. Liver disease in cystic fibrosis. Neth. J. Med. 41: 119-122 (1992).

• Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int. 29 Suppl. 1: 143-147 (2009).

• Congiu M, Mashford ML, Slavin JL, Desmond PV. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J. Gastroenterol. Hepatol. 24: 1038-1044 (2009). *

• Conti E, De Checchi G, Mencarelli R, Pinato S, Rovere P. Lycopodium similiaplex-induced acute hepatitis: a case report. Eur. J. Gastroenterol. Hepatol. 20: 469-471 (2008).

• Contreras AM, Monteon FJ, Flores MR, Mendoza-Sanchez F, Ruiz I. Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C. Ann. Hepatol. 6: 70-73 (2007). *

• Contreras AM, Ruiz I, Polanco-Cruz G, Monteon FJ, Celis A, Vazquez G, Gomez-Herrera E, Garcia-Correa JE, Male-Velazquez R, Ruelas-Hernandez S. End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann. Hepatol. 6: 48-54 (2007). *

• Coppola N, De Stefano G, Marrocco C, Scarano F, Scolastico C, Tarantino L, Rossi G, Battaglia M, Onofrio M, D'Aniello F, Pisapia R, Sagnelli C, Sagnelli E, Piccinino F, Giorgio A, Filippini P. Helicobacter spp. and liver diseases. Infez. Med. 11: 201-207 (2003).

• Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK, Chung RT. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 29: 748-753 (2009). *

• Coriat R, Podevin P. Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient. Int. J. STD AIDS 19: 208-210 (2008).

• Cornelis T, Claes K, Gillard P, Nijs E, Roskams T, Lombaerts R, Nevens F, Cassiman D. Cholestatic liver disease in long-term infantile nephropathic cystinosis. J. Gastroenterol. Hepatol. 23: e428-e431 (2008). *

• Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32: 1196-1199 (2000). *

• Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 122: 652-658 (2002). *

• Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, de Ledinghen V, Dhumeaux D, Marcellin P, Beaugrand M, Poupon R. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 43: 1118-1124 (2006). *

• Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chretien Y, Poupon RE, Poupon R. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 24: 187-193 (2004). *

• Correa GH, Paredes SN. Serum liver tests in patients treated with methotrexate: a retrospective analysis. Rev. Med. Chil. 135: 1002-1008 (2007).

• Cortez-Pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 18: 1089-1104 (2004).

• Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J. Clin. Gastroenterol. 32: 428-430 (2001).

• Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 38: 801-804 (2004).

• Covelli M, Favia I, Marrone M, Iannone F, Gentile A, Lastilla G, Lapadula G. Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset. Clin. Rheumatol. 25: 919-922 (2006). *

• Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583 (1998). *

• Crawford DH, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, Subramaniam VN, Powell LW, Ramm GA. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 49: 418-425 (2009). *

• Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol. Res. 38: 762-769 (2008). *

• Cross TJ, Berry PA, Akbar N, Wendon J, Thein SL, Harrison PM. Sickle liver disease - an unusual presentation in a compound heterozygote for HbS and a novel beta-thalassemia mutation. Am. J. Hematol. 82: 852-854 (2007). *

• Csepregi A, Treiber G, Rocken C, Malfertheiner P. Acute exacerbation of autoimmune hepatitis induced by Twinrix. World J. Gastroenterol. 11: 4114-4116 (2005). *

• Cubelic S, Misak Z, Gasparov S, Kolacek S. Nonalcoholic steatohepatitis in children. Lijec. Vjesn. 126: 197-200 (2004).

• Cui B, Abe M, Hidata S, Nakanishi S, Matsuura B, Michitaka K, Yamamoto K, Horiike N, Onji M. Autoimmune hepatitis associated with Graves' disease. Intern. Med. 42: 331-335 (2003). *

• Culafic D, Perisic M, Boricic I, Culafic-Vojinovic V, Vukcevic M. Primary amyloidosis presenting with cholestasis and hyperkinetic portal hypertension. J. Gastrointestin. Liver Dis. 16: 201-204 (2007). *

• Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective? J. Hepatol. 48: 792-800 (2008). *

• Cunnigham D, Mills PR, Quigley EM, Patrick RS, Watkinson G, MacKenzie JF, Russell RI. Hepatic granulomas: experience over a 10-year period in the West of Scotland. Q. J. Med. 51: 162-170 (1982).

• Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262 (2007).

• Czaja AJ. Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70 (1999).

• Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *

• D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig. Dis. Sci. 40: 2113-2116 (1995).

• Daberkow U, Dorffel Y, Schmidt H, Scholze J. Multifocal nodular fatty infiltration of the liver associated with porphyria and haemochromatosis. Dtsch. Med. Wochenschr. 129: 617-620 (2004).

• Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-onset primary biliary cirrhosis. Gastroenterology 125: 1476-1479 (2003). *

• Dahms BB. Hepatoma in familial cholestatic cirrhosis of childhood: its occurrence in twin brothers. Arch. Pathol. Lab. Med. 103: 30-33 (1979).

• Dahshan A. Prenatal exposure to methamphetamine presenting as neonatal cholestasis. J. Clin. Gastroenterol. Jul 15 [Epub ahead of print] (2008).

• Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53: 750-755 (2004). *

• Daniels JA, Torbenson M, Anders RA, Boitnott JK. Immunostaining of plasma cells in primary biliary cirrhosis. Am. J. Clin. Pathol. 131: 243-249 (2009). *

• Dantas W. Primary sclerosing cholangitis. Rev. Gastroenterol. Peru 20: 270-284 (2000).

• Das K, Kar P. Non-alcoholic steatohepatitis. J. Assoc. Physicians India 53: 195-199 (2005).

• Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J. Hepatol. 51: 1061-1067 (2009).

• Dash A, Kragel P. Primary biliary cirrhosis in an elderly man with normal liver tests. South. Med. J. 102: 1272-1274 (2009).

• David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH CRN Research Group. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49: 1904-1912 (2009). *

• Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J. Pediatr. Gastroenterol. Nutr. 47: 61-67 (2008). *

• Davies YK, Cox KM, Abdullah BA, Terry AB, Cox KL. Oral vancomycin: treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 37: 345-346 (2003). *

• Day CP, James OF, Brown AS, Bennett MK, Fleming IN, Yeaman SJ. The activity of the metabolic form of hepatic phosphatidate phosphohydrolase correlates with the severity of alcoholic fatty liver in human beings. Hepatology 18: 832-838 (1993).

• Day DG. Feline cholangiohepatitis complex. Vet. Clin. North Am. Small Anim. Pract. 25: 375-385 (1995).

• de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 48 Suppl. 1: S104-S112 (2008). *

• de Andrade AR, Cotrim HP, Alves E, Soares D, Rocha R, Almeida A, Almeida CG, de Freitas LA. Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery. Ann. Hepatol. 7: 364-368 (2008).

• de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth. J. Med. 63: 444-446 (2005). *

• De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand. J. Gastroenterol. 43: 604-608 (2008). *

• de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis. 40: 108-113 (2008).

• de Hoyos A, Loredo ML, Martinez MA, Gil MR. Use of a stiff guidewire in transjugular liver biopsy in patients with a pronounced angle of the suprahepatic veins. Ann. Hepatol. 3: 72-73 (2004). *

• de Ledinghen V, Ratziu V, Causse X, Le Bail B, Capron D, Renou C, Pilette C, Oules V, Gelsi E, Oberti F, Vallet-Pichard A, Le Provost N, Cadranel JF; Association Francaise pour l'Etude du Foie Groupe Epidemiologie et Evaluation. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J. Hepatol. 45: 592-599 (2006). *

• de Seze J, Canva-Delcambre V, Fajardy I, Delalande S, Stojkovic T, Godet E, Vermersch P. Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult. Scler. 11: 691-693 (2005). *

• Dedek P, Pozler O, Cihula J. Hepatobiliary disorders in chronic nonspecific intestinal inflammation. Cesk. Pediatr. 48: 590-594 (1993).

• Deen ME, Porta G, Fiorot FJ, Campos LM, Sallum AM, Silva CA. Autoimmune hepatitis and juvenile systemic lupus erythematosus. Lupus 18: 747-751 (2009). *

• Deguchi A, Arima K, Masaki T, Yachida M, Nakai S, Ito T, Kita Y, Kurokohchi K, Watanabe S, Kuriyama S. Enhanced expression of Bcl-2 in lymphocytes infiltrating into the liver of patients with primary biliary cirrhosis. Int. J. Mol. Med. 9: 571-577 (2002).

• Dehghani SM, Haghighat M, Imanieh MH, Geramizadeh B. Comparison of different diagnostic methods in infants with cholestasis. World J. Gastroenterol. 12: 5893-5896 (2006). *

• Demetris AJ. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 44: 489-501 (2006). *

• Demir K, Akyuz F, Ozdil S, Aksoy N, Kaymakoglu S, Poturoglu S, Akyuz U, Besisik F, Boztas G, Mungan Z, Cevikbas U, Cakaloglu Y, Okten A. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann. Hepatol. 6: 92-96 (2007). *

• Demirhan B, Bilezikci B, Haberal AN, Sevmis S, Arat Z, Haberal M. Hepatic parenchymal changes and histologic eosinophilia as predictors of subsequent acute liver allograft rejection. Liver Transpl. 14: 214-219 (2008). *

• Denk H. Pathology of portal hypertension. J. Gastroenterol. Hepatol. 19: S346-S348 (2004). *

• Denkinger CM, Harigopal P, Ruiz P, Dowdy LM. Cryptosporidium parvum-associated sclerosing cholangitis in a liver transplant patient. Transpl. Infect. 10: 133-136 (2008). *

• Desai CS, Josh AG, Abraham P, Desai DC, Deshpande RB, Bhaduri A, Shah SR. Hepatic tuberculosis in absence of disseminated abdominal tuberculosis. Ann. Hepatol. 5: 41-43 (2006).

• DeSalvo D, Pohl JF, Wilson DP, Bryant W, Easley D, Greene J, Santiago J. Cholestasis secondary to panhypopituitarism in an infant. J. Natl. Med. Assoc. 100: 342-344 (2008).

• Deshpande V, Sainani NI, Chung RT, Pratt DS, Mentha G, Rubbia-Brandt L, Lauwers GY. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod. Pathol. 22: 1287-1295 (2009).

• Desmet VJ. Classification of chronic hepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 44-45. October 17 - 19 (2003). *

• Desmet VJ. Histology of autoimmune cholestatic liver diseases. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 25-26. October 15-16 (2003). *

• Dewitt J, McGreevy K, Cummings O, Sherman S, Leblanc JK, McHenry L, Al-Haddad M, Chalasani N. Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest. Endosc. 69: 535-542 (2009).

• Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128: 334-342 (2005). *

• Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, Malinchoc M, Chapman RW, Kaplan MM, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103: 1893-1901 (1992).

• Dienes HP. Viral and autoimmune hepatitis. Morphologic and pathogenetic aspects of cell damage in hepatitis with potential chronicity. Veroff. Pathol. 132: 1-107 (1989).

• Dienes HP. Liver histology in autoimmune hepatitis - diagnostic implications. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 51 (2004). *

• Dienes HP. Autoimmune hepatitis and autoimmune cholangitis. Verh. Dtsch. Ges. Pathol. 89: 155-162 (2005).

• Dietrich CF, Mertens JC, Braden B, Schuessler G, Ott M, Ignee A. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 45: 1139-1145 (2007). *

• Dietrich CG, Gartung C, Lorenzen J, Geier A, Wasmuth HE, Matern S, Lammert F. Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma. Ann. Hepatol. 3: 118-120 (2004). *

• Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98 (1999).

• Diwakar V, Pearson L, Beath S. Liver disease in children with cystic fibrosis. Paediatr. Respir. Rev. 2: 340-349 (2001).

• Doganci T, Sayli T, Gulderen F, Erden E, Sencer H. Case of disseminated Langerhans' cell histiocytosis presenting with sclerosing cholangitis. Int. J. Dermatol. 43: 673-675 (2004). *

• Dominguez M, Miquel R, Colmenero J, Moreno M, Garcia-Pagan JC, Bosch J, Arroyo V, Gines P, Caballería J, Bataller R. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 136: 1639-1650 (2009). *

• Donaldson GW, Davies SH, Darg A, Richmond J. Coagulation factors in chronic liver disease. J. Clin. Pathol. 22: 199-204 (1969). *

• Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin. Liver Dis. 6: 419-437 (2002).

• Dorney SF, Hassall EG, Arbuckle SM, Vargas JH, Berquist WE. SZ phenotype alpha-1-antitrypsin deficiency with paucity of the interlobular bile ducts. Aust. Paediatr. J. 23: 55-56 (1987).

• Dossing M, Arlien-Soborg P, Milling Petersen L, Ranek L. Liver damage associated with occupational exposure to organic solvents in house painters. Eur. J. Clin. Invest. 13: 151-157 (1983).

• Douglass HO Jr. Idiopathic sclerosing cholangitis. Pathophysiologic observations. Am. J. Surg. 130: 82-87 (1975).

• Dourakis SP, Saramadou R, Alexopoulou A, Kafiri G, Deutsch M, Koskinas J, Archimandritis AJ. Hepatic granulomas: a 6-year experience in a single center in Greece. Eur. J. Gastroenterol. Hepatol. 19: 101-104 (2007).

• Dranoff JA, Kruglov EA, Toure J, Braun N, Zimmermann H, Jain D, Knowles AF, Sevigny J. Ectonucleotidase NTPDase2 is selectively down-regulated in biliary cirrhosis. J. Investig. Med. 52: 475-482 (2004).

• Drebber U, Mueller JJ, Klein E, Kasper HU, Schulze F, Schardt K, Quasdorff M, Schulte S, Odenthal M, Dienes HP. Liver biopsy in primary biliary cirrhosis: clinicopathological data and stage. Pathol. Int. 59: 546-554 (2009). *

• Dubel L, Farges O, Johanet C, Sebagh M, Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 65: 1072-1075 (1998).

• Dubertret L. Retinoids, methotrexate and cyclosporine. Curr. Probl. Dermatol. 38: 79-94 (2009).

• Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125: 298-303 (2003). *

• Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J. Clin. Gastroenterol. 31: 292-296 (2000).

• Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 15: S25-S34 (2009).

• Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Intern. Med. 127: 981-985 (1997). *

• Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4: 1537-1543 (2006). *

• Dumortier J, Boillot O, Chevallier M, Berger F, Potier P, Valette PJ, Paliard P, Scoazec JY. Familial occurrence of nodular regenerative hyperplasia of the liver: a report on three families. Gut 45: 289-294 (1999). *

• Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am. J. Gastroenterol. Dec 29 [Epub ahead of print] (2009). *

• Duro D, Duggan C, Valim C, Bechard L, Fitzgibbons S, Jaksic T, Yu YM. Novel intravenous (13)C-methionine breath test as a measure of liver function in children with short bowel syndrome. J. Pediatr. Surg. 44: 236-240 (2009).

• Duvoux C. Epidemiology and diagnosis of hepatocellular carcinomas in cirrhosis. Ann. Chir. 52: 511-517 (1998).

• Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D. Nodular regenerative hyperplasia of the liver associated with azathioprine therapy. Gastroenterol. Clin. Biol. 15: 968-973 (1991).

• Duvoux C, Radier C, Roudot-Thoraval F, Maille F, Anglade MC, Van Nhieu JT, Rosa I, Hospitel S, Abd-Alsamad I, Sitruk V, Seror O, Ziol M, Blondon H, Dhumeaux D, Richardet JP. Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. Hepatology 40: 1370-1378 (2004). *

• Ebrahimi Daryani N, Aghamohammadi A, Mousavi Mirkala MR, Bashashati M, Rezaei N, Haghpanah B, Hashtroudi AA, Sayyah A. Gastrointestinal complications in two patients with common variable immunodeficiency. Iran. J. Allergy Asthma Immunol. 3: 149-152 (2004).

• Eckhauser FE, Appelman HD, O'Leary TJ, Polley TZ, Bloch DM, Turcotte JG. Hepatic pathology as a determinant of prognosis after portal decompression. Am. J. Surg. 139: 105-112 (1980).

• Eckhoff DE, Baron TH, Blackard WG, Morgan DE, Crowe R, Sellers M, McGuire B, Contreras JL, Bynon JS. Role of ERCP in asymptomatic orthotopic liver transplant patients with abnormal liver enzymes. Am. J. Gastroenterol. 95: 141-144 (2000). *

• Eguchi S, Takatsuki M, Hidaka M, Tajima Y, Zen Y, Nakanuma Y, Kanematsu T. De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease. J. Gastroenterol. Hepatol. 23: e165-e169 (2008). *

• Ehmsen L, Marko C, Breidert M. Portal vein hypertension with azathioprine therapy in patients with Crohn's disease - is it a frequent phenomenon? Dtsch. Med. Wochenschr. 133: 950-953 (2008).

• Ehrmann J, Strojil J. Current concepts and morphological aspects of drug induced liver injury. Cesk. Patol. 44: 4-7 (2008).

• Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J. Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol. Immunotoxicol. 27: 77-83 (2005).

• Eklund A, Stjernberg N, Uddenfeldt P, Danielsson A. Kveim test and mitochondrial antibodies in the differential diagnosis between primary biliary cirrhosis and sarcoidosis. Sarcoidosis 2: 38-41 (1985).

• Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 47: 135-141 (2007). *

• Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873 (2006). *

• Elam MB, Cowan GS Jr, Rooney RJ, Hiler ML, Yellaturu CR, Deng X, Howell GE, Park EA, Gerling IC, Patel D, Corton JC, Cagen LM, Wilcox HG, Gandhi M, Bahr MH, Allan MC, Wodi LA, Cook GA, Hughes TA, Raghow R. Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity (Silver Spring) 17: 1563-1573 (2009). *

• Elefsiniotis IS, Liatsos GD, Stamelakis D, Moulakakis A. Case report: mixed cholestatic/hepatocellular liver injury induced by the herbicide quizalofop-p-ethyl. Environ. Health Perspect. 115: 1479-1481 (2007). *

• Elmetwally IM, Elmahalaway AM, Abuhashem SH, Ahmed AM. Determination of serum fibrosis index in patients with chronic hepatitis and its relationship to histological activity index. Saudi Med. J. 30: 638-646 (2009).

• Elphick DA, Dube AK, McFarlane E, Jones J, Gleeson D. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am. J. Gastroenterol. 102: 780-788 (2007). *

• Epstein O, Jain S, Lee RG, Cook DG, Boss AM, Scheuer PJ, Sherlock S. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1: 1275-1277 (1981).

• Etxagibel A, Julia MR, Brotons A, Company MM, Dolz C. Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J. Med. Case Reports 2: 25 (2008). *

• Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl. 15: 629-633 (2009).

• Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44: 472-477 (2006). *

• Falkenstein K, Flynn L, Kirkpatrick B, Casa-Melley A, Dunn S. Non-compliance in children post-liver transplant. Who are the culprits? Pediatr. Transplant. 8: 233-236 (2004).

• Fanning PA, Jonsson JR, Clouston AD, Edwards-Smith C, Balderson GA, Macdonald GA, Crawford DH, Kerlin P, Powell LW, Powell EE. Detection of male DNA in the liver of female patients with primary biliary cirrhosis. J. Hepatol. 33: 690-695 (2000). *

• Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28: 1026-1033 (2008). *

• Farkkila M, Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Niemela O. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int. 28: 787-797 (2008). *

• Farrell GC. Drug-induced hepatic injury. J. Gastroenterol. Hepatol. 12: S242-S250 (1997).

• Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820-826 (2004). *

• Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin. Liver Dis. 20: 481-495 (2000). *

• Faust TW, Reddy KR. Postoperative jaundice. Clin. Liver Dis. 8: 151-166 (2004).

• Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42: 53-62 (2005). *

• Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 49: S96-S102 (2009).

• Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078 (2009).

• Ferenci P, Czlonkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W. Late-onset Wilson's disease. Gastroenterology 132: 1294-1298 (2007). *

• Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H. 6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am. J. Gastroenterol. 102: 2495-2503 (2007). *

• Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am. J. Gastroenterol. 93: 459-460 (1998).

• Ferreira AR, Roquete ML, Toppa NH, de Castro LP, Fagundes ED, Penna FJ. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 46: 65-70 (2008). *

• Ferreira S, Baldaia C, Fatela N, Ramalho F, Costa MA, Brito D, Esteves G, Monteiro E. Severe intrahepatic cholestasis, erythrocytosis and hypoglycemia: unusual presenting features of systemic AL amyloidosis. Scand. J. Gastroenterol. 43: 375-379 (2008). *

• Ferrell LD, Lee R, Brixko C, Bass NM, Lake JR, Roberts JP, Ascher N, Rabkin J. Hepatic granulomas following liver transplantation. Clinicopathologic features in 42 patients. Transplantation 60: 926-933 (1995).

• Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, Pellecchia A, Wolkoff AW, Gaglio PJ, Reinus JF. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology Nov 13 [Epub ahead of print] (2009). *

• Fickert P, Trauner M. When lightning strikes twice: the plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. J. Hepatol. 50: 633-635 (2009). *

• Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 14: 861-871 (2008). *

• Fiel MI, Schiano TD, Klion FM, Emre S, Hytiroglou P, Ishak KG, Suriawinata A, Thung SN. Recurring fibro-obliterative venopathy in liver allografts. Am. J. Surg. Pathol. 23: 734-737 (1999).

• Findor JA, Sorda JA, Daruich JR, Manero EF. Familial association in autoimmune liver disease. Medicina (B. Aires) 62: 241-244 (2002).

• Fischer HP, Flucke U, Zhou H. Pathology along the liver sinusoids: endothelial and perisinusoidal findings. Pathologe 29: 37-46 (2008).

• Fishman S, Lurie Y, Peretz H, Morad T, Grynberg E, Blendis LM, Leshno M, Brazowski E, Rosner G, Halpern Z, Oren R. Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C. Liver Int. 26: 279-284 (2006). *

• Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, Ferrari C. Anti-viral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138: 682-693.e4 (2010). *

• Fitzgibbons SC, Jones BA, Hull MA, Zurakowski D, Duro D, Duggan C, Boctor D, Sigalet DL, Jaksic T. Relationship between biopsy-proven parenteral nutrition-associated liver fibrosis and biochemical cholestasis in children with short bowel syndrome. J. Pediatr. Surg. 45: 95-99 (2010).

• Fleming KA. Histology and brush cytology for diagnosis of bile duct carcinoma in primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 92. October 15-16 (2003). *

• Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J. Hepatol. 34: 360-365 (2001). *

• Floreani A, Lazzari R, Macchi V, Porzionato A, Variola A, Colavito D, Leon A, Guido M, Baldo V, De Caro R, Bergasa NV. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis. J. Gastroenterol. Sep 4 [Epub ahead of print] (2009). *

• Fodor M, Nagy V, Berta A, Tornai I, Pfliegler G. Hepatitis C virus presumably associated bilateral consecutive anterior ischemic optic neuropathy. Eur. J. Ophthalmol. 18: 313-315 (2008).

• Foroncewicz B, Mucha K, Paczek L, Oldakowska-Jedynak U, Gornicka B, Zieniewicz K, Nyckowski P, Krawczyk M. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. Transplant. Proc. 35: 2310-2312 (2003). *

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J,Couzigou P, de Ledinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408 (2006). *

• Fox VL, Cohen MB, Whitington PF, Colletti RB. Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 23: 213-216 (1996). *

• Fracanzani AL, Burdick L, Borzio M, Roncalli M, Bonelli N, Borzio F, Maraschi A, Fiorelli G, Fargion S. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 34: 1109-1112 (2001). *

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56: 968-973 (2007). *

• Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 50: 1360-1369 (2009).

• Freese D, Latimer JS, Gilberstadt S, Kane W, Sharp HL. Sclerosing cholangitis associated with inflammatory bowel disease. Clin. Pediatr. (Phila.) 21: 11-16 (1982).

• Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 4: 830-834 (1984).

• Friedman SL. Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies. Clin. Liver Dis. 12: xiii-xiv (2008). *

• Fujikura S, Davis PA, Prindiville T, Leung P, Fox RI, Gershwin ME. Sjogren's syndrome and primary biliary cirrhosis: presence of autoantibodies to purified mitochondrial 2-oxo acid dehydrogenases. J. Rheumatol. 17: 1453-1457 (1990).

• Fujisawa T, Kage M, Ushijima K, Kimura A, Ono E, Kato H. Alagille syndrome with a spontaneous appearance of the interlobular bile ducts. Acta Paediatr. Jpn. 36: 506-509 (1994).

• Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 50: 772-780 (2009).

• Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J. Gastroenterol. 43: 951-958 (2008). *

• Furuta K, Sato S, Yamauchi T, Ozawa T, Harada M, Kakumu S. Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease. J. Gastroenterol. 43: 866-874 (2008). *

• Furuya CK Jr, de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, Vezozzo DC, Halpern A, Garrido AB Jr, Alves VA, Carrilho FJ. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J. Gastroenterol. Hepatol. 22: 510-514 (2007). *

• Furuya KN, Roberts EA, Canny GJ, Phillips MJ. Neonatal hepatitis syndrome with paucity of interlobular bile ducts in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 12: 127-130 (1991).

• Furuya T, Tateishi M, Nishinarita M, Kashiwazaki S. Primary biliary cirrhosis in patients with Sjogren's syndrome. Nippon Rinsho 53: 2536-2539 (1995).

• Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families, and populations. Curr. Gastroenterol. Rep. 6: 44-51 (2004).

• Gamlen TR, Triger DR, Ackery DM, Fleming JS, Grant RW, Kenny RW, Maciver AG, Wright R. Quantitative liver imaging using 131-I Rose Bengal as an index of liver function and prognosis. Gut 16: 738-743 (1975). *

• Garcia-Compean D, Cortes C. Transjugular liver biopsy. An update. Ann. Hepatol. 3: 100-103 (2004). *

• Garred P, Lyon H, Christoffersen P, Mollnes TE, Tranum-Jensen J. Deposition of C3, the terminal complement complex and vitronectin in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 13: 305-310 (1993).

• Garrido MC, Hubscher SG. Accuracy of staging in primary biliary cirrhosis. J. Clin. Pathol. 49: 556-559 (1996). *

• Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig. Dis. Sci. 52: 2433-2437 (2007). *

• Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50: 1087-1093 (2009).

• Gaya DR, Oien KA, Stanley AJ, Morris AJ. Bleeding gastric varices and antiphospholipid syndrome. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 156-159 (2005). *

• Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. Hepatic granulomas: a 10 year single centre experience. J. Clin. Pathol. 56: 850-853 (2003). *

• Geier A, Gartung C, Dietrich CG, Lammert F, Wasmuth HE, Matern S. Diagnosis of cholestatic disorders. Med. Klin. (Munich) 98: 499-509 (2003).

• Gelbmann CM, Rummele P, Wimmer M, Hofstadter F, Gohlmann B, Endlicher E, Kullmann F, Langgartner J, Scholmerich J. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am. J. Gastroenterol. 102: 1221-1229 (2007). *

• Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis. 16: 39-46 (2007). *

• Geraghty JM, Goldin RD. Liver changes associated with cholecystitis. J. Clin. Pathol. 47: 457-460 (1994). *

• Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 71: 444-449 (1976).

• Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 100: 1701-1709 (1991).

• Geuken E, Visser DS, Leuvenink HG, de Jong KP, Peeters PM, Slooff MJ, Kuipers F, Porte RJ. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. Hepatology 42: 1166-1174 (2005). *

• Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R. Steroid therapy for a case of severe drug-induced cholestasis. Ann. Pharmacother. 40: 1196-1199 (2006).

• Giezendanner S, Zala G, Jost J, Greminger P, Meyenberger C. HIV infection, fever and cholestasis. Schweiz. Rundsch. Med. Prax. 83: 757-760 (1994).

• Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrugger RW, Engels LG. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig. Liver Dis. 39: 156-159 (2007).

• Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 36: 437-441 (1995). *

• Ginestal-Cruz A, Pinto-Correia J, Camilo E, Grima N, Cardoso A, Baptista A, Gargate A, Ribeiro JC, Lacerda A. Combined approach to the differential diagnosis of cholestatic jaundice with endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, ultrasonography, and liver biopsy. Gastrointest. Radiol. 6: 177-183 (1981).

• Ginsberg GG, Goodman ZD, Lewis JH. A 22-year-old man with thyroid cancer and cholestatic liver disease. Semin. Liver Dis. 11: 64-71 (1991).

• Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Campostrini N, Martinelli N, Vantini I, Corrocher R, Ganz T, Fattovich G. Reduced serum hepcidin levels in patients with chronic hepatitis C. J. Hepatol. 51: 845-852 (2009).

• Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 1: CD000551 (2002). *

• Gluud C, Dejgaard A, Clemmensen I. Plasma fibronectin concentrations in patients with liver diseases. Scand. J. Clin. Lab. Invest. 43: 533-537 (1983).

• Goddard CJ, Smith A, Hoyland JA, Baird P, McMahon RF, Freemont AJ, Shomaf M, Haboubi NY, Warnes TW. Localisation and semiquantitative assessment of hepatic procollagen mRNA in primary biliary cirrhosis. Gut 43: 433-440 (1998). *

• Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A. Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J. Hepatol. 30: 321-324 (1999). *

• Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am. J. Clin. Pathol. 114: 591-598 (2000). *

• Goldstein NS, Soman A, Gordon SC. Portal tract eosinophils and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and autoimmune hepatitis. Am. J. Clin. Pathol. 116: 846-853 (2001). *

• Goldwire FW, Norris WE, Koff JM, Goodman ZD, Smith MT. An unusual presentation of primary sclerosing cholangitis. World J. Gastroenterol. 14: 6748-6749 (2008). *

• Gomez-Dominguez E, Mendoza J, Garcia-Buey L, Trapero M, Gisbert JP, Jones EA, Moreno-Otero R. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment. Pharmacol. Ther. 27: 441-447 (2008). *

• Gonzalez M, Ribalta J, Reyes H, Klinger J, Maggiolo P, Varleta P, Hernandez I, Delgado M, Donoso S. Primary biliary cirrhosis. The clinical experience in 31 patients. Rev. Med. Chil. 118: 1350-1354 (1990).

• Gonzalez U, Reyes E, Kershenovich J, Orozco-Topete RL. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev. Invest. Clin. 47: 409-413 (1995).

• Gonzalez-Huezo MS, Villela LM, Zepeda-Florencio Mdel C, Carrillo-Ponce CS, Mondragon-Sanchez RJ. Nodular regenerative hyperplasia associated to aplastic anemia: a case report and literature review. Ann. Hepatol. 5: 166-169 (2006). *

• Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB, Wiesner RH. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 7: 302-310 (2001). *

• Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol. 47: 598-607 (2007). *

• Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J. Clin. Gastroenterol. 37: 344-347 (2003).

• Gordon F. Recurrent primary sclerosing cholangitis: clinical diagnosis and long-term management issues. Liver Transpl. 12: S73-S75 (2006). *

• Gores GJ. Apoptosis and liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 25. September 12 - 13 (2003). *

• Goring HD, Panzner M, Lakotta W, Ziemer A. Coincidence of scleroderma and primary biliary cirrhosis. Results of a systematic study of a dermatologic patient sample. Hautarzt. 49: 361-366 (1998).

• Goto T, Komatsu M, Fujii T, Ohshima S, Nakane K, Yoneyama K, Shibuya T, Meng XW, Masamune O, Imai H. Primary biliary cirrhosis associated with membranous glomerulonephritis. Intern. Med. 38: 22-26 (1999). *

• Goudie BM, Birnie GG, Watkinson G, MacSween RN. A case of longstanding primary sclerosing cholangitis. J. Clin. Pathol. 36: 1298-1301 (1983). *

• Granito A, Muratori P, Ferri S, Pappas G, Quarneti C, Lenzi M, Bianchi FB, Muratori L. Diagnosis and therapy of autoimmune hepatitis. Mini Rev. Med. Chem. 9: 847-860 (2009).

• Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 45 Suppl. 4: IV1-IV11 (1999). *

• Grauer L, Padilla VM 3rd, Bouza L, Barkin JS. Eosinophilic sclerosing cholangitis associated with hypereosinophilic syndrome. Am. J. Gastroenterol. 88: 1764-1769 (1993).

• Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 8: 575-581 (2002). *

• Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33: 544-553 (2001). *

• Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G. Acute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all? J. Hepatol. 50: 1273-1277 (2009).

• Griga T, Tromm A, Muller KM, May B. Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases. Eur. J. Gastroenterol. Hepatol. 12: 559-564 (2000).

• Grima P, Chiavaroli R, Calabrese P, Tundo P, Grima P. Severe hepatitis with autoimmune features following a HHV-6: a case report. Cases J. 1: 110 (2008). *

• Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J. Clin. Rheumatol. 7: 224-227 (2001).

• Gronlund J, Nanto-Salonen K, Venetoklis J, Holmberg RL, Heinonen A, Stahlberg MR. Poor cognitive development and abdominal pain: Wilson's disease. Scand. J. Gastroenterol. 41: 361-364 (2006). *

• Gross JB Jr, Kumar N. Simultaneous occurrence of PSC and MS in a patient. Dig. Dis. Sci. 48: 1397 (2003). *

• Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA. Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia. Dtsch. Med. Wochenschr. 122: 1516-1520 (1997).

• Grunhage F, Fischer HP, Sauerbruch T, Reichel C. Drug- and toxin-induced hepatotoxicity. Z. Gastroenterol. 41: 565-578 (2003).

• Gruttadauria S, Mandala' L, Miraglia R, Caruso S, Minervini MI, Biondo D, Volpes R, Vizzini G, Marsh JW, Luca A, Marcos A, Gridelli B. Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin. Transplant. 21: 761-766 (2007). *

• Guarascio P, Yentis F, Cevikbas U, Portmann B, Williams R. Value of copper-associated protein in diagnostic assessment of liver biopsy. J. Clin. Pathol. 36: 18-23 (1983). *

• Gubergrits NB. Primary sclerosing cholangitis: a clinical case. Dig. Dis. 27: 522-525 (2009).

• Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin. Liver Dis. 12: 883-900 (2008).

• Gundling F, Rohrbach H, Schepp W. Cholestatic hepatitis in situs inversus abdominalis. Schweiz. Rundsch. Med. Prax. 96: 1029-1033 (2007).

• Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J. Gastroenterol. Hepatol. 16: 1144-1148 (2001). *

• Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 19: 854-858 (2004). *

• Gut J, Christen U, Huwyler J, Burgin M, Kenna JG. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur. J. Biochem. 210: 569-576 (1992).

• Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 11: 1252-1257 (2005). *

• Guyader D, Latournerie M. Incidental ultrasound finding of a 3cm liver nodule in a 45-year-old woman taking hormonal substitution after hysterectomy performed for cervix carcinoma. Gastroenterol. Clin. Biol. 33: F60-F67 (2009).

• Haas S, Theuerkauf I, Kuhnen A, Wickesberg A, Fischer HP. Langerhans' cell histiocytosis of the liver. Differential diagnosis of a rare chronic destructive sclerosing cholangitis. Pathologe 24: 119-123 (2003).

• Hadchouel M, Hugon RN, Gautier M. Reduced ratio of portal tracts to paucity of intrahepatic bile ducts. Arch. Pathol. Lab. Med. 102: 402 (1978).

• Hakem D, Berrah A, Berkane S, Asselah H, Ait-Younes S, Asselah F, Salah S, Merriche S, Abbadi MC. Autoimmune chronic active hepatitis: anatomoclinic's study of 50 patients. Rev. Med. Interne. 26: 858-865 (2005).

• Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Levy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl. J. Med. 344: 418-423 (2001). *

• Han SH, Ki CS, Lee JE, Hong YJ, Son BK, Lee KH, Choe YH, Lee SY, Kim JW. A novel mutation (A148V) in the glucose 6-phosphate translocase (SLC37A4) gene in a Korean patient with glycogen storage disease type 1b. J. Korean Med. Sci. 20: 499-501 (2005). *

• Hanif M, Raza J, Qureshi H, Issani Z. Etiology of chronic liver disease in children. J. Pak. Med. Assoc. 54: 119-122 (2004).

• Hanje AJ, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26: 1018-1022 (2006). *

• Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin. Rheumatol. 27: 1063-1066 (2008). *

• Haratake J, Horie A, Ishii N, Okuno F. Familial intrahepatic cholestatic cirrhosis in young adults. Gastroenterology 89: 202-209 (1985).

• Harputluoglu MM, Demirel U, Karadag N, Karahan D, Aladag M, Karincaoglu M, Hilmioglu F. Severe hepatitis with prolonged cholestasis and bile duct injury due the long-term use of ornidazole. Acta Gastroenterol. Belg. 70: 293-295 (2007).

• Harrison PM. Diagnosis of primary sclerosing cholangitis. J. Hepatobiliary Pancreat. Surg. 6: 356-360 (1999).

• Harrison SA. Non-alcoholic steatohepatitis. Preface. Clin. Liver Dis. 13: xiii-xiv (2009). *

• Hartmann U, Schmitt S, Reuss-Borst M. Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report. Z. Rheumatol. 67: 440-444 (2008).

• Hasan MK, Tierney WM, Baker MZ. Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. Am. J. Med. Sci. 328: 348-350 (2004).

• Hasegawa Y, Kawachi S, Shimazu M, Hoshino K, Tanabe M, Fuchimoto Y, Obara H, Shinoda M, Shimizu H, Yamada Y, Akatsu T, Irie R, Sakamoto M, Morikawa Y, Kitajima M. Discontinuation of living donor liver transplantation for PSC due to histological abnormalities in intraoperative donor liver biopsy. Am. J. Transplant. 7: 2204-2207 (2007). *

• Hasegawa Y, Ohi M, Fujisaku A. Autoimmune cholangitis (AIC) associated with myositis in monozygotic twins. Ryumachi 40: 898-903 (2000).

• Hashimoto E, Taniai M, Yatsuji S, Tokushige K, Shiratori K, Yamamoto M, Fuchinoue S. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S455-S461 (2007). *

• Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM. Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren's syndrome. J. Rheumatol. 35: 2012-2016 (2008). *

• Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, Druez P, Omar M, Kockx M, Hubens H, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J. Hepatol. 22: 71-77 (1995). *

• Hay JE, Wiesner RH, Shorter RG, LaRusso NF, Baldus WP. Primary sclerosing cholangitis and celiac disease. A novel association. Ann. Intern. Med. 109: 713-717 (1988).

• Hayashi H, Fujita Y, Tatsumi Y, Hattori A, Hayashi K, Katano Y, Wakusawa S, Yano M, Itoh M, Mizutani N, Goto H. Special stain and X-ray probe microanalysis of livers with Wilson disease. Hepatol. Res. 39: 563-568 (2009).

• Hayashida M, Nishimoto Y, Matsuura T, Takahashi Y, Kohashi K, Souzaki R, Taguchi T. The evidence of maternal microchimerism in biliary atresia using fluorescent in situ hybridization. J. Pediatr. Surg. 42: 2097-2101 (2007).

• Heathcote EJ. Diagnosis and management of cholestatic liver disease. Clin. Gastroenterol. Hepatol. 5: 776-782 (2007). *

• Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: 1149-1156 (1994).

• Heathcote J. Round table: classification of autoimmune liver diseases and diagnostic criteria. Overlap syndromes – don’t exist. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 61-62 (2004). *

• Hebbard GS, Smith KG, Gibson PR, Bhathal PS. Augmentin-induced jaundice with a fatal outcome. Med. J. Aust. 156: 285-286 (1992).

• Hebuterne X, Wang XD, Johnson EJ, Krinsky NI, Russell RM. Intestinal absorption and metabolism of 9-cis-beta-carotene in vivo: biosynthesis of 9-cis-retinoic acid. J. Lipid Res. 36: 1264-1273 (1995). *

• Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am. Fam. Physician 74: 756-762 (2006). *

• Heikius B, Niemela O, Niemela S, Karttunen TJ, Lehtola J. Elevated serum PIIINP and laminin in inflammatory bowel disease indicate hepatobiliary and pancreatic dysfunction. Hepatogastroenterology 49: 404-11 (2002).

• Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 32: 153-161 (1997).

• Heim MH. Autoimmune hepatitis. Ther. Umsch. 61: 499-504 (2004).

• Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117: 400-407 (1999). *

• Hermans D, Talbotec C, Lacaille F, Goulet O, Ricour C, Colomb V. Early central catheter infections may contribute to hepatic fibrosis in children receiving long-term parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 44: 459-463 (2007). *

• Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J. Pediatr. Gastroenterol. Nutr. 32: 131-136 (2001). *

• Hernandez-Boluda JC, Jimenez M, Rosinol L, Cervantes F. Idiopathic myelofibrosis associated with primary biliary cirrhosis. Leuk. Lymphoma 43: 673-674 (2002).

• Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl. 14: 946-955 (2008). *

• Herzog K, Goldblum JR. Gallbladder adenocarcinoma and acalculous chronic lymphoplasmacytic cholecystitis associated with ulcerative colitis. Mod. Pathol. 9: 194-198 (1996).

• Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38: 1122-1129 (2008). *

• Hindupur S, Yeung M, Shroff P, Fritz J, Kirmani N. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med. 8: 70-72 (2007). *

• Hiramatsu K, Aoyama H, Zen Y, Aishima S, Kitagawa S, Nakanuma Y. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology 49: 466-478 (2006). *

• Hirano K, Shiratori Y, Komatsu Y, Yamamoto N, Sasahira N, Toda N, Isayama H, Tada M, Tsujino T, Nakata R, Kawase T, Katamoto T, Kawabe T, Omata M. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin. Gastroenterol. Hepatol. 1: 453-464 (2003). *

• Hirschfield GM, Al-Harthi N, Heathcote EJ. Review: current status of therapy in autoimmune liver disease. Ther. Adv. Gastroenterol. 2: 11-28 (2009). *

• Hodgson RS, Taylor-Robinson SD, Jackson JE. Haematochezia in Crohn's disease caused by late-onset haemobilia following percutaneous liver biopsy. Eur. J. Gastroenterol. Hepatol. 16: 229-232 (2004).

• Hoffmann R, Germann EJ, Schmidt U, Jenss H. Primary biliary liver cirrhosis and granulomatous pulmonary infiltrates. Schweiz. Med. Wochenschr. 116: 1098-1102 (1986).

• Holoman J, Glasa J, Galbavy S, Danis D, Molnarova A, Kazar J, Bednarova A, Misianik J. Serum markers of liver fibrogenesis, and liver histology findings in patients with chronic liver diseases. Bratisl. Lek. Listy. 103: 70-75 (2002).

• Holt KM, Miyai K, Chojkier M. Asymptomatic primary biliary cirrhosis in an old man. J. Clin. Gastroenterol. 8: 203-206 (1986).

• Holtmeier J, Leuschner M, Schneider A, Leuschner U, Caspary WF, Braden B. 13C-Methacetin and 13C-galactose breath tests can assess restricted liver function even in early stages of primary biliary cirrhosis. Scand. J. Gastroenterol. 41: 1336-1341 (2006). *

• Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, Kate FT, van Deventer SJ. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J. Clin. Gastroenterol. 42: 522-526 (2008).

• Honda M, Kawai H, Shirota Y, Yamashita T, Kaneko S. Differential gene expression profiles in stage I primary biliary cirrhosis. Am. J. Gastroenterol. 100: 2019-2030 (2005). *

• Honda M, Kawai H, Shirota Y, Yamashita T, Takamura T, Kaneko S. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J. Autoimmun. 25: 133-140 (2005).

• Honeckman A. Current concepts in the treatment of canine chronic hepatitis. Clin. Tech. Small Anim. Pract. 18: 239-244 (2003).

• Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J. Clin. Gastroenterol. 25: 376-378 (1997).

• Hong-Curtis J, Yeh MM, Jain D, Lee JH. Rapid progression of autoimmune hepatitis in the background of primary sclerosing cholangitis. J. Clin. Gastroenterol. 38: 906-909 (2004).

• Honkaniemi E, Gustafsson B, Fischler B, Nemeth A, Frost BM, Papadogiannakis N, Winiarski J. Acquired aplastic anaemia in seven children with severe hepatitis with or without liver failure. Acta Paediatr. 96: 1660-1664 (2007).

• Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, Hanson RG, Minuk GY, Dusheiko GM, Campbell G, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 91: 1327-1334 (1986).

• Hopf U, Moller B, Lobeck H, Klein R, Berg PA. Immunoserologic differentiation of chronic cholestatic hepatitis. Significance of antimitochondrial antibodies and hepatic membrane antibodies. Dtsch. Med. Wochenschr. 110: 1924-1929 (1985).

• Hopf U, Moller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, Galanos C, Huhn D. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 2: 1419-1422 (1989).

• Horiuchi K, Kakizaki S, Kosone T, Ichikawa T, Sato K, Takagi H, Mori M, Sakurai S, Fukusato T. Marked eosinophilia as the first manifestation of sclerosing cholangitis. Intern. Med. 48: 1377-1382 (2009). *

• Horslen SP, McCowan TC, Goertzen TC, Warkentin PI, Cai HB, Strom SC, Fox IJ. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 111: 1262-1267 (2003). *

• Hosokawa A, Takahashi H, Akaike J, Okuda H, Murakami R, Kawahito Y, Tokuno T, Makiguchi Y, Sakamoto H, Hinoda Y, Imai K. A case of Sjogren's syndrome associated with inflammatory pseudotumor of the liver. Nihon Rinsho Meneki Gakkai Kaishi 21: 226-233 (1998).

• Hsiao PJ, Tsai KB, Shin SJ, Wang CL, Lee ST, Lee JF, Kuo KK. A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis. J. Hepatol. 47: 303-306 (2007). *

• Hsieh CS, Huang CC, Wu JJ, Chaung HC, Wu CL, Chang NK, Chang YM, Chou MH, Chuang JH. Ascending cholangitis provokes IL-8 and MCP-1 expression and promotes inflammatory cell infiltration in the cholestatic rat liver. J. Pediatr. Surg. 36: 1623-1628 (2001).

• Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 100: 1072-1081 (2005). *

• Hubscher SG. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 16: 1107-1115 (2004).

• Hull K, Horenstein R, Naglieri R, Munir K, Ghany M, Celi FS. Two cases of thyroid storm-associated cholestatic jaundice. Endocr. Pract. 13: 476-480 (2007).

• Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: a case report. J. Med. Case Reports 1: 88 (2007). *

• Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am. J. Gastroenterol. 97: 2402-2407 (2002). *

• Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, Ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135: 32-40 (2008). *

• Hyslop WB, Kierans AS, Leonardou P, Fritchie K, Darling J, Elazazzi M, Semelka RC. Overlap syndrome of autoimmune chronic liver diseases: MRI findings. J. Magn. Reson. Imaging 31: 383-389 (2010). *

• Hytiroglou P, Gutierrez JA, Freni M, Odin JA, Stanca CM, Merati S, Schiano TD, Branch AD, Thung SN. Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: a blind histologic study. Hepatol. Res. 39: 577-584 (2009). *

• Iacono OL, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, Mineo C, De Lisi S, Almasio PL , Craxi A. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am. J. Gastroenterol. 100: 2472-2477 (2005). *

• Idilman R, Erden E, Arat M, Soydan E, Erkan O, Kuzu I, Sahin Y, Coban S, Bozdayi M, Giraud A, Akan H, Karayalcin S, Ozden A. Trefoil factor expression in biliary epithelium of graft-versus-host disease of the liver after allogeneic hematopoietic cell transplantation. Transplantation 80: 1099-1104 (2005).

• Ikeda F, Yamamoto K, Fujioka S, Okamoto R, Yabushita K, Miyake M, Shimada N, Kono H, Nakamura M, Terada R, Miyake Y, Tsuji T. Laparoscopic findings in primary sclerosing cholangitis. Endoscopy 33: 267-270 (2001).

• Ilan Y, Shouval D. Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687 (1992).

• Imanieh MH, Dehghani SM, Bagheri MH, Emad V, Haghighat M, Zahmatkeshan M, Forutan HR, Rasekhi AR, Gheisari F. Triangular cord sign in detection of biliary atresia: is it a valuable sign? Dig. Dis. Sci. 55: 172-175 (2010). *

• Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, Ohta Y, Onji M, Muto Y, Moriwaki H. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 15: 70-77 (1995).

• Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, Maggioni M, Meroni PL, Penner E, Wesierska-Gadek J. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J. Hepatol. 34: 366-372 (2001). *

• Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *

• Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, Toyota T. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver 13: 227-231 (1993).

• Ishikawa T, Aoyama H, Ohtake H, Ohnishi S, Aburatani H, Imawari M, Shiga J, Takaku F. Primary intrahepatic sclerosing cholangitis with inflammatory bowel disease. Acta Pathol. Jpn. 37: 1637-1643 (1987).

• Iwai M, Harada Y, Ishii M, Tanaka S, Muramatsu A, Mori T, Nakashima T, Okanoue T, Hirohata S. Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin. Rheumatol. 22: 234-236 (2003). *

• Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol. Res. 38: 784-789 (2008). *

• Jackson CC, Wu Y, Chenren S, Somme S, Chwals WJ, Liu DC. Bile decompression in children with histopathological evidence of pre-existing liver cirrhosis. Am. Surg. 68: 816-819 (2002).

• Jaeckel E, Manns MP. The role of autoantigens and autoantibodies in PBC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 28. October 15-16 (2003). *

• Jain A, Demetris AJ, Kashyap R, Blakomer K, Ruppert K, Khan A, Rohal S, Starzl TE, Fung JJ. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl. 7: 623-630 (2001). *

• Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation 75: 1020-1025 (2003).

• Jain S, Scheuer PJ, Samourian S, McGee JO. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. Lancet 1: 831-834 (1977).

• Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann. Intern. Med. 118: 96-98 (1993). *

• Jankowska I, Pawlowska J, Teisseyre M, Kalicinski P, Kaminski A, Czubkowski P, Cielecka-Kuszyk J, Kluge P, Wozniak M, Oldakowska-Jedynak U, Socha J. Autoimmune hepatitis in transplanted liver. Transplant. Proc. 36: 3077-3082 (2004). *

• Jansen PL, Sanders JB. Primary sclerosing cholangitis. An unresolved enigma. Scand. J. Gastroenterol. Suppl. 194: 76-81 (1992).

• Jaroszewicz J, Flisiak R. Primary biliary cirrhosis. Pol. Merkuriusz. Lek. 8: 369-372 (2000).

• Javid PJ, Collier S, Richardson D, Iglesias J, Gura K, Lo C, Kim HB, Duggan CP, Jaksic T. The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants. J. Pediatr. Surg. 40: 1015-1018 (2005).

• Javor ED, Ghany MG, Cochran EK, Oral EA, Depaoli AM, Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41: 753-760 (2005). *

• Jazia EB, Khalifa M, Abdelkader AB, Kaabia N, Ghannouchi N, Braham A, Letaief A, Bahri F. A case of primary biliary cirrhosis associated with pernicious anemia: a case report. Cases J. 3: 11 (2010). *

• Jeffrey GP, Reed WD, Carrello S, Shilkin KB. Histological and immunohistochemical study of the gall bladder lesion in primary sclerosing cholangitis. Gut 32: 424-429 (1991). *

• Jeffrey GP, Reed WD, Laurence BH, Shilkin KB. Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases. J. Gastroenterol. Hepatol. 5: 135-140 (1990).

• Johnson K, Kotiesh A, Boitnott JK, Torbenson M. Histology of symptomatic acute hepatitis C infection in immunocompetent adults. Am. J. Surg. Pathol. 31: 1754-1758 (2007).

• Johnson SR, Koehler A, Pennington LK, Hanto DW. Long-term results of surgical repair of bile duct injuries following laparoscopic cholecystectomy. Surgery 128: 668-677 (2000). *

• Jonas E, Hultcrantz R, Slezak P, Blomqvist L, Schnell PO, Jacobsson H. Dynamic 99Tcm-HIDA SPET: non-invasive measuring of intrahepatic bile flow. Description of the method and a study in primary sclerosing cholangitis. Nucl. Med. Commun. 22: 127-134 (2001). *

• Jones DE, Donaldson PT. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin. Liver Dis. 7: 841-864 (2003).

• Jones DE, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 30: 53-57 (1999). *

• Jorge AD, Stati AO, Roig LV, Ponce G, Jorge OA, Ciocca DR. Steroid receptors and heat-shock proteins in patients with primary biliary cirrhosis. Hepatology 18: 1108-1114 (1993).

• Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 35: 409-413 (2002). *

• Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742-755 (2005). *

• Kabaroff LC, Rodriguez A, Quinton M, Boermans H, Karrow NA. Assessment of the ovine acute phase response and hepatic gene expression in response to Escherichia coli endotoxin. Vet. Immunol. Immunopathol. 113: 113-124 (2006).

• Kadry Z, Mullhaupt B, Renner EL, Bauerfeind P, Schanz U, Pestalozzi BC, Studer G, Zinkernagel R, Clavien PA. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 76: 1003-1006 (2003).

• Kaji K, Tsuneyama K, Nakanuma Y, Harada K, Sasaki M, Kaneko S, Kobayashi K. B7-2 positive cells around interlobular bile ducts in primary biliary cirrhosis and chronic hepatitis C. J. Gastroenterol. Hepatol. 12: 507-512 (1997).

• Kakar S, Batts KP, Poterucha JJ, Burgart LJ. Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. Mod. Pathol. 17: 874-878 (2004). *

• Kakumu S, Yoshioka K, Tsutsumi Y, Wakita T, Arao M. Production of tumor necrosis factor, interleukin 1, and interferon-gamma by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Clin. Immunol. Immunopathol. 56: 54-65 (1990).

• Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, Burroughs AK. Transjugular liver biopsy - indications, adequacy, quality of specimens, and complications - a systematic review. J. Hepatol. 47: 284-294 (2007). *

• Kallwitz ER, Guzman G, Tencate V, Vitello J, Layden-Almer J, Berkes J, Patel R, Layden TJ, Cotler SJ. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am. J. Gastroenterol. 104: 64-69 (2009). *

• Kaneko F, Yokomori H, Tahara K, Takeshita T, Takeuchi H, Yoshida H, Hoshi K, Kondo H, Ohbu M, Sato T, Hibi T. Autoimmune hepatitis associated with pulmonary arterial hypertension. Intern. Med. 47: 1971-1976 (2008). *

• Kapelari K, Fruehwirth M, Heitger A, Konigsrainer A, Margreiter R, Simma B, Offner FA. Loss of intrahepatic bile ducts: an important feature of familial hemophagocytic lymphohistiocytosis. Virchows Arch. 446: 619-625 (2005). *

• Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA. A prospective trial of colchicine for primary biliary cirrhosis. N. Engl. J. Med. 315: 1448-1454 (1986).

• Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann. Intern. Med. 106: 231-235 (1987).

• Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann. Intern. Med. 126: 682-688 (1997). *

• Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 101: 1332-1338 (1991).

• Kapp P, Bely M, Nemesanszky E. Ultrastructural findings in the liver due to long-term retinol (isotretinoin) treatment. Significance of the perisinusoidal (Ito) cells. Orv. Hetil. 145: 173-179 (2004).

• Karnsakul W, Arkachaisri T, Atisook K, Wisuthsarewong W, Sattawatthamrong Y, Aanpreung P. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms. Ann. Hepatol. 5: 116-119 (2006). *

• Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin. Liver Dis. 28: 396-406 (2008). *

• Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int. 26: 1225-1233 (2006). *

• Kay M, Wyllie R, Michener W, Caulfield M, Steffen R. Associated ulcerative colitis, sclerosing cholangitis, and insulin-dependent diabetes mellitus. Cleve. Clin. J. Med. 60: 473-478 (1993).

• Kayser K, Bohrer M, Kayser C, Weiser WY, Zeng FY, Gabius HJ, Tungerthal S, Schulz V. Alteration of human lung parenchyma associated with primary biliary cirrhosis. Zentralbl. Pathol. 139: 377-380 (1993).

• Keaveny AP, Karasik MS. Hepatobiliary and pancreatic infections in AIDS: part one. AIDS Patient Care STDS 12: 347-357 (1998).

• Keeffe EB, Davis GL. Advances in liver disease: highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42 (2004). *

• Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131: 624-629 (2006). *

• Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J.Transplant. 5: 1085-1089 (2005). *

• Kessel A, Elias G, Pavlotzky E, Zuckerman E, Rosner I, Toubi E. Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity. Hum. Immunol. 68: 844-848 (2007).

• Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 2: 625-631 (2004). *

• Khanlou H, Sass D, Rothstein K, Manzarbeitia C, Reich D, Jacobson L, Fleischer D, Munoz SJ. Idiopathic adulthood ductopenia: case report and review of the literature. Arch. Intern. Med. 160: 1033-1036 (2000). *

• Kharchafi A, Morlat P, Bernard PH, Bernard N, Balabaud C, Beylot J. Hepatitis C-autoimmune hepatitis overlap syndrome: a five new cases study. Rev. Med. Interne. 27: 916-923 (2006).

• Khoo AL, Tham LS, Lee KH, Lim GK. Acute liver failure with concurrent bupropion and carbimazole therapy. Ann. Pharmacother. 37: 220-223 (2003).

• Khouri MR, Saul SH, Dlugosz AA, Soloway RD. Hepatocanalicular injury associated with vitamin A derivative etretinate. An idiosyncratic hypersensitivity reaction. Dig. Dis. Sci. 32: 1207-1211 (1987).

• Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Han KH. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. Jan 13 [Epub ahead of print] (2010). *

• Kim JH, Kim BH, Kim YW, Park JC, Jung YH, Lee BO, Han YS, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Autoimmune cholangitis in a patient with thymoma. J. Gastroenterol. Hepatol. 19: 1324-1327 (2004). *

• Kim SU, Kim JK, Park JY, Ahn SH, Lee JM, Baatarkhuu O, Choi EH, Han KH, Chon CY, Kim do Y. Variability in liver stiffness values from different intercostal spaces. Liver Int. 29: 760-766 (2009). *

• Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, Lindor KD, Dickson ER. A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc. 75: 688-694 (2000). *

• Kimura A, Kage M, Nagata I, Mushiake S, Ohura T, Tazawa Y, Maisawa S, Tomomasa T, Abukawa D, Okano Y, Sumazaki R, Takayanagi M, Tamamori A, Yorifuji T, Yamato Y, Maeda K, Matsushita M, Matsuishi T, Tanikawa K, Kobayashi K, Saheki T. Histological findings in the livers of patients with neonatal intrahepatic cholestasis caused by citrin deficiency. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Kiriyama K, Usui T, Takemura T, Ikeda K, Kishida H, Izumoto T, Kanayama Y, Hirota S. A case of rapid-onset antimitochondrial antibody-positive autoimmune hepatitis possibly triggered by a urinary tract infection. Nippon Shokakibyo Gakkai Zasshi 107: 270-277 (2010).

• Kirsch R, Yap J, Roberts EA, Cutz E. Clinicopathologic spectrum of massive and submassive hepatic necrosis in infants and children. Hum. Pathol. 40: 516-526 (2009).

• Kishi Y, Sugawara Y, Tamura S, Kaneko J, Akamatsu N, Togashi J, Makuuchi M. Is blood eosinophilia an effective predictor of acute rejection in living donor liver transplantation? Transpl. Int. 18: 1147-1151 (2005). *

• Kishi Y, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Makuuchi M. Histologic eosinophilia as an aid to diagnose acute cellular rejection after living donor liver transplantation. Clin. Transplant. 21: 214-218 (2007). *

• Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003). *

• Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am. J. Gastroenterol. 86: 546-552 (1991).

• Ko GT, Szeto CC, Yeung VT, Chow CC, Chan H, Cockram CS. Autoimmune polyglandular syndrome and primary biliary cirrhosis. Br. J. Clin. Pract. 50: 344-346 (1996).

• Koay LB, Tsai SL, Sun CS, Wu KT. Chronic autoimmune hepatitis with Epstein-Barr virus superinfection: a case report and review of literature. Hepatogastroenterology 55: 1781-1784 (2008).

• Kobori L, Kohalmy K, Porrogi P, Sarvary E, Gerlei Z, Fazakas J, Nagy P, Jaray J, Monostory K. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br. J. Clin. Pharmacol. 65: 428-436 (2008). *

• Kodama T, Imai H, Wakui H, Ohtani H, Komatsuda A, Miura AB. Tubulointerstitial nephritis with renal tubular acidosis and asymptomatic primary biliary cirrhosis accompanied by antibody to a 52-kDa mitochondrial protein alone. Clin. Nephrol. 45: 401-405 (1996).

• Koffron A, Geller D, Gamblin TC, Abecassis M. Laparoscopic liver surgery: shifting the management of liver tumors. Hepatology 44: 1694-1700 (2006). *

• Kogawa H, Migita K, Ito M, Takii Y, Daikoku M, Nakao M, Miyashita T, Kimura H, Ezaki H, Nakamura M, Yatsuhashi H, Eguchi K, Ishibashi H. Idiopathic portal hypertension associated with systemic sclerosis and Sjogren's syndrome. Clin. Rheumatol. 24: 544-547 (2005). *

• Kogure T, Ueno Y, Fukushima K, Nagasaki F, Inoue J, Kakazu E, Matsuda Y, Kido O, Nakagome Y, Kimura O, Obara N, Wakui Y, Iwasaki T, Shimosegawa T. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J. Gastroenterol. 13: 4394-4397 (2007). *

• Kolmannskog F, Aakhus T, Fausa O, Schrumpf E, Ritland S, Gjone E, Elgjo K. Cholangiographic findings in ulcerative colitis. Acta Radiol. Diagn. (Stockh.) 22: 151-157 (1981).

• Konig H, Hermanek P, Rosch W. Clinical conference: unusual course of chronic colitis. Acta Hepatogastroenterol. (Stuttg.) 23: 227-231 (1976).

• Konopelska S, Kienitz T, Hughes B, Pirlich M, Bauditz J, Lochs H, Strasburger CJ, Stewart PM, Quinkler M. Hepatic 11beta-HSD1 mRNA expression in fatty liver and non-alcoholic steatohepatitis. Clin. Endocrinol. (Oxf.) 70: 554-560 (2009). *

• Kopec E, Mietkiewski J. Primary biliary cirrhosis - an attempt to evaluate the usefulness of selected tests in differential diagnosis. Pol. Tyg. Lek. 46: 896-898 (1991).

• Korkut E, Kisacik B, Akcan Y, Belenli O, Bicik Z, Yucel OG. Two successive pregnancies after ursodeoxycholic acid therapy in a previously infertile woman with antimitochondrial antibody-negative primary biliary cirrhosis. Fertil. Steril. 83: 761-763 (2005). *

• Koshy A, Ramesh H, Mahadevan P, Mukkada RJ, Francis VJ, Chettupuzha AP, Mathew PG, Cyriac J, Augustine P. Progressive familial intrahepatic cholestasis: a case with improvement in liver tests and growth following partial external biliary diversion. Indian J. Gastroenterol. 28: 107-108 (2009). *

• Koskinas J, Gomatos IP, Tiniakos DG, Memos N, Boutsikou M, Garatzioti A, Archimandritis A, Betrosian A. Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J. Gastroenterol. 14: 1389-1393 (2008). *

• Kouklakis G, Mpoumponaris A, Zezos P, Moschos J, Koulaouzidis A, Nakos A, Pehlivanidis A, Iosiphidis M, Molyvas E, Nikolaidis N. Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. Ann. Hepatol. 6: 63-65 (2007). *

• Kowdley KV, Trainer TD, Saltzman JR, Pedrosa M, Krawitt EL, Knox TA, Susskind K, Pratt D, Bonkovsky HL, Grace ND, Kaplan MM. Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. Gastroenterology 113: 1270-1277 (1997). *

• Koyabu M, Uchida K, Miyoshi H, Sakaguchi Y, Fukui T, Ikeda H, Takaoka M, Hirohara J, Nishio A, Uemura Y, Uemoto S, Okazaki K. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J. Gastroenterol. Jan 20 [Epub ahead of print] (2010). *

• Krasinskas AM, Ruchelli ED, Rand EB, Chittams JL, Furth EE. Central venulitis in pediatric liver allografts. Hepatology 33: 1141-1147 (2001). *

• Kraus MR, Scheurlen M. Diagnosis and treatment of intrahepatic cholestasis syndrome. MMW Fortschr. Med. 146: 34-37 (2004).

• Krawitt EL. Sampling variability in liver biopsies. J. Hepatol. 41: 886-887 (2004). *

• Krayenbuehl PA, Hersberger M, Truninger K, Mullhaupt B, Maly FE, Bargetzi M, Schulthess G. Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. Eur. J. Gastroenterol. Hepatol. Oct 3 [Epub ahead of print] (2009).

• Krier M, Ahmed A. The asymptomatic outpatient with abnormal liver function tests. Clin. Liver Dis. 13: 167-177 (2009). *

• Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, Neuhaus P, Krenn V. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 78: 65-70 (2004).

• Kryczka W, Walewska-Zielecka B, Dutkiewicz E. Acute seronegative hepatitis C manifesting itself as adult giant cell hepatitis - a case report and review of literature. Med. Sci. Monit. 9 Suppl. 3: 29-31 (2003).

• Kucinskas L, Jeroch J, Vitkauskiene A, Sakalauskas R, Petrenkiene V, Kucinskas V, Naginiene R, Schmidt H, Kupcinskas L. High frequency of the c.3207C>A (p.H1069Q) mutation in ATP7B gene of Lithuanian patients with hepatic presentation of Wilson's disease. World J. Gastroenterol. 14: 5876-5879 (2008). *

• Kugelmas M. Liver biopsy. Am. J. Gastroenterol. 99: 1416-1417 (2004). *

• Kuiper EM, den Ouden-Muller JW, van Buuren HR. Primary biliary cirrhosis. Ned. Tijdschr. Geneeskd. 153: A483 (2009).

• Kulkarni PB, Beatty E Jr. Cholangiocarcinoma associated with biliary cirrhosis due to congenital biliary atresia. Am. J. Dis. Child. 131: 442-444 (1977).

• Kumagi T, Heathcote JE. Primary biliary cirrhosis. Orphanet J. Rare Dis. 3: 1 (2008). *

• Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin. Proc. 75: 733-739 (2000). *

• Kunze KD, Kobe E. Differential diagnosis and staging of chronic nonsuppurative destructive cholangitis in liver biopsies. Zentralbl. Allg. Pathol. 132: 223-232 (1986).

• Kurbegov AC, Setchell KD, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 125: 1227-1234 (2003). *

• Kwauk ST, Cameron R, Burbridge B, Keith RG. Traumatic pseudoaneurysm of the hepatic artery after percutaneous liver biopsy and laparoscopic cholecystectomy in a patient with biliary cirrhosis: a case report. Can. J. Surg. 41: 316-320 (1998).

• Kwon YD, Lee HS, Park CH, Jeen YT, Chun HJ, Lee SW, Choi JH, Kim CD, Ryu HS, Hyun JH. A case of auto-immune hepatitis associated with primary Sjogren's syndrome. Taehan Kan Hakhoe Chi 9: 25-30 (2003).

• Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P, de Ledinghen V. The liver and methotrexate. Gastroenterol. Clin. Biol. 32: 134-142 (2008).

• Laharie D, Zerbib F, Adhoute X, Boue-Lahorgue X, Foucher J, Castera L, Rullier A, Bertet J, Couzigou P, Amouretti M, DE Ledinghen V. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment. Pharmacol. Ther. 23: 1621-1628 (2006). *

• Laine F, Bendavid C, Moirand R, Tessier S, Perrin M, Guillygomarc'h A, Guyader D, Calon E, Renault A, Brissot P, Turlin B, Deugnier Y. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 39: 1639-1646 (2004). *

• Landa Garrido L, Huaman Munnte J, Valencia Caballero V, Lozano Miranda Z, Nago Nago A. Hereditary hemochromatosis. Rev. Gastroenterol. Peru 23: 302-306 (2003).

• Lang ZW, Shen B, Zhang L, Shi XH, Ma PQ, Lan MD, Ma ZC, Jin SH. Detection of CD4+CD25+ regulatory T cells in liver tissues of fibrosing cholestatic hepatitis after liver and kidney transplantation. Zhonghua Gan Zang Bing Za Zhi 15: 667-671 (2007).

• Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 117: 129-132 (1992).

• Larroche C, Ziol M, Zidi S, Dhote R, Roulot D. Liver involvement in hemophagocytic syndrome. Gastroenterol. Clin. Biol. 31: 959-966 (2007).

• LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology 44: 746-764 (2006). *

• LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N. Engl. J. Med. 310: 899-903 (1984).

• LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 95: 1036-1042 (1988).

• Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23: 1464-1467 (1996). *

• Lautenschlager I, Halme L, Hockerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl. Infect. Dis. 8: 21-30 (2006). *

• Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).

• Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J. Clin. Gastroenterol. 41: 494-500 (2007).

• Lee HS, Shun CT, Chiou LL, Chen CH, Huang GT, Sheu JC. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: emphasis on sampling variability. J. Gastroenterol. Hepatol. 20: 1109-1114 (2005). *

• Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol. 47: 239-244 (2007). *

• Lee RG, Epstein O, Jauregui H, Sherlock S, Scheuer PJ. Granulomas in primary biliary cirrhosis: a prognostic feature. Gastroenterology 81: 983-986 (1981).

• Lee SP, Tasman-Jones C, Wattie WJ. Traumatic hemobilia: a complication of percutaneous liver biopsy. Gastroenterology 72: 941-944 (1977).

• Lee SY, Joo HJ, Cho YS, Jeon WJ, Chae HB, Park SM, Youn SJ, Sung RH. A case of congenital hepatic fibrosis presented with recurrent acute cholangitis. Korean J. Gastroenterol. 54: 404-408 (2009).

• Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol. Pathol. 33: 155-164 (2005). *

• Lee WS, Looi LM. Usefulness of a scoring system in the interpretation of histology in neonatal cholestasis. World J. Gastroenterol. 15: 5326-5333 (2009). *

• Lee WS, Saw CB, Sarji SA. Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in a child: diagnostic usefulness of magnetic resonance cholangiopancreatography. J. Paediatr. Child. Health 41: 225-227 (2005).

• Leeuwenburgh I, Lugtenburg EP, van Buuren HR, Zondervan PE, de Man RA. Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy. Eur. J. Gastroenterol. Hepatol. 20: 145-147 (2008).

• Leevy CB, Holt J Jr, Buniak B. Immunologic effects of ursodeoxycholic acid in primary biliary cirrhosis. J. Assoc. Acad. Minor Phys. 4: 30-32 (1993).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 20: 188-197 (2004).

• Lefkowitch JH. Liver histopathology. Clin. Liver Dis. 6: xv-xix (2002). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Lefkowitch JH. Diagnostic issues in liver transplantation pathology. Clin. Liver Dis. 6: 555-570, ix (2002).

• Lefkowitch JH. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and "cholangitis lenta". Hum. Pathol. 13: 19-24 (1982).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 21: 260-269 (2005).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 22: 198-208 (2006).

• Leiser A, Kadish U. Beneficial effect of colchicine in a case of sclerosing cholangitis. Am. J. Med. Sci. 291: 416-418 (1986).

• Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am. J. Gastroenterol. 95: 1730-1734 (2000). *

• Lemmer ER, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin. Liver Dis. 26: 373-384 (2006).

• Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Deviere J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49: 646-657 (2009). *

• Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 20: 387-395 (2006). *

• Leo MA, Kim C, Lowe N, Lieber CS. Interaction of ethanol with beta-carotene: delayed blood clearance and enhanced hepatotoxicity. Hepatology 15: 883-891 (1992).

• Lepisto A, Karkkainen P, Jarvinen HJ. Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm. Bowel Dis. 14: 775-779 (2008). *

• Lesna M, Hamlyn AN, Watson AJ. Intrahepatocytic copper and copper-binding protein in primary biliary cirrhosis. Discrimination from chronic active hepatitis by means of orcein and rubeanic acid techniques. Digestion 22: 113-118 (1981).

• Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117: 918-925 (1999). *

• Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig. Dis. Sci. 30: 642-649 (1985).

• Levin DM, Baker AL, Riddell RH, Rochman H, Boyer JL. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am. J. Med. 66: 429-434 (1979).

• Levinson JR, Gordon SC. Liver diseases in the elderly. Clin. Geriatr. Med. 7: 371-385 (1991).

• Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin. Liver Dis. 24: 233-247 (2004).

• Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, Ziol M, Arrive L, Beaugrand M, Poupon R, Valla D, Chazouilleres O, Corpechot C. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective MRI and histological study. Hepatology 50: 528-537 (2009). *

• Lewindon PJ, Pereira TN, Hoskins AC, Bridle KR, Williamson RM, Shepherd RW, Ramm GA. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am. J. Pathol. 160: 1705-1715 (2002). *

• Li CP, Tong MJ, Hwang SJ, Luo JC, Co RL, Tsay SH, Chang FY, Lee SD. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J. Gastroenterol. Hepatol. 15: 95-98 (2000). *

• Li MK, Crawford JM. The pathology of cholestasis. Semin. Liver Dis. 24: 21-42 (2004).

• Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am. J. Gastroenterol. 101: 1500-1508 (2006). *

• Lieberman DA, Keeffe EB, Stenzel P. Severe and prolonged oral contraceptive jaundice. J. Clin. Gastroenterol. 6: 145-148 (1984).

• Lim EM, Rossi E, De Boer WB, Reed WD, Jeffrey GP. Hepatic iron loading in patients with compound heterozygous HFE mutations. Liver Int. 24: 631 (2004). *

• Lima LC, Matte U, Leistner S, Bopp AR, Scholl VC, Giugliani R, da Silveira TR. Molecular analysis of the Pi*Z allele in patients with liver disease. Am. J. Med. Genet. 104: 287-290 (2001).

• Lin SC, Shyur SD, Ma YC, Huang LH, Lee HC, Lee WI. Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome. J. Formos. Med. Assoc. 104: 421-426 (2005).

• Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjogren's syndrome. J. Hepatol. 20: 354-358 (1994).

• Lindgren S, Nilsson S, Nassberger L, Verbaan H, Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK) J. Gastroenterol. Hepatol. 15: 437-442 (2000). *

• Lindor KD. Primary biliary cirrhosis: questions and promises. Ann. Intern. Med. 126: 733-735 (1997). *

• Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, Rodes J, McGill DB, Reading CC, James EM, Charboneau JW, Ludwig J, Batts KP, Zinsmeister AR. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 23: 1079-1083 (1996). *

• Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106: 1284-1290 (1994).

• Lindor KD, Fleming CR, Abrams A, Hirschkorn MA. Liver function values in adults receiving total parenteral nutrition. JAMA 241: 2398-2400 (1979).

• Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39: 770-778 (2004). *

• Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50: 808-814 (2009). *

• Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 48: 569-572 (2009).

• Lintas C, Cappa M, Comparcola D, Nobili V, Fierabracci A. An 8-year-old boy with autoimmune hepatitis and Candida onychosis as the first symptoms of autoimmune polyglandular syndrome (APS1): identification of a new homozygous mutation in the autoimmune regulator gene (AIRE). Eur. J. Pediatr. 167: 949-953 (2008).

• Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int. 28: 233-239 (2008). *

• Liu C, Crawford JM. Chapter 10. Clinical use of immunopathology techniques in liver diseases. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 123-136 (2007). *

• Liu FC, Chang DM, Lai JH, Lin CK, Chen HC, Hou TY, Kuo SY. Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus: a case report. Rheumatol. Int. 27: 489-491 (2007). *

• Loaeza-Del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann. Hepatol. 7: 350-357 (2008). *

• Loginov AS, Aruin LI, Sepeleva SD. On the pathomorphology of primary biliary cirrhosis of the liver. Dtsch. Z. Verdau Stoffwechselkr. 41: 261-269 (1981).

• Loguercio C, De Simone T, D'Auria MV, de Sio I, Federico A, Tuccillo C, Abbatecola AM, Del Vecchio Blanco C; Italian AISF Clinical Group. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig. Liver Dis. 36: 398-405 (2004).

• Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH, Fleischer B. The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. Hepatology 12: 1314-1320 (1990).

• Lohse AW. Standard treatment of autoimmune hepatitis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 65-66 (2004). *

• Lohse AW. Is small duct PSC a separate disease? Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 9 (2006). *

• Lohse AW, Hennes E. Diagnostic criteria for autoimmune hepatitis. Hepatol. Res. 37 Suppl. 3: S509 (2007). *

• Longerich T, Flechtenmacher C, Schirmacher P. Quality and quantity in hepatopathology: diagnostic and clinically relevant grading for non-tumourous liver diseases. Pathologe 29: 15-26 (2008).

• Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50: 1282-1293 (2009). *

• Lopez MJ, Lee YM. Primary sclerosing cholangitis and primary biliary cirrhosis. The American College of Gastroenterology (http://www.acg.gi.org/patients/gihealth/pdf/sclerosing.pdf) (2005). *

• Lopez-Mendez E, Lopez-Mendez E, Lopez-Mendez I, Hernandez-Reyes P, Galindo-Uribe J, Angulo-Ramirez V, Avila-Escobedo L, Uribe M. A 57 year old man with chronic renal failure and cardiac tamponade who developed ischemic hepatitis. Ann. Hepatol. 5: 50-52 (2006).

• Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, Borsatti A, Bertolotti M, Cassani F, Bagni A, Muratori P, Ganazzi D, Bianchi FB, Carulli N. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig. Dis. Sci. 48: 2173-2181 (2003). *

• Lovisetto P, Raviolo P. Intrahepatic cholestasis caused by biochemical errors of bile acids. Part I - Nosographic, pathogenetic, diagnostic features. Minerva Med. 85: 589-596 (1994).

• Lu S, Furth EE, Blumberg EA, Bing Z. Hepatic involvement in a liver transplant recipient with disseminated cryptococcosis. Transpl. Infect. Dis. 11: 179-182 (2009).

• Luca G, Orietta S, Caterina P, Giovambattista DS, Maria F. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr. Drug Saf. 4: 204-206 (2009).

• Luca V, Ludovica FA, Elisabetta B, Paola D, Enrico G, Ester V, Elena C, Ezio L, Giancarlo R, Giulio M, Silvia F. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology Nov 17 [Epub ahead of print] (2009). *

• Lucena MI, Andrade RJ, Vicioso L, Gonzalez FJ, Pachkoria K, Garcia-Munoz B. Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report. World J. Gastroenterol. 12: 5244-5246 (2006). *

• Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, Forzy G, Filoche B, Couzigou P, de Ledinghen V. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 49: 1083-1089 (2009). *

• Ludtke A, Genschel J, Brabant G, Bauditz J, Taupitz M, Koch M, Wermke W, Worman HJ, Schmidt HH. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol. 100: 2218-2224 (2005). *

• Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1: 632-640 (1981).

• Ludwig J, Colina F, Poterucha JJ. Granulomas in primary sclerosing cholangitis. Liver 15: 307-312 (1995).

• Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 4: 105-116 (1984).

• Luth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP, Schramm C, Lohse AW. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J. Clin. Gastroenterol. 42: 926-930 (2008).

• Luth S, Weiler-Normann C, Schramm C, Lohse AW. Autoimmune liver diseases. Internist (Berl.) 50: 310-317 (2009).

• Lyttkens K, Prytz H, Forsberg L, Hederstrom E, Hagerstrand I. Ultrasound, hepatic lymph nodes and primary biliary cirrhosis. J. Hepatol. 15: 136-139 (1992).

• Machado NO, Grant CS, Alkindi S, Daar S, Al-Kindy N, Al Lamki Z, Ganguly S. Splenectomy for haematological disorders: a single center study in 150 patients from Oman. Int. J. Surg. 7: 476-481 (2009).

• Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, Merino D, Cano P, Mira JA, Arizcorreta-Yarza A, Ruíz-Morales J, Lomas-Cabeza JM, García-García JA, Corzo JE, Pineda JA. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55: 409-414 (2006). *

• Madacsy L, Szepes A, Nagy I, Velosy B, Tiszlavicz L, Pavics L, Csernay L, Lonovics J. Congenital hepatic fibrosis in a patient with suspected postcholecystectomy syndrome: hepatobiliary scintigraphy at diagnosis and during follow-up. Clin. Nucl. Med. 29: 55-59 (2004).

• Madan K, Batra Y, Sreenivas V, Mizokami M, Tanaka Y, Chalamalasetty SB, Panda SK, Acharya SK. HBV genotypes in India: do they influence disease severity? Hepatol. Res. 39: 157-163 (2009). *

• Maekawa S, Yano E, Shintani S. A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies. Ryumachi. 32: 515-521 (1992).

• Maffei M, Hadengue A. Cholestasis of adult: diagnosis of the cause. Rev. Med. Suisse. 2: 1960-1962, 1964 (2006).

• Maggiore G, Riva S, Sciveres M. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood. Minerva Gastroenterol. Dietol. 55: 53-70 (2009).

• Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J. Hepatol. 20: 707-713 (1994).

• Mahtab MA, Karim MF, Rahman S, Adnan AB. Dubin-Johnson syndrome with systemic lupus erythematosus: a case report. Hepatobiliary Pancreat. Dis. Int. 5: 617-619 (2006). *

• Maia JM, Maranhao HD, Sena LV, Rocha LR, Medeiros LA, Ramos AM. Hepatic stellate cell activation and hepatic fibrosis in children with type 1 autoimmune hepatitis: an immunohistochemical study of paired liver biopsies before treatment and after clinical remission. Eur. J. Gastroenterol. Hepatol. Dec 14 [Epub ahead of print] (2009).

• Maier KP. The patient with slightly increased liver function tests. Schweiz. Rundsch. Med. Prax. 94: 139-143 (2005).

• Majeed M, Babu A. Cholestasis secondary to hyperthyroidism made worse by methimazole. Am. J. Med. Sci. 332: 51-53 (2006).

• Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int. J. Infect. Dis. 13: e157-e160 (2009).

• Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaux AS, Verkarre V, Bechade D, Poynard T, Hermine O, Cellier C. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J. Hepatol. 48: 74-82 (2008). *

• Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. Chin. J. Dig. Dis. 8: 58-64 (2007). *

• Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig. Dis. Sci. 42: 1486-1488 (1997). *

• Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, Vallet-Pichard A, Fontaine H, Pol S. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment. Pharmacol. Ther. 29: 409-415 (2009). *

• Mallory MA, Lee SW, Kowdley KV. Abnormal liver test results on routine screening. How to evaluate, when to refer for a biopsy. Postgrad. Med. 115: 53-56, 59-62, 66 (2004). *

• Mambelli E, Mancini E, Casanova S, Di Felice A, Santoro A. Severe ticlopidine-induced cholestatic syndrome. Blood Purif. 25: 441-445 (2007). *

• Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology 49: S61-S71 (2009).

• Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 134: 1670-1681 (2008). *

• Manns M, Meyer zum Buschenfelde KH. A mitochondrial antigen-antibody system in cholestatic liver disease detected by radioimmunoassay. Hepatology 2: 1-7 (1982).

• Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Buschenfelde KH, Meyer UA, Eichelbaum M. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 12: 127-132 (1990).

• Marbello L, Anghilieri M, Nosari A, Minola E, Cairoli R, Ricci F, Morra E. Aggressive systemic mastocytosis mimicking sclerosing cholangitis. Haematologica 89: ECR35 (2004). *

• Marchesini G, Bugianesi E, Forlani G, Marzocchi R, Zannoni C, Vanni E, Manini R, Rizzetto M, Melchionda N. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res. Clin. Pract. 63: 143-151 (2004).

• Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, Sebastiani G, Palu G, Alberti A. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 50: 1038-1044 (2009).

• Marigold JH, Bull HJ, Gilmore IT, Coltart DJ, Thompson RP. Direct measurement of hepatic extraction of chenodeoxycholic acid and ursodeoxycholic acid in man. Clin. Sci. (Lond.) 63: 197-203 (1982).

• Marinelli Ibarreta A, Sanchez Movilla A, Izquierdo F, Burgos Lazaro F, Arce Alvarez A, del Castillo-Olivares Ramos JL. Morphopathological changes before and after biliodigestive derivation in experimental cirrhosis induced by biliary ligation in the rat. Rev. Esp. Enferm. Dig. 87: 25-31 (1995).

• Marinho R, Graca H, Ramalho F, Costa A, Batista A, De Moura MC. Autoimmune cholangiopathy. Acta Med. Port. 14: 361-366 (2001).

• Marinho R, Graca H, Ramalho F, Costa A, Batista A, de Moura MC. Autoimmune cholangitis: case report. Hepatogastroenterology 46: 1949-1952 (1999).

• Marino M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR, Pollina LE, Campani D, Vitti P, Bartalena L, Pincheral A, Marcocci C. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J. Endocrinol. Invest. 28: 280-284 (2005).

• Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch. Dis. Child. 89: 648-652 (2004). *

• Marmur J, Bergquist A, Stal P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. Scand. J. Gastroenterol. 45: 60-69 (2010). *

• Marra F. NASH: are genes blowing the hits? J. Hepatol. 40: 853-856 (2004). *

• Marrero JA. Modern diagnosis of hepatocellular carcinoma: utilization of liver biopsy and genomic markers. J. Hepatol. 50: 659-661 (2009). *

• Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *

• Marschall HU, Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Diczfalusy U, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Comprehensive study of the effects of rifampicin and ursodeoxycholic acid on genes and proteins involved in regulation, transport and detoxification of biliary compounds in gallstone patients. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 47. June 18-19 (2004). *

• Martin J, Dufour JF. Cholestasis shuts down calcium signaling in cholangiocytes. Hepatology 39: 248-249 (2004). *

• Masumoto T, Ninomiya T, Michitaka K, Horiike N, Yamamoto K, Akbar SM, Abe M, Onji M. Three patients with autoimmune cholangiopathy treated with prednisolone. J. Gastroenterol. 33: 909-913 (1998). *

• Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49: 1954-1961 (2009). *

• Matheus T, Munoz S. Granulomatous liver disease and cholestasis. Clin. Liver Dis. 8: 229-246 (2004).

• Mathew J, Hines JE, Toole K, Johnson SJ, James OF, Burt AD. Quantitative analysis of macrophages and perisinusoidal cells in primary biliary cirrhosis. Histopathology 25: 65-70 (1994).

• Mathew J, Igbokwe UO, Morley N, Burt AD. Tempting liver fibrosis? Long-term psoriatic methotrexate therapy and heterozygous alpha(1)-antitrypsin deficiency. Dermatology 213: 147-149 (2006).

• Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand. J. Gastroenterol. 34: 85-91 (1999). *

• Matiushin BN, Loginov AS, Tkachev VD. Activities of glutathione enzymes in liver biopsy specimens in chronic lesions of hepatocytes. Klin. Lab. Diagn. 4: 16-18 (1998).

• Matiushin BN, Loginov AS, Tkachev VD. Cytochrome P-450-dependent hydroxylation in liver tissue of patients with hepatobiliary diseases. Klin. Lab. Diagn. 1: 25-27 (1994).

• Matsuda Y, Amuro Y, Hada T, Higashino K, Ueki N, Fujikura M, Tonomura A, Yamamoto T, Yamaguchi K, Shimomura S, et al. Aspartate aminotransferase-linked immunoglobulin complexes in serum of a patient with primary biliary cirrhosis. J. Gastroenterol. 29: 218-222 (1994).

• Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, Sato N, Abe H, Aoki Y, Hoshi T, Hashimoto H. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 20: 366-373 (2000).

• Matsushita M, Takemura T, Imai Y, Takimoto K, Kuchide M, Kajikawa H, Kojima Y, Shimamoto F, Yamauchi H, Matsuyama K, Yoshikawa T. A case of probable autoimmune hepatitis from which the persistence of hepatitis A IgM antibody, and the improvement was pathologically obtained by ursodeoxycholic acid medication. Nippon Shokakibyo Gakkai Zasshi 105: 1367-1374 (2008).

• Matsuzaki Y, Doy M, Tanaka N, Shoda J, Osuga T, Nakano M, Aikawa T. Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis. J. Clin. Gastroenterol. 18: 36-41 (1994).

• Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 85: 15-23 (1990).

• Mattila J, Aitola P, Matikainen M. Liver lesions found at colectomy in ulcerative colitis: correlation between histological findings and biochemical parameters. J. Clin. Pathol. 47: 1019-1021 (1994). *

• Mayo MJ. Patients and patience: the pitfalls of primary biliary cirrhosis trials. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 552-553 (2005). *

• Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg W. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 48: 1549-1557 (2008). *

• McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I. Mechanisms of non-alcoholic steatohepatitis. Alcohol 34: 67-79 (2004). *

• McConnachie L, Bodor M, Kowdley K, Levy A, Tung B, Thummel K, Phillips B, Bajpai M, Chi V, Esmay JD, Shen DD, Ho RJ. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate. Clin. Pharmacol. Ther. 75: 282-297 (2004). *

• McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J. Hepatol. 21: 496-499 (1994).

• McDonald PJ, Stehman FB, Stewart DR. Infantile obstructive cholangiopathy. Am. J. Dis. Child. 133: 518-522 (1979).

• McIntyre N. Sheila: Professor Dame Sheila Sherlock (1918-2001). Hepatology 35: 507-509 (2002). *

• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 49: S45-S55 (2009).

• McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am. J. Gastroenterol. 93: 777-784 (1998). *

• McPherson S, Jonsson JR, Cowin GJ, O'Rourke P, Clouston AD, Volp A, Horsfall L, Jothimani D, Fawcett J, Galloway GJ, Benson M, Powell EE. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J. Hepatol. 51: 389-397 (2009).

• Meagher S, Yusoff I, Kennedy W, Martel M, Adam V, Barkun A. The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. Endoscopy 39: 222-228 (2007).

• Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Lopez-Cabrera M, Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J. Hepatol. 42: 124-131 (2005). *

• Medina JF, Martinez-Anso, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25: 12-17 (1997). *

• Mehrany K, Drage LA, Brandhagen DJ, Pittelkow MR. Association of porphyria cutanea tarda with hereditary hemochromatosis. J. Am. Acad. Dermatol. 51: 205-211 (2004).

• Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J. Hepatol. 50: 36-41 (2009). *

• Melegh B, Skuta G, Pajor L, Hegedus G, Sumegi B. Autoantibodies against subunits of pyruvate dehydrogenase and citrate synthase in a case of paediatric biliary cirrhosis. Gut 42: 753-756 (1998). *

• Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl. 15: 931-938 (2009).

• Mendez-Sanchez N, Almeda-Valdes P, Uribe M. Alcoholic liver disease. An update. Ann. Hepatol. 4: 32-42 (2005).

• Mendez-Sanchez N, Motola-Kuba D, Bahena-Aponte J, Chavez-Tapia N, Pichardo-Bahena R, Uribe M. Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. Ann. Hepatol. 2: 183-185 (2003). *

• Mendez-Sanchez N, Uribe M. Infectious mononucleosis hepatitis: a case-report. Ann. Hepatol. 3: 75-76 (2004). *

• Mennesson N, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec JY, Pilleul F. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. J. Comput. Assist. Tomogr. 33: 672-677 (2009).

• Menten R, Leonard A, Clapuyt P, Vincke P, Nicolae AC, Lebecque P. Transient elastography in patients with cystic fibrosis. Pediatr. Radiol. Feb 5 [Epub ahead of print] (2010). *

• Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44: 874-880 (2006). *

• Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 348: 1399-1402 (1996). *

• Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61 (2008). *

• Michalska Z, Stalke P, Witczak-Malinowska K, Lakomy EA, Sikorska K, Radowska D, Stolarczyk J, Trocha H. Autoimmune reactions in HBV and HCV. Med. Sci. Monit. 7 Suppl. 1: 175-180 (2001).

• Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, Friedman SL, Narla G, Bugianesi E, Day CP, Reeves HL. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135: 282-291.e1 (2008). *

• Mieli-Vergani G, Vergani D. Autoimmune liver disease - therapeutic aspects in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 89-91 (2004). *

• Mieli-Vergani G, Vergani D. Liver transplantation in metabolic liver diseases. J. Gastroenterol. Hepatol. 19: S396-S397 (2004). *

• Mieli-Vergani G, Vergani D. Approach to a child with chronic liver disease. J. Gastroenterol. Hepatol. 19: S377-S378 (2004). *

• Mikata R, Yokosuka O, Imazeki F, Fukai K, Kanda T, Saisho H. Prolonged acute hepatitis A mimicking autoimmune hepatitis. World J. Gastroenterol. 11: 3791-3793 (2005). *

• Miles L, Heubi JE, Bove KE. Hepatocyte glycogen accumulation in patients undergoing dietary management of urea cycle defects mimics storage disease. J. Pediatr. Gastroenterol. Nutr. 40: 471-476 (2005). *

• Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur. J. Gastroenterol. Hepatol. 17: 445-447 (2005).

• Milman N, Koefoed P, Pedersen P, Nielsen FC, Eiberg H. Frequency of the HFE C282Y and H63D mutations in Danish patients with clinical haemochromatosis initially diagnosed by phenotypic methods. Eur. J. Haematol. 71: 403-407 (2003). *

• Min JK, Han NI, Kim JA, Lee YS, Cho CS, Kim HY. A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjogren's syndrome. J. Korean Med. Sci. 16: 512-515 (2001). *

• Mindikoglu AL, Anantharaju A, Hartman GG, Li SD, Villanueva J, Van Thiel DH. Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepatogastroenterology 50: 1338-1340 (2003).

• Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, De Vera ME, Gruttadauria S, Miraglia R, Pipitone L, Marsh JW, Marcos A, Gridelli B, Demetris AJ. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests? J. Hepatol. 50: 501-510 (2009).

• Minuk GY, Bohme CE, Burgess E, Hershfield NB, Kelly JK, Shaffer EA, Sutherland LR, Van Rosendaal G. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology 95: 1356-1363 (1988).

• Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 5: 8-13 (1987).

• Mirza R, Abbas Z, Luck NH, Azam SM, Aziz S, Hassan SM, Soomro GB. Progressive familial intrahepatic cholestasis. J. Coll. Physicians Surg. Pak. 16: 673-675 (2006).

• Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121: 900-907 (2001). *

• Mitsui F, Aikata H, Azakami T, Katamura Y, Kimura T, Kawaoka T, Saneto H, Takaki S, Hiraga N, Tsuge M, Waki K, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Arihiro K, Chayama K. The first Japanese case of COACH syndrome. Hepatol. Res. 39: 318-323 (2009).

• Miura F, Asano T, Amano H, Yoshida M, Toyota N, Wada K, Kato K, Takada T, Fukushima J, Kondo F, Takikawa H. Resected case of eosinophilic cholangiopathy presenting with secondary sclerosing cholangitis. World J. Gastroenterol. 15: 1394-1397 (2009). *

• Miura H, Kitamura S, Yamada H. A variant form of autoimmune pancreatitis successfully treated by steroid therapy, accompanied by von Meyenburg complex. World J. Gastroenterol. 15: 622-627 (2009). *

• Miyaguchi S, Oda M, Saito H, Ishii H. Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy. Hepatogastroenterology 45: 1457-1461 (1998).

• Miyake Y, Iwasaki Y, Takaki A, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K, Shiratori Y. Human leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitis. Hepatol. Res. 38: 96-102 (2008). *

• Miyake Y, Sakaguchi K, Tanaka H, Nakamura S, Kobayashi Y, Fujioka S, Iwasaki Y, Shiratori Y. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern. Med. 44: 949-953 (2005). *

• Mjahed K, Sadraoui A, Salmi S, Laraki M, Benaguida M. Fatal hepatitis in a young child: probable role of halothane. Ann. Fr. Anesth. Reanim. 16: 531-533 (1997).

• Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 51: 201-209 (2010). *

• Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stuhler K. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 49: 1257-1266 (2009).

• Moller JM, Santoni-Rugiu E, Chabanova E, Logager V, Hansen AB, Thomsen HS. Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis. Acta Radiol. 48: 145-149 (2007).

• Monajemzadeh M, Tabriz HM, Mahjoub F, Fallahi G, Farahmand F. Liver needle biopsy in Iraninan pediatric patients: diagnostic significance and pattern of liver diseases. Indian J. Pathol. Microbiol. 52: 10-13 (2009). *

• Montalto M, Santoro L, Vastola M, Curigliano V, Ricci R, Vecchio FM, Manna R, Gasbarrini G. Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment. Int. J. Immunopathol. Pharmacol. 18: 603-608 (2005).

• Monti V, Aghemo A, Rumi MG, Donato MF, Del Ninno E, Colombo M. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir. Ther. 10: 715-720 (2005).

• Moore L, Xu X, Davidson G, Moore D, Carli M, Ferrante A. Autoimmune enteropathy with anti-goblet cell antibodies. Hum. Pathol. 26: 1162-1168 (1995).

• Mor-Cohen R, Zivelin A, Rosenberg N, Goldberg I, Seligsohn U. A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients. Hepatol. Res. 31: 104-111 (2005).

• Moraru E, Cuvinciuc O, Antonesei L, Mihaila D, Bozomitu L, Rusu T, Stana B, Sacaci P, Luchian A, Bratu L, Popescu A, Mircan O, Moraru D. Glycogen storage disease type I - between chronic ambulatory follow-up and pediatric emergency. J. Gastrointestin. Liver Dis. 16: 47-51 (2007). *

• Moreno Borque A, Gonzalez Moreno L, Mendoza-Jimenez J, Garcia-Buey L, Moreno Otero R. Utilty of analitical parameters in the diagnosis of liver disease. An. Med. Interna 24: 38-46 (2007).

• Morita Y, Ueno T, Sasaki N, Tateishi Y, Nagata E, Kage M, Sata M. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 52: 1338-1343 (2005).

• Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann. Intern. Med. 138: 627-633 (2003). *

• Moschos J, Leontiadis GI, Kelly C, Henry J, Kadis S. Idiopathic portal hypertension complicating systemic sclerosis: a case report. BMC Gastroenterol. 5: 16 (2005). *

• Motamed F, Aghamohammadi A, Soltani M, Mansouri M, Rezaei N, Teimourian S, Pouladi N, Abdollahzadeh S, Parvaneh N. Evaluation of liver diseases in Iranian patients with primary antibody deficiencies. Ann. Hepatol. 8: 196-202 (2009).

• Mottu A, Rubbia-Brandt L, Bihl F, Hadengue A, Spahr L. Acute hepatitis due to brivudin: a case report. J. Hepatol. 51: 967-969 (2009).

• Mouelhi L, Chaieb M, Sfar I, Debbeche R, Trabelsi S, Gorgi Y, Najjar T. Chronic viral C hepatitis associated with primary biliary cirrhosis. Report of two cases. Rev. Med. Interne. 30: 537-539 (2009).

• Mueller S, Boehme MW, Hofmann WJ, Stremmel W. Extrapulmonary sarcoidosis primarily diagnosed in the liver. Scand. J. Gastroenterol. 35: 1003-1008 (2000). *

• Mueller T, Bianchi L, Menges M. Autoimmune hepatitis 2 years after the diagnosis of primary sclerosing cholangitis: an unusual overlap syndrome in a 17-year-old adolescent. Eur. J. Gastroenterol. Hepatol. 20: 232-236 (2008).

• Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J. Cyst. Fibros. 7: 215-221 (2008).

• Muir AJ, Trotter JF. A survey of current liver biopsy practice patterns. J. Clin. Gastroenterol. 35: 86-88 (2002).

• Muller KE, Muller K, Dezsofi A, Kis E, Mattyus I, Veres G, Arato A, Szonyi L. Vena portae obstruction as a cause of portal hypertension in a child with Turner syndrome. Orv. Hetil. 149: 1079-1084 (2008).

• Munoz LE, Thomas HC, Scheuer PJ, Doniach D, Sherlock S. Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut 22: 136-140 (1981). *

• Murphy JR, Sjogren MH, Kikendall JW, Peura DA, Goodman Z. Small bile duct abnormalities in sarcoidosis. J. Clin. Gastroenterol. 12: 555-561 (1990).

• Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann. Hepatol. 8 Suppl. 1: S25-S33 (2009). *

• Nadalin S, Malago M, Valentin-Gamazo C, Testa G, Baba HA, Liu C, Fruhauf NR, Schaffer R, Gerken G, Frilling A, Broelsch CE. Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl. 11: 980-986 (2005). *

• Nagafuchi Y, Hobbs KE, Thomas HC, Scheuer PJ. Expression of beta-2-microglobulin on hepatocytes after liver transplantation. Lancet 1: 551-554 (1985).

• Nagai H, Matsumaru K, Shiozawa K, Momiyama K, Wakui N, Shinohara M, Watanabe M, Ishii K, Nonaka H, Hasegawa A, Teramoto T, Yamamuro W, Sumino Y, Miki K. Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation. J. Gastroenterol. 40: 848-853 (2005). *

• Nagai T, Imamura M, Kamiya Y, Mori M. Graves' disease accompanied by anti-myeloperoxidase antibody-related nephropathy and autoimmune hepatitis. Intern. Med. 43: 516-520 (2004). *

• Nagami S, Konisi T, Kataoka H, Kikui S, Takayanagi T, Suzumura A. A case with HTLV-I associated myelopathy (HAM) accompanied by primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH). Rinsho Shinkeigaku 39: 1132-1134 (1999).

• Nagasaka H, Miida T, Hirano KI, Ota A, Murayama K, Yorifuji T, Kobayashi K, Takatani T, Tsukahara H, Hui SP, Takayanagi M, Chiba H. Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome. Atherosclerosis 198: 434-440 (2008).

• Nair V, Fischer SE, Adeyi OA. Non-viral-related pathologic findings in liver needle biopsy specimens from patients with chronic viral hepatitis. Am. J. Clin. Pathol. 133: 127-132 (2010). *

• Nakajima S, Umebayashi H, Kurosawa R, Imagawa T, Katakura S, Mori M, Aihara Y, Yokota S, Sogo T, Inui A, Fujisawa T, Hanzawa N. A case of autoimmune hepatitis needed to be differentiated from EBV hepatitis, in that the histology of liver biopsy specimen was useful for diagnosis. Nihon Rinsho Meneki Gakkai Kaishi 28: 154-158 (2005).

• Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45: 118-127 (2007). *

• Nakamura T, Higashi SI, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjogren's syndrome and thyroid dysfunction. Clin. Rheumatol. 26: 596-600 (2007). *

• Nakanuma Y, Kouda W, Harada K, Hiramatsu K. Hepatic sarcoidosis with vanishing bile duct syndrome, cirrhosis, and portal phlebosclerosis. Report of an autopsy case. J. Clin. Gastroenterol. 32: 181-184 (2001).

• Nakanuma Y, Ohta G. Quantitation of hepatic granulomas and epithelioid cells in primary biliary cirrhosis. Hepatology 3: 423-427 (1983).

• Nakanuma Y, Zen Y. Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatol. Res. 37 Suppl. 3: S478-S486 (2007). *

• Nakayama S, Mukae H, Morisaki T, Sakamoto N, Ohba K, Abe K, Takeshima F, Mizuta Y, Ida H, Ozono Y, Kohno S. Sarcoidosis accompanied by systemic lupus erythematosus and autoimmune hepatitis. Intern. Med. 46: 1657-1661 (2007). *

• Nakazawa T, Ohara H, Sano H, Ando T, Aoki S, Kobayashi S, Okamoto T, Nomura T, Joh T, Itoh M. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 30: 20-25 (2005).

• Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocr. Pract. 9: 307-309 (2003).

• Nanda K. Non-alcoholic steatohepatitis in children. Pediatr. Transplant. 8: 613-618 (2004). *

• Narbutt J, Lesiak A, Kwiecien A, Sysa-Jedrzejowska A, Kuydowicz J. Scleroderma-like lesions in the course of autoimmune hepatitis. Case report. Przegl. Lek. 62: 314-316 (2005).

• Narumoto J. Studies on circulating soluble immune complexes of the liver disease. 7. Immune complexes in the clinical course and their ultracentrifugal analysis. Gastroenterol. Jpn. 16: 186-192 (1981).

• Navasa M, Pares A, Bruguera M, Caballeria J, Bosch J, Rodes J. Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J. Hepatol. 5: 292-298 (1987).

• Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prevot S, Ngo Y, Munteanu M, Balian A, Njike-Nakseu M, Perlemuter G, Poynard T. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49: 97-105 (2009).

• Naveh Y, Mendelsohn H, Spira G, Auslaender L, Mandel H, Berant M. Primary sclerosing cholangitis associated with immunodeficiency. Am. J. Dis. Child. 137: 114-117 (1983).

• Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46: 2347-2352 (2001). *

• Neo SY, Leow CK, Vega VB, Long PM, Islam AFM, Lai PBS, Liu ET, Ren EC. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 39: 944-953 (2004). *

• Neuberger J, Wallace L, Joplin R, Hubscher S. Hepatic distribution of E2 component of pyruvate dehydrogenase complex after transplantation. Hepatology 22: 798-801 (1995).

• Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. Can. J. Gastroenterol. 14: 321-326 (2000). *

• Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr. Gastroenterol. Rep. 4: 31-36 (2002).

• Neuschwander-Tetri BA. Nonalcoholic steatohepatitis. Clin. Liver Dis. 2: 149-173 (1998).

• Neuschwander-Tetri BA. Fatty liver and nonalcoholic steatohepatitis. Clin. Cornerstone 3: 47-57 (2001).

• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-10017 (2003). *

• Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Intern. Med. 129: 38-41 (1998).

• Newton JL, Jones DE, Metcalf JV, Park JB, Burt AD, Bassendine MF, James OF. Presentation and mortality of primary biliary cirrhosis in older patients. Age Ageing 29: 305-309 (2000). *

• Ng SS, Yu SC, Lai PB, Lau WY. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. Dig. Dis. Sci. 53: 2813-2817 (2008). *

• Nicolas I, Pons JA, Vargas A, Gallardo F, Albaladejo A, Nicolas JM. Ursodeoxycholic acid treatment shortens the course of cholestasis in two patients with benign recurrent intrahepatic cholestasis. Gastroenterol. Hepatol. 26: 421-423 (2003).

• Niederau C, Lange S, Fruhauf M, Thiel A. Cutaneous signs of liver disease: value for prognosis of severe fibrosis and cirrhosis. Liver Int. 28: 659-666 (2008). *

• Nieminen U, Koivisto T, Kahri A, Farkkila M. Sjogren's syndrome with chronic pancreatitis, sclerosing cholangitis, and pulmonary infiltrations. Am. J. Gastroenterol. 92: 139-142 (1997).

• Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 29: 1396-1398 (1999). *

• Nikolaidis NL, Giouleme OI, Tziomalos KA, Patsiaoura K, Kazantzidou E, Voutsas AD, Vassiliadis T, Eugenidis NP. Small-duct primary sclerosing cholangitis. A single-center seven-year experience. Dig. Dis. Sci. 50: 324-326 (2005). *

• Nikolovska D, Vasilev P, Mikhova A. Treatment of primary biliary cirrhosis with ursodeoxycholic acid. Vutr. Boles. 32: 25-27 (2000).

• Nisa AU, Ahmad Z. Dubin-Johnson syndrome. J. Coll. Physicians Surg. Pak. 18: 188-189 (2008).

• Nishiki M, Murakami Y, Koshimura K, Sohmiya M, Tanaka J, Yabe S, Kobayashi I, Kato Y. A case of autoimmune hypophysitis associated with asymptomatic primary biliary cirrhosis. Endocr. J. 45: 697-700 (1998).

• Nishino T, Oyama H, Hashimoto E, Toki F, Oi I, Kobayashi M, Shiratori K. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J. Gastroenterol. 42: 550-559 (2007). *

• Nishio A, Keeffe EB, Gershwin ME. Immunopathogenesis of primary biliary cirrhosis. Semin. Liver Dis. 22: 291-302 (2002). *

• Nishio A, Keeffe EB, Gershwin ME. Primary biliary cirrhosis: lessons learned from an organ-specific disease. Clin. Exp. Med. 1: 165-178 (2001). *

• Noack KB, Osmon DR, Batts KP, Wilhelm M, Krom RA, Lindor KD. Successful orthotopic liver transplantation in a patient with refractory biliary candidiasis. Gastroenterology 101: 1728-1730 (1991).

• Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44: 458-465 (2006). *

• Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 48: 442-448 (2008). *

• Nolte W, Polzien F, Sattler B, Ramadori G, Hartmann H. Recurrent episodes of acute hepatitis associated with LKM-1 (cytochrome P450 2D6) antibodies in identical twin brothers. J. Hepatol. 23: 734-739 (1995). *

• Nunes AC, Amaro P, Mac as F, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur. J. Gastroenterol. Hepatol. 13: 279-282 (2001).

• Nunez L, Amigo L, Mingrone G, Rigotti A, Puglielli L, Raddatz A, Pimentel F, Greco AV, Gonzalez S, Garrido J, et al. Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis. Gut 37: 422-426 (1995). *

• Nuttall KL, Palaty J, Lockitch G. Reference limits for copper and iron in liver biopsies. Ann. Clin. Lab. Sci. 33: 443-450 (2003).

• Nwomeh BC, Caniano DA, Hogan M. Definitive exclusion of biliary atresia in infants with cholestatic jaundice: the role of percutaneous cholecysto-cholangiography. Pediatr. Surg. Int. 23: 845-849 (2007). *

• Nyberg A, Engstrom-Laurent A, Loof L. Serum hyaluronate in primary biliary cirrhosis- a biochemical marker for progressive liver damage. Hepatology 8: 142-146 (1988).

• Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int. 27: 694-699 (2007). *

• O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14: 838-847 (1991).

• O'Donohue J, Fidler H, Garcia-Barcelo M, Nouri-Aria K, Williams R, McFadden J. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J. Hepatol. 28: 433-438 (1998). *

• O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47: 717-720 (2000). *

• Ocel JJ, Edwards WD, Tazelaar HD, Petrovic LM, Edwards BS, Kamath PS. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation. Mayo Clin. Proc. 79: 492-501 (2004). *

• Ochiai H, Sekine H, Ohira H, Kuroda M, Miyata M, Obara K, Nishimaki T, Kasukawa R. Analysis of peripheral blood mononuclear cell stimulated with pyruvate dehydrogenase complex, T-cell receptors from patients with primary biliary cirrhosis. J. Gastroenterol. 33: 694-701 (1998).

• Ohge H, Takesue Y, Yokoyama T, Hiyama E, Murakami Y, Imamura Y, Shimamoto F, Matsuura Y. Progression of primary biliary cirrhosis after proctocolectomy for ulcerative colitis. J. Gastroenterol. 35: 870-872 (2000). *

• Ohira H, Takiguchi J, Rai T, Shishido S, Sato Y. Two cases of primary biliary cirrhosis complicated with syringomyelia. Am. J. Gastroenterol. 98: 224-226 (2003). *

• Oikawa T, Takahashi H, Ishikawa T, Hokari A, Otsuki N, Azuma M, Zeniya M, Tajiri H. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol. Int. 57: 485-492 (2007). *

• Okada T, Sasaki F, Kurauchi N, Kubota M, Itoh T, Honda S, Naito S, Todo S. Laparoscopic liver biopsy using cup-shaped punch biopsy forceps and argon beam coagulator in children. Pediatr. Surg. Int. 23: 947-951 (2007). *

• Oki K, Yamane K, Koide J, Mandai K, Nakanishi S, Fujikawa R, Kohno N. A case of polyglandular autoimmune syndrome type III complicated with autoimmune hepatitis. Endocr. J. 53: 705-709 (2006). *

• Okolicsanyi L, Fabris L. Diagnostic approach to primary sclerosing cholangitis: open questions. Ital. J. Gastroenterol. 23: 436-441 (1991).

• Okuno T, Seto Y, Okanoue T, Takino T. Chronic active hepatitis with histological features of primary biliary cirrhosis. Dig. Dis. Sci. 32: 775-779 (1987).

• Olsson R. Small duct primary sclerosing cholangitis: a separate disease? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 62. October 15-16 (2003). *

• Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, Prytz H, Ryden BO, Wallerstedt S. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 108: 1199-1203 (1995). *

• Olsson R, Glaumann H, Almer S, Broome U, Lebrun B, Bergquist A, Bjornsson E, Prytz H, Danielsson A, Lindgren S. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur. J. Intern. Med. 20: 190-196 (2009).

• Olsson R, Hagerstrand I, Broome U, Danielsson A, Jarnerot G, Loof L, Prytz H, Ryden BO, Wallerstedt S. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J. Clin. Pathol. 48: 933-935 (1995). *

• Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am. J. Gastroenterol. 100: 837-841 (2005). *

• Ong JC, O'Loughlin EV, Kamath KR, Dorney SF, de Silva M, Gaskin KJ. Sclerosing cholangitis in children with inflammatory bowel disease. Aust. N. Z. J. Med. 24: 149-153 (1994).

• Ong SL, Garcea G, Puls F, Richards C, Mulcahy K, Grant A, Dennison AR, Berry DP. IgG4-positive sclerosing cholangitis following autoimmune pancreatitis with deranged CA19.9. Int. J. Surg. Pathol. Jul 8 [Epub ahead of print] (2008). *

• Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J. Rheumatol. 31: 107-109 (2004).

• Ono M, Sekiya C, Ohhira M, Ohhira M, Namiki M, Endo Y, Suzuki K, Matsuda Y, Taniguchi N. Elevated level of serum Mn-superoxide dismutase in patients with primary biliary cirrhosis: possible involvement of free radicals in the pathogenesis in primary biliary cirrhosis. J. Lab. Clin. Med. 118: 476-483 (1991).

• Orellana NI, Valera MJM, Nei LC, Poniachik TJ, Berger FZ, Latorre MR, Smok SG, Brahm BJ. Primary sclerosing cholangitis: a twelve-year experience. Rev. Med. Chil. 133: 776-780 (2005). *

• Orlando R, Lirussi F. Are liver cirrhosis and portal hypertension associated with an increased risk of bleeding during laparoscopy? A retrospective analysis of 1,000 consecutive cases. Surg. Laparosc. Endosc. Percutan. Tech. 10: 208-210 (2000).

• Orlowski M, Stalke P, Michalska Z, Sikorska K, Witczak-Malinowska K, Eilert-Zygadlowska J, Stolarczyk J. Assessment of correlation between histopathologic changes of gastric mucosa according to Whitehead's classification and extent of liver damage according to Knodell's scale in patients with chronic hepatopathy. Med. Sci. Monit. 9 Suppl. 3: 60-63 (2003).

• Oruc N, Lamb J, Whitcomb DJ, Sass DA. The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC. Turk. J. Gastroenterol. 19: 250-253 (2008). *

• Oruc N, Ozutemiz O, Berdeli A, Ersoz G, Gunsar F, Karasu Z, Ilter T, Batur Y, Akarca US. Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease. Ann. Hepatol. 8: 116-119 (2009). *

• Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, Penner E, Schuppan D, Ferenci P. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 31: 142-148 (2005).

• Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, Penner E, Schuppan D, Ferenci P. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J. Hepatol. 42: 914-919 (2005). *

• Pagadala M, Zein CO, McCullough AJ. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin. Liver Dis. 13: 591-606 (2009).

• Pagnoux C, Hayem G, Roux F, Palazzo E, Meyer O. Sclerosing cholangitis as a complication of Langerhans' cell histiocytosis. Rev. Med. Interne. 24: 324-327 (2003).

• Paine P, Hobday C, Keating JJ, Brown CM, Morris JA. Ulcerative pan-colitis and primary sclerosing cholangitis with hyposplenism complicated by fatal pneumococcal meningitis. CME Gastroenterology 4: 95-96 (2001). *

• Panes J, Bordas JM, Bruguera M, Cortes M, Rodes J. Localized sclerosing cholangitis? Endoscopy 17: 121-122 (1985).

• Papachristou GI, Demetris AJ, Craig F, Lee KKW, Rabinovitz M. Cholestatic jaundice and bone lesions in an elderly woman. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 53-57 (2004). *

• Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, Andrioti E, Theodossiades G, Archimandritis AJ. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J. Hepatol. 51: 931-938 (2009).

• Papatheodoridis GV, Manolakopoulos S. EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J. Hepatol. 51: 226-227 (2009).

• Paradis V. Glycomics: a new taste of cirrhosis marker. J. Hepatol. 43: 913-914 (2005). *

• Parana R, Codes L, Andrade Z, Freitas LA, Santos-Jesus R, Reis M, Cotrim H, Cunha S, Trepo C. Clinical, histologic and serologic evaluation of patients with acute non-A-E hepatitis in north-eastern Brazil: is it an infectious disease? Int. J. Infect. Dis. 7: 222-230 (2003).

• Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann. Pharmacother. 41: 880-884 (2007).

• Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, Berenguer J, Rodriguez-Martinez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J. Hepatol. 32: 561-566 (2000). *

• Park BC, Park SM, Choi EY, Chae HB, Yoon SJ, Sung R, Lee SK. A case of idiopathic adulthood ductopenia. Korean J. Intern. Med. 24: 270-273 (2009).

• Park HJ, Choi YJ, Kim JE, Ye YM, Park HS, Suh CH. Successful treatment of pediatric systemic polyarteritis nodosa with cholestatic hepatitis. Clin. Rheumatol. 26: 122-124 (2007). *

• Park SH, Kim DJ, Lee HY. Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection. Am. J. Gastroenterol. 104: 1135-1139 (2009). *

• Park YW, Woo H, Jeong YY, Lee JH, Park JJ, Lee SS. Association of nodular regenerative hyperplasia of the liver with porto-pulmonary hypertension in a patient with systemic lupus erythematosus. Lupus 15: 686-688 (2006).

• Parlak E, Cicek B, Disibeyaz S, Koksal AS, Sahin B. An endoscopic finding in patients with primary sclerosing cholangitis: retraction of the main duodenal papilla into the duodenum wall. Gastrointest. Endosc. 65: 532-536 (2007).

• Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B. Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey. J. Clin. Gastroenterol. 33: 299-301 (2001).

• Pasha T, Gabriel S, Therneau T, Dickson ER, Lindor KD. Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology 27: 1220-1226 (1998). *

• Pasha TM, Lindor KD. Diagnosis and therapy of cholestatic liver disease. Med. Clin. North Am. 80: 995-1019 (1996).

• Patel KJ, Latif SU, Calaca WD. An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report. J. Hematol. Oncol. 2: 12 (2009).

• Patton H, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135: 1961-1971.e2 (2008). *

• Paukov VS, Ermakova OM, Kostornaia IV. Hepatopathies in concomitance of chronic drug and alcoholic intoxications. Arkh. Patol. 70: 25-29 (2008).

• Pazo M, Abdulkader I, Otero-Anton E, Tome S, Villamil I, Gonzalez-Quintela A. Liver abnormalities in adult celiac disease. Clinicopathologic characterization and outcome after therapy. Gastroenterol. Hepatol. 29: 383-390 (2006).

• Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology 102: 1389-1391 (1992).

• Perez-Aguilar F, Benlloch S, Berenguer M. Study of patients referred for elevated ferritin levels and/or transferrin saturation: significance of non-alcoholic fatty liver disease. Gastroenterol. Hepatol. 27: 508-514 (2004).

• Perkins JD. Treatment of small-for-size syndrome. Liver Transpl. 14: 571-575 (2008). *

• Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, Liang TJ, Hoofnagle JH, Ghany MG. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 43: 780-787 (2006). *

• Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int. Jan 7 [Epub ahead of print] (2010). *

• Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl. Acad. Sci. U.S.A. 104: 5079-5084 (2007). *

• Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, Stremmel W, Andreone P, Garuti C. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 128: 470-479 (2005). *

• Pincon JA, Chatelain P, Mallet-Guy Y, Bouvier R, de Parscau L, Francois R. Byler's disease. Ultrastructural study. Apropos of a case in an infant. Pediatrie. 39: 279-288 (1984).

• Pinzani M. Non-invasive evaluation of hepatic fibrosis: don’t count your chickens before they’re hatched. Gut 55: 310-312 (2006). *

• Pippert H, Gross-Fengels W, Siemens P, Kruse T. A rare constellation of findings: bile duct cancer, ulcerative colitis, deep venous thrombosis of the leg. Aktuelle. Radiol. 1: 259-261 (1991).

• Pischke S, Ehmer U, Schedel I, Gratz WF, Wedemeyer H, Ziesing S, Bange FC, Burchard GD, Manns MP, Bahr MJ, Strassburg CP. Of guinea pigs and men - an unusual case of jaundice. Z. Gastroenterol. 48: 33-37 (2010).

• Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, Hayes PC. Serum hyaluronan - a non-invasive test for diagnosing liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 12: 1121-1127 (2000).

• Plodziszewska M, Slodkowska J, Orlowski T, Pawlicka L, Rowinska-Zakrzewska E. Primary biliary cirrhosis with sarcoid-like infiltrations in the lung. Pneumonol. Alergol. Pol. 66: 330-336 (1998).

• Poddar U, Bhattacharya A, Thapa BR, Mittal BR, Singh K. Ursodeoxycholic acid-augmented hepatobiliary scintigraphy in the evaluation of neonatal jaundice. J. Nucl. Med. 45: 1488-1492 (2004). *

• Poddar U, Thapa BR, Das A, Bhattacharya A, Rao KN, Singh K. Neonatal cholestasis: differentiation of biliary atresia from neonatal hepatitis in a developing country. Acta Paediatr. 98: 1260-1264 (2009).

• Pohl JF. Mauriac syndrome in a child with a positive antinuclear antibody screen. Gastroenterol. Res. Pract. 2009: 765318 (2009).

• Pometta R, Callea F, Mangano M, Zuccoli E, Conte D. Recurrent cholestasis and hypereosinophilia in a young female. Dig. Liver Dis. 32: 630-633 (2000).

• Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest. Endosc. 43: 568-571 (1996).

• Poo JL, Sanchez Avila F, Kershenobich D, Garcia Samper X, Torress-Ibarra R, Gongora J, Cano C, Parada M, Uribe M. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. Ann. Hepatol. 7: 369-375 (2008).

• Popov MS, Rutkovskii OV. Primary biliary liver cirrhosis with a granulomatous reaction. Arkh. Patol. 44: 60-63 (1982).

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Portmann B. Biliary pathology. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 47-48. October 17 - 19 (2003). *

• Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 88: 1777-1790 (1985).

• Portmann BC. Primary biliary cirrhosis and sclerosing cholangitis. Current Diagnostic Pathology 8: 133-143 (2002). *

• Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? J. Pediatr. Gastroenterol. Nutr. 25: 32-36 (1997). *

• Poupon R, Chazouilleres O, Balkau B, Poupon RE. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J. Hepatol. 30: 408-412 (1999). *

• Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 44: 85-90 (2006). *

• Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology 24: 1098-1103 (1996). *

• Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, Fletcher LM, Powell LW, Jonsson JR. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 129: 1937-1943 (2005). *

• Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, Subramaniam VN, Hewett DG, Searle JW, Fletcher LM, Crawford DH, Rodgers H, Allen KJ, Cavanaugh JA, Bassett ML. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Intern. Med. 166: 294-301 (2006). *

• Poynard T, Benhamou Y, Thabut D, Ratziu V. Liver biopsy: the best standard...when everything else fails. J. Hepatol. 50: 1267-1268 (2009).

• Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 128: 1146-1148 (2005). *

• Prall RT, Lindor KD, Wiesner RH, LaRusso NF. Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103 (2000).

• Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 105: 572-578 (1993).

• Puius YA, Dove LM, Brust DG, Shah DP, Lefkowitch JH. Three cases of autoimmune hepatitis in HIV-infected patients. J. Clin. Gastroenterol. 42: 425-429 (2008).

• Puoti L, Bellis L, Guarisco R. Liver biopsy in hepatitis C virus carriers with normal alanine aminotransferase levels. Hepatology 50: 655 (2009).

• Quail MA, Russell RK, Bellamy C, Mieli-Vergani G, Gillett PM. Seronegative autoimmune hepatitis presenting after diagnosis of coeliac disease: a case report. Eur. J. Gastroenterol. Hepatol. 21: 576-579 (2009).

• Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig. Dis. Sci. 37: 1606-1611 (1992).

• Rahhal FE, Schade RR, Nayak A, Coleman TA. Hepatic failure caused by plasma cell infiltration in multiple myeloma. World J. Gastroenterol. 15: 2038-2040 (2009). *

• Rai T, Ohira H, Fukaya E, Abe K, Yokokawa J, Takiguchi J, Shishido S, Sato Y. A case of merged idiopathic portal hypertension in course of mixed connective tissue disease. Hepatol. Res. 30: 51-55 (2004).

• Raiford DS. Pruritus of chronic cholestasis. QJM 88: 603-607 (1995).

• Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28: 491-513 (1999).

• Rajeshwari K, Gogia S. The clinical spectrum of chronic liver disease in children presenting to a tertiary level teaching hospital in New Delhi. Trop. Doct. 38: 101-102 (2008).

• Ramakrishna B, Eapen CE, Kang G, Kurian G, Chandy GM. Familial intrahepatic cholestatic cirrhosis with positive antimitochondrial antibody: familial primary biliary cirrhosis. J. Clin. Gastroenterol. 30: 255-258 (2000).

• Ramos R, Mascarenhas J, Duarte P, Vicente C, Casteleiro C. Conjugated linoleic acid-induced toxic hepatitis: first case report. Dig. Dis. Sci. 54: 1141-1143 (2009). *

• Rasmussen HH, Fallingborg JF, Mortensen PB, Freund LG, Tage-Jensen U, Rasmussen SN. Primary sclerosing cholangitis. Ugeskr. Laeger. 153: 1487-1491 (1991).

• Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand. J. Gastroenterol. 32: 604-610 (1997).

• Rastogi A, Krishnani N, Yachha SK, Khanna V, Poddar U, Lal R. Histopathological features and accuracy for diagnosing biliary atresia by prelaparotomy liver biopsy in developing countries. J. Gastroenterol. Hepatol. 24: 97-102 (2009). *

• Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T; LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51: 445-453 (2010).

• Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906 (2005). *

• Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Pikkarainen P, Nuutinen H, Farkkila M. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41: 747-752 (2005). *

• Ray MB. Distribution patterns of cytokeratin antigen determinants in alcoholic and nonalcoholic liver diseases. Hum. Pathol. 18: 61-66 (1987).

• Reggiani A, Dizioli P, Quattrocchi D, Quinzani M, Marelli A, Bodini P. Intrahepatic cholestasis: clinical and nosological classification. Critical survey of personal experience. Minerva Gastroenterol. Dietol. 43: 71-81 (1997).

• Remacle JP, Pellissier JF, Chamlian A, Benkoel L, Aubert L, Monges H. Progressive ophthalmoplegia associated with asymptomatic primary biliary cirrhosis. Histologic, histochemical, cytochemical, and ultrastructural studies of muscle and liver biopsy specimens. Hum. Pathol. 11: S540-S548 (1980).

• Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin. Transplant. 21: 427-432 (2007).

• Riemann JF, Schmidt H, Flugel H. Early diagnosis of primary biliary cirrhosis. Dtsch. Med. Wochenschr. 106: 933-936 (1981).

• Rigamonti C, Vidali M, Donato MF, Sutti S, Occhino G, Ivaldi A, Arosio E, Agnelli F, Rossi G, Colombo M, Albano E. Serum autoantibodies against cytochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of recurrent hepatitis C. Am. J. Transplant. 9: 601-609 (2009).

• Rigato I, Cravatari M, Avellini C, Ponte E, Croce SL, Tiribelli C. Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 403-408 (2007). *

• Roberts EA. Nonalcoholic steatohepatitis in children. Curr. Gastroenterol. Rep. 5: 253-259 (2003).

• Roberts EA. Steatohepatitis in children. Best Pract. Res. Clin. Gastroenterol. 16: 749-765 (2002).

• Robles-Medranda C, Lukashok H, Biccas B, Pannain VL, Fogaca HS. Budd-Chiari like syndrome in decompensated alcoholic steatohepatitis and liver cirrhosis. World J. Gastroenterol. 12: 6564-6566 (2006). *

• Roche SP, Kobos R. Jaundice in the adult patient. Am. Fam. Physician 69: 299-304 (2004). *

• Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin. Liver Dis. 12: 939-962, xi (2008).

• Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 43: S113-S120 (2006). *

• Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 49: 1017-1044 (2009). *

• Rodriguez C, Carrion F, Marinovic MA, Chavez E, Preisler J, Pooley F, Futatani T, Ochs HD. X-linked hyper-IGM syndrome associated to sclerosing cholangitis and gallbladder neoplasm: clinical case. Rev. Med. Chil. 131: 303-308 (2003).

• Rodriguez HJ, Bass NM. Primary sclerosing cholangitis. Semin. Gastrointest. Dis. 14: 189-198 (2003).

• Rodriguez VE, Costas P. Systemic lupus erythematosus presenting as acute iceric hepatitis: a case report. Bol. Asoc. Med. P. R. 100: 54-57 (2008).

• Rodriguez-Hernandez H, Gonzalez JL, Marquez-Ramirez MD, Flores-Hernandez M, Rodriguez-Moran M, Guerrero-Romero F. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur. J. Gastroenterol. Hepatol. 20: 399-403 (2008).

• Rodriguez-Leal GA, Moran-Villota S, Arista-Nasr J, Uribe-Esquivel M. Case report of multiple myeloma and hypothyroidism in primary biliary cirrhosis. Rev. Invest. Clin. 49: 215-220 (1997).

• Roenigk HH Jr. Liver toxicity of retinoid therapy. J. Am. Acad. Dermatol. 19: 199-208 (1988).

• Rohrmann CA Jr, Ansel HJ, Ayoola EA, Silvis SE, Vennes JA. Endoscopic retrograde intrahepatic cholangiogram: radiographic findings in intrahepatic disease. AJR Am. J. Roentgenol. 128: 45-52 (1977). *

• Romanelli RG, La Villa G, Almerigogna F, Vizzutti F, Di Pietro E, Fedi V, Gentilini P, Laffi G. Uveitis in autoimmune hepatitis: a case report. World J. Gastroenterol. 12: 1637-1640 (2006). *

• Roquete ML, Ferreira AR, Fagundes ED, Castro LP, Silva RA, Penna FJ. Accuracy of echogenic periportal enlargement image in ultrasonographic exams and histopathology in differential diagnosis of biliary atresia. J. Pediatr. (Rio J.) 84: 331-336 (2008).

• Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713 (2004). *

• Rossi M, Vajro P, Iorio R, Battagliese A, Brunetti-Pierri N, Corso G, Di Rocco M, Ferrari P, Rivasi F, Vecchione R, Andria G, Parenti G. Characterization of liver involvement in defects of cholesterol biosynthesis: long-term follow-up and review. Am. J. Med. Genet. 132A: 144-151 (2005). *

• Rubin R, Munoz SJ, Moritz M. Rejection-independent cholangitis and cirrhosis following orthotopic liver transplantation. Hum. Pathol. 24: 996-1002 (1993).

• Rubio-Tapia A, Murray JA. Liver involvement in celiac disease. Minerva Med. 99: 595-604 (2008).

• Rubio-Tapia A, Murray JA. The liver in celiac disease. Hepatology 46: 1650-1658 (2007). *

• Rudic J, Jesic R, Culafic D, Sarenac-Kovac R, Bulat V, Cvejic T. Sepsis as a cause of intrahepatic cholestasis. Srp. Arh. Celok. Lek. 137: 278-281 (2009).

• Rumbo C, Shneider BL, Emre SH. Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. Pediatr. Transplant. 8: 571-575 (2004). *

• Rutgers HC, Stradley RP, Johnson SE. Serum bile acid analysis in dogs with experimentally induced cholestatic jaundice. Am. J. Vet. Res. 49: 317-320 (1988).

• Ryu RK, Durham JD, Krysl J, Shrestha R, Shrestha R, Everson GT, Stephens J, Kam I, Wachs M, Kumpe DA. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J. Vasc. Interv. Radiol. 10: 799-805 (1999).

• Saadoun D, Cazals-Hatem D, Denninger MH, Boudaoud L, Pham BN, Mallet V, Condat B, Briere J, Valla D. Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome. Gut 53: 1516-1519 (2004). *

• Sacher M, Paky F, Stogmann W, Thaler H. Transient hypoplasia of the intrahepatic bile ducts. Clinical and morphologic studies. Monatsschr. Kinderheilkd. 133: 840-842 (1985).

• Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J. Gastroenterol. 14: 331-337 (2008). *

• Said A, Einstein M, Lucey MR. Liver transplantation: an update 2007. Curr. Opin. Gastroenterol. 23: 292-298 (2007).

• Sakugawa H, Nakasone H, Nakayoshi T, Yamashiro T, Maeshiro T, Kobashigawa K, Kinjo F, Saito A, Zukeran H, Nakanuma Y, Ohba K. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan. Hepatol. Res. 26: 330-336 (2003).

• Salaspuro MP, Laitinen OI, Lehtola J, Makkonen H, Rasanen JA, Sipponen P. Immunological parameters, viral antibodies, and biochemical and histological findings in relatives of patients with chronic active hepatitis and primary biliary cirrhosis. Scand. J. Gastroenterol. 11: 313-320 (1976).

• Salaspuro MP, Sipponen P, Ikkala E, Kolho L, Makkonen HM, Miettinen TA, Rasanen JA, Siurala M. Clinical correlations and significance of orceinpositivity in chronic active hepatitis and primary biliary cirrhosis. Ann. Clin. Res. 8: 206-215 (1976).

• Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S, Beck-Peccoz P. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 14: 631-634 (2004).

• Sanchez-Pobre P, Castellano G, Colina F, Dominguez P, Rodriguez S, Canga F, Herruzo JA. Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis? J. Clin. Gastroenterol. 23: 191-198 (1996).

• Sanchez-Tapias J, Thomas HC, Sherlock S. Lymphocyte populations in liver biopsy specimens from patients with chronic liver disease. Gut 18: 472-475 (1977). *

• Sanghai SR, Shah I, Bhatnagar S, Murthy A. Incidence and prognostic factors associated with biliary atresia in Western India. Ann. Hepatol. 8: 120-122 (2009). *

• Sapey T, Mendler MH, Guyader D, Morio O, Corbinais S, Deugnier Y, Brissot P. Respective value of alkaline phosphatase, gamma-glutamyl transpeptidase and 5' nucleotidase serum activity in the diagnosis of cholestasis: a prospective study of 80 patients. J. Clin. Gastroenterol. 30: 259-263 (2000).

• Sapey T, Turlin B, Canva-Delcambre V, Mendler MH, Deugnier Y, Brissot P, Guyader D. Importance of liver puncture biopsy and endoscopic retrograde cholangiography in patients with chronic anicteric unexplained cholestasis. A retrospective study in 79 patients. Gastroenterol. Clin. Biol. 23: 178-185 (1999).

• Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, Cooper JN, Di Bisceglie A, Seneca R, Younossi ZM. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig. Dis. Sci. 49: 850-853 (2004). *

• Sarin SK, Monga R, Sandhu BS, Sharma BC, Sakhuja P, Malhotra V. Primary biliary cirrhosis in India. Hepatobiliary Pancreat. Dis. Int. 5: 105-109 (2006). *

• Sasajima T, Suzuki T, Mori K, Ichii O, Tai M, Ochiai H, Ejiri Y, Watanabe H, Ohira H, Obara K, Sato Y. A case of idiopathic portal hypertension associated with rheumatoid arthritis. Mod. Rheumatol. 16: 92-96 (2006). *

• Sasaki N, Ueno T, Morita Y, Nagata E, Sata M. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology 53: 678-681 (2006).

• Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 29: 409-416 (1998). *

• Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig. Dis. Sci. 50: 171-180 (2005). *

• Sato Y, Harada K, Sudo Y, Watanabe K, Nakahama T, Morimoto H, Nakanuma Y. Autoimmune hepatitis associated with bile duct injury resembling chronic non-suppurative destructive cholangitis. Pathol. Int. 52: 478-482 (2002). *

• Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. 53: 3218-3224 (2008). *

• Sazci A, Ergul E, Aygun C, Akpinar G, Senturk O, Hulagu S. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell. Biochem. Funct. 26: 291-296 (2008). *

• Scalone O, Bonaventure C, Pasquier D, Faucheron JL. Should liver biopsy be systematic during surgery for ulcerative colitis? Gastroenterol. Clin. Biol. 27: 94-99 (2003).

• Schaffner F. The history of liver disease at The Mount Sinai Hospital. Mt. Sinai J. Med. 67: 76-83 (2000). *

• Schattner A, Kozak N, Lassry Y, Sokolovskaya N. Primary intestinal T-cell lymphoma and sclerosing cholangitis: a cytokine-mediated association? J. Intern. Med. 244: 537-541 (1998). *

• Schedel J, Mayer S, Woenckhaus M, Kiss E, Scholmerich J, Rogler G. Autoimmune cholangitis with vasculitic ulcers, rheumatoid arthritis and IgA glomerulonephritis. Dtsch. Med. Wochenschr. 129: 2409-2412 (2004).

• Scheuer PJ. Liver biopsy in chronic hepatitis: 1968-78. Gut 19: 554-557 (1978). *

• Schiff ER. Cholestatic evaluation. Lab. Res. Methods Biol. Med. 7: 517-528 (1983).

• Schlichting P, Holund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand. J. Gastroenterol. 18: 27-32 (1983).

• Schnitzbauer AA, Tsui TY, Kirchner G, Scherer MN, Bein T, Schlitt HJ, Obed A. Liver transplantation for sclerosing cholangitis in a polytraumatized patient. Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 121-126 (2009).

• Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, Oneta CM. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife((R)) products. J. Hepatol. 47: 521-526 (2007). *

• Schoniger-Hekele M, Petermann D, Muller C. Mutation of keratin 8 in patients with liver disease. J. Gastroenterol. Hepatol. 21: 1466-1469 (2006). *

• Schott E, Witt H, Neumann K, Taube S, Oh DY, Schreier E, Vierich S, Puhl G, Bergk A, Halangk J, Weich V, Wiedenmann B, Berg T. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J. Hepatol. 47: 203-211 (2007). *

• Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann. Intern. Med. 131: 943-946 (1999). *

• Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30 (2006). *

• Schrumpf E, Fausa O, Kolmannskog F, Elgjo K, Ritland S, Gjone E. Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand. J. Gastroenterol. 17: 33-39 (1982).

• Schulte S, Oidtmann A, Kociok N, Demir M, Odenthal M, Drebber U, Dienes HP, Nierhoff D, Goeser T, Toex U, Steffen HM. Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis. Liver Int. 29: 384-391 (2009). *

• Schuppan D. Markers of progression. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 37. October 17 - 19 (2003). *

• Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104 (1999). *

• Schwarze C, Schmitz V, Fischer HP, Sauerbruch T, Spengler U. Vanishing bile duct syndrome associated with elevated pancreatic enzymes after short-term administration of amoxicillin. Eur. J. Gastroenterol. Hepatol. 14: 1275-1277 (2002).

• Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51: 433-445 (2009).

• Sebagh M, Farges O, Kalil A, Samuel D, Bismuth H, Reynes M. Sclerosing cholangitis following human orthotopic liver transplantation. Am. J. Surg. Pathol. 19: 81-90 (1995).

• Sebagh M, Samuel D. Place of the liver biopsy in liver transplantation. J. Hepatol. 41: 897-901 (2004). *

• Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol. 12: 3682-3694 (2006). *

• Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Marco VD, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 49: 1821-1827 (2009).

• Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac disease-associated autoimmune cholangitis. Am. J. Gastroenterol. 97: 3196-3198 (2002). *

• Selinger MJ, Matloff DS, Kaplan MM. gamma-Glutamyl transpeptidase activity in liver disease: serum elevation is independent of hepatic GGTP activity. Clin. Chim. Acta 125: 283-290 (1982).

• Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch. Dis. Child. 67: 1447-1453 (1992). *

• Senzolo M, Burra P, Cholongitas E, Lodato F, Marelli L, Manousou P, Patch D, Sturniolo GC, Burroughs AK. The transjugular route: the key hole to the liver world. Dig. Liver Dis. 39: 105-116 (2007).

• Senzolo M, Cholongitas EC, Patch D, Burroughs AK. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 182-190 (2005). *

• Serfaty L. Pioglitazone: the beginning of a new era for NASH? J. Hepatol. 47: 160-162 (2007). *

• Serov VV, Drozd TN, Lebedev SP. Hepatitis and cirrhosis of the liver (classification, morphology and morphological differential diagnosis). Arkh. Patol. 41: 3-14 (1979).

• Setchell KD, Heubi JE, Bove KE, O'Connell NC, Brewsaugh T, Steinberg SJ, Moser A, Squires RH Jr. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 124: 217-232 (2003). *

• Sethy PK, Dutta U, Aggrawal AN, Das R, Gulati M, Sinha SK, Singh K. Pulmonary and hematological alterations in idiopathic ulcerative colitis. Indian J. Gastroenterol. 22: 176-179 (2003).

• Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am. J. Gastroenterol. 102: 2589-2600 (2007). *

• Shanmugam NP, Harrison PM, Devlin J, Peddu P, Knisely A, Davenport M, Hadzic N. Selective use of endoscopic retrograde cholangiopancreatography in the diagnosis of biliary atresia in infants younger than 100 days. J. Pediatr. Gastroenterol. Nutr. Aug 11 [Epub ahead of print] (2009).

• Sharma A, Chakraborti A, Das A, Dhiman RK, Chawla Y. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 128: e514-e522 (2009).

• Shastri S, Dubinsky MC, Fred Poordad F, Vasiliauskas EA, Geller SA. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch. Pathol. Lab. Med. 128: 49-53 (2004). *

• Sherlock S. Primary biliary cirrhosis: critical evaluation and treatment policies. Scand. J. Gastroenterol. Suppl. 77: 63-74 (1982).

• Sherman KE, Goodman ZD, Sullivan ST, Faris-Young S; for the GILF Study Group. Liver biopsy in cirrhotic patients. Am. J. Gastroenterol. 102: 789-793 (2007). *

• Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25: 143-154 (2005).

• Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 125: 1175-1187 (2003). *

• Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7s level to predict the early stage of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 102: 1931-1938 (2007). *

• Shin YS, Jang YS, Kang MK, Jang BK, Park KS, Hwang JS, Kwon JH, Kang YN. A case of sclerosing cholangitis showing response to prednisolone. Korean J. Gastroenterol. 50: 402-406 (2007).

• Shinkai M, Shinkai T, Puri P, Stringer MD. Increased CXCR3 expression associated with CD3-positive lymphocytes in the liver and biliary remnant in biliary atresia. J. Pediatr. Surg. 41: 950-954 (2006).

• Shiraoku H, Hokamura M, Sagara K, Fujiyama S. A case of primary sclerosing cholangitis. Gastroenterol. Jpn. 20: 368-373 (1985).

• Shirokova EN. Diagnosis and differential diagnosis of primary sclerosing cholangitis. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 8 (2006). *

• Shoda J, Kano M, Oda K, Kamiya J, Nimura Y, Suzuki H, Sugiyama Y, Miyazaki H, Todoroki T, Stengelin S, Kramer W, Matsuzaki Y, Tanaka N. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol. 96: 3368-3378 (2001). *

• Shorbagi A, Bayraktar Y. Experience of a single center with congenital hepatic fibrosis: a review of the literature. World J. Gastroenterol. 16: 683-690 (2010). *

• Siboni AH. Treatment of primary biliary cirrhosis with ursodeoxycholic acid without liver biopsy? Ugeskr. Laeger. 166: 2688 (2004).

• Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 12: 2161-2167 (2006). *

• Siegel CA, Silas AM, Suriawinata AA, van Leeuwen DJ. Liver biopsy 2005: when and how? Cleve. Clin. J. Med. 72: 199-201, 206, 208 (2005). *

• Siegel EG, Schmidt WE, Folsch UR. Severe ischemic-type biliary strictures due to hepatic artery occlusion seven years after liver transplantation - a rare cause of late cholestatic graft failure. Z. Gastroenterol. 36: 509-513 (1998).

• Sikora SS, Srikanth G, Agrawal V, Gupta RK, Kumar A, Saxena R, Kapoor VK. Liver histology in benign biliary stricture: fibrosis to cirrhosis . . . and reversal? J. Gastroenterol. Hepatol. 23: 1879-1884 (2008). *

• Silva MO, Reddy KR, McDonald T, Jeffers LJ, Schiff ER. Danazol-induced cholestasis. Am. J. Gastroenterol. 84: 426-428 (1989).

• Simonovic-Babic J, Delic D, Svirtlih N, Dordevic M. Elevated aminotransferse levels - diagnostic approach. Med. Pregl. 57: 429-433 (2004).

• Sinha CK, Davenport M. Biliary atresia. J. Indian Assoc. Pediatr. Surg. 13: 49-56 (2008).

• Sipponen P, Pikkarainen P, Vuori E, Salaspuro M. Copper deposits in fine needle aspiration biopsies in primary biliary cirrhosis. Acta Cytol. 24: 203-207 (1980).

• Siroen MP, Warle MC, Teerlink T, Nijveldt RJ, Kuipers EJ, Metselaar HJ, Tilanus HW, Kuik DJ, van der Sijp JR, Meijer S, van der Hoven B, van Leeuwen PA. The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl. 10: 1524-1530 (2004). *

• Sivak MV Jr, Farmer RG, Lalli AF. Sclerosing cholangitis: its increasing frequency of recognition and association with inflammatory bowel disease. J. Clin. Gastroenterol. 3: 261-266 (1981).

• Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J. Hepatol. 35: 195-199 (2001). *

• Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjogren's syndrome. Br. J. Rheumatol. 33: 745-748 (1994).

• Skulina D, Owczarek D, Ciecko-Michalska I, Szczepanski W, Tetnowski J, Garlicka M, Janas-Skulina U. The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis. Przegl. Lek. 56: 201-204 (1999).

• Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment. Pharmacol. Ther. 30: 557-576 (2009). *

• Smith MA, Kozarek RA. Does infliximab improve liver function tests in patients with primary sclerosing cholangitis? Am. J. Gastroenterol. 97: S71 (2002). *

• Smith SR, Shneider BL, Magid M, Martin G, Rothschild M. Minor salivary gland biopsy in neonatal hemochromatosis. Arch. Otolaryngol. Head Neck Surg. 130: 760-763 (2004).

• Snape WJ Jr, Long WB, Trotman BW, Marin GA, Czaja AJ. Marked alkaline phosphatase elevation with partial common bile duct obstruction due to calcific pancreatitis. Gastroenterology 70: 70-73 (1976).

• Snover DC, Weisdorf SA, Ramsay NK, McGlave P, Kersey JH. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4: 123-130 (1984).

• Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J. Pediatr. 156: 327-331 (2010). *

• Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28 year follow up. Hepatology 51: 595-602 (2010). *

• Solberg HE, Skrede S, Blomhoff JP. Diagnosis of liver diseases by laboratory results and discriminant analysis. Identification of best combinations of laboratory tests. Scand. J. Clin. Lab. Invest. 35: 713-721 (1975).

• Sonomoto K, Miyamura T, Watanabe H, Takahama S, Nakamura M, Ando H, Minami R, Yamamoto M, Suematsu E. A case of systemic lupus erythematosus complicated with autoimmune hepatitis and thrombotic thrombocytic purpura. Nihon Rinsho Meneki Gakkai Kaishi 32: 110-115 (2009.

• Sookoian S, Castano G, Gemma C, Gianotti TF, Pirola CJ. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J. Gastroenterol. 13: 4242-4248 (2007). *

• Sookoian S, Castano GO, Burgueno AL, Fernandez Gianotti T, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. May 20 [Epub ahead of print] (2009). *

• Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 50: 2111-216 (2009). *

• Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am. J. Gastroenterol. 94: 1018-1022 (1999). *

• Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am. J. Gastroenterol. 95: 3206-3210 (2000). *

• Sorda J, Findor J. Methotrexate therapy in primary biliary cirrhosis. Acta Gastroenterol. Latinoam. 30: 221-225 (2000).

• Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R. Silent non-alcoholic fatty liver disease-a clinical-histological study. J. Hepatol. 41: 751-757 (2004). *

• Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. Oct 27 [Epub ahead of print] (2009). *

• Sotelo N, Lopez G. Autoimmune-type chronic active hepatitis in children. A report of 23 cases at a Hospital in Northwestern Mexico. Ann. Hepatol. 4: 255-260 (2005).

• Soua H, Pousse H, Ladeb F, Korbi S, Ayadi A, Boussoffara R, Belkhir Y, Descos B, Sfar MT, Harbi A, et al. Histiocytosis X and sclerosing cholangitis. Ann. Pediatr. (Paris) 40: 316-319 (1993).

• Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M. Hepatotoxicity by amoxicillin/clavulanic acid: case report. Rev. Med. Chil. 127: 1487-1491 (1999).

• Spengler U, Fischer HP. Liver biopsy at the intersection of clinical and pathological diagnosis. Pathologe 29: 6-14 (2008).

• Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J. Gastroenterol. 14: 3396-3402 (2008). *

• Sporea I, Sirli R, Popescu A, Cornianu M, Manciu C, Focsa M. The quality of the fragment obtained by liver biopsy for staging chronic hepatitis. J. Gastrointestin. Liver Dis. 16: 263-266 (2007). *

• Spycher C, Zimmermann A, Reichen J. The diagnostic value of liver biopsy. BMC Gastroenterol. 1: 12 (2001). *

• Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38: 244-251 (2003). *

• Srivastava S, Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology 42: 490-492 (2005). *

• Stadlbauer V, Fickert P, Lackner C, Schmerlaib J, Krisper P, Trauner M, Stauber RE. Hepatotoxicity of NONI juice: report of two cases. World J. Gastroenterol. 11: 4758-4760 (2005). *

• Stanca CM, Fiel MI, Schiano TD. Exacerbation of sickle cell disease itself as a cause of abnormal liver chemistry tests. Dig. Dis. Sci. 52: 176-178 (2007). *

• Stazi F, Farello P, Stazi C. Intrahepatic cholestasis Clin. Ter. 147: 575-583 (1996).

• Steele IL, Levy C, Lindor KD. Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20 (2007). *

• Stemerowicz R, Moller B, Martin P, Heesemann J, Wenzel BE, Galanos C, Freudenberg M, Hopf U. Antibody activity against lipopolysaccharides, lipid A and proteins from Enterobacteriaceae in patients with chronic inflammatory liver diseases. Autoimmunity 7: 305-315 (1990).

• Sterling RK, Salvatori JJ, Luketic VA, Sanyal AJ, Fulcher AS, Stravitz RT, Contos MJ, Mills AS, Shiffman ML. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 20: 943-949 (2004). *

• Stickel F, Osterreicher CH, Datz C, Ferenci P, Wolfel M, Norgauer W, Kraus MR, Wrba F, Hellerbrand C, Schuppan D. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch. Intern. Med. 165: 1835-1840 (2005). *

• Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann. Med. 26: 345-349 (1994).

• Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. Dtsch. Med. Wochenschr. 123: 1410-1414 (1998).

• Strandvik B, Hjelte L, Gabrielsson N, Glaumann H. Sclerosing cholangitis in cystic fibrosis. Scand. J. Gastroenterol. Suppl. 143: 121-124 (1988). *

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Strassburg CP, Manns MP. Approaches to liver biopsy techniques-revisited. Semin. Liver Dis. 26: 318-327 (2006).

• Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD, Wu JC. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J. Clin. Gastroenterol. Feb 25 [Epub ahead of print] (2009).

• Su CW, Wu JC, Chiou YY, Tsay SH, Huo TI, Huang YH, Hung HH, Lin HC, Lee SD. Successful radiofrequency ablation therapy for hepatocellular carcinoma in a male patient with early stage primary biliary cirrhosis and positive serum hepatitis B core antibody. J. Chin. Med. Assoc. 71: 40-44 (2008).

• Suarez Gonzalez A, Rodriguez Garcia M, Gonzalez Gonzalez M, Alvarez Navascues C, Gonzalez Sotorrio N, Rodrigo Saez L. Acute indomethacin-induced hepatitis in a female patient with asymptomatic primary biliary cirrhosis. An. Med. Interna 11: 549-550 (1994).

• Sugimoto M, Sadamoto T, Nonaka H. Clinical and pathological differences between alcoholic hepatitis and non-alcoholic steatohepatitis. Nihon Arukoru Yakubutsu Igakkai Zasshi 38: 34-45 (2003).

• Sugimura T, Shiokawa S, Haraoka S, Fujimoto K, Ohshima K, Nakamuta M, Nishimura J. Local antigen-driven oligoclonal expansion of B cells in the liver portal areas of patients with primary biliary cirrhosis. Liver Int. 23: 323-328 (2003). *

• Sumitran-Holgersson S, Ge X, Karrar A, Xu B, Nava S, Broome U, Nowak G, Ericzon BG. A novel mechanism of liver allograft rejection facilitated by antibodies to liver sinusoidal endothelial cells. Hepatology 40: 1211-1221 (2004). *

• Sunagawa H, Takayama H, Yamashiro T, Sasaki H, Sashida Y, Matsuura K, Kayou M. Hepatocellular carcinoma in a patient with primary biliary cirrhosis and seronegativity for markers of hepatitis B virus and hepatitis C virus: report of a case. Surg. Today 33: 219-223 (2003). *

• Suriawinata A, Fiel MI. Liver pathology in obesity. Semin. Liver Dis. 24: 363-370 (2004).

• Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin. Diagn. Pathol. 23: 132-148 (2006).

• Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 26: 1209-1216 (2006). *

• Suzuki Y, Ikeda K, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Saitoh S, Arase Y, Kobayashi M, Miyakawa Y, Kumada H. Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis. Dig. Dis. Sci. Jan 22 [Epub ahead of print] (2010). *

• Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch. Intern. Med. 138: 997-998 (1978).

• Syn WK, Bruckner-Holt C, Farmer A, Howdle S, Bateman J. Liver biopsy in a district general hospital: changes over two decades. World J. Gastroenterol. 13: 5336-5342 (2007). *

• Szabo Z. The role of liver biopsy in the diagnosis of autoimmune hepatitis. Orv. Hetil. 147: 1697-1702 (2006).

• Taal BG, Schalm SW, ten Kate FW, Hermans J, Geertzen RG, Feltkamp BE. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology 30: 178-182 (1983).

• Tabatabai L, Lewis WD, Gordon F, Jenkins R, Khettry U. Fibrosis/cirrhosis after orthotopic liver transplantation. Hum. Pathol. 30: 39-47 (1999).

• Tagle A M DR. Hepatobiliary infections in AIDS. Rev. Gastroenterol. Peru 17: 107-114 (1997).

• Tagle M, Nolte C, Luna E, Scavino Y. Coexistence of celiac disease and autoimmune hepatitis case study and literature review. Rev. Gastroenterol. Peru 26: 80-83 (2006).

• Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 49: 1859-1867 (2009).

• Takahashi A, Hasegawa M, Sumazaki R, Suzuki M, Toki F, Suehiro T, Onigata K, Tomomasa T, Suzuki T, Matsui A, Morikawa A, Kuwano H. Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2. Eur. J. Gastroenterol. Hepatol. 19: 942-946 (2007).

• Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. Oct 27 [Epub ahead of print] (2009). *

• Takaya J, Nakano S, Imai Y, Fujii Y, Kaneko K. Usefulness of magnetic resonance cholangiopancreatography in biliary structures in infants: a four-case report. Eur. J. Pediatr. 166: 211-214 (2007). *

• Takeshima H, Yagi A, Yano M, Sakamoto N, Kato S, Kuriki J, Arao M, Takikawa T, Hayashi H. Hepatic copper accumulation in patients with primary biliary cirrhosis. Nagoya J. Med. Sci. 55: 115-123 (1993).

• Tamai K, Fukushima K, Ueno Y, Moritoki Y, Yamagiwa Y, Kanno N, Jefferson DM, Shimosegawa T. Differential expressions of aquaporin proteins in human cholestatic liver diseases. Hepatol. Res. 34: 99-103 (2006).

• Tanaka H, Tujioka H, Ueda H, Hamagami H, Kida Y, Ichinose M. Autoimmune hepatitis triggered by acute hepatitis A. World J. Gastroenterol. 11: 6069-6071 (2005). *

• Tanaka K, Shimada M, Sasahara A, Yamamoto H, Naruto T, Tomida Y. Chronic hepatitis associated with Epstein-Barr virus infection in an infant. J. Pediatr. Gastroenterol. Nutr. 5: 467-471 (1986).

• Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42: 413-418 (2008).

• Tanaka Y, Naitoh M, Yoshiura K, Ookubo K, Uegaki S, Matsumoto K, Sawabe M, Esaki Y, Kino K, Tsuru M, Fukazawa T, Takubo K. Hepatocellular carcinoma arising in an elderly male with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 12: 239-241 (2000).

• Tang CP, Shiau YT, Huang YH, Tsay SH, Huo TI, Wu JC, Lin HC, Lee SD. Cholestatic jaundice as the predominant presentation in a patient with autoimmune hepatitis. J. Chin. Med. Assoc. 71: 45-48 (2008).

• Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, Mamada Y, Yoshida H, Tajiri T. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J. Nippon Med. Sch. 75: 187-191 (2008). *

• Tanne F, Gagnadoux F, Chazouilleres O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 41: 1290-1296 (2005). *

• Targonska-Stepniak B, Majdan M, Suszek D, Laskowska K. Overlap syndrome autoimmune hepatitis and primary biliary cirrhosis associated with antiphospholipid syndrome. Pol. Merkur. Lekarski. 21: 480-483 (2006).

• Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology 49: S85-S95 (2009).

• Taylor J, Lindor K. Metastatic prostate cancer simulating sclerosing cholangitis. J. Clin. Gastroenterol. 16: 143-145 (1993).

• Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am. J. Surg. Pathol. 18: 91-99 (1994).

• Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF. Drug use and toxicity in psoriatic disease: focus on methotrexate. J. Rheumatol. 35: 1454-1457 (2008).

• Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 95: 3150-3156 (2000). *

• Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342: 895-898 (1993).

• Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch. Pediatr. Adolesc. Med. 152: 1132-1136 (1998).

• Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien. Klin. Wochenschr. 119: 519-526 (2007). *

• Terasaki S, Nakanuma Y, Hoso M, Ogino H, Unoura M, Kobayashi K, Mizuno Y, Nakagawa H, Shimizu M, Kanai M, et al. Three cases of primary biliary cirrhosis associated with bronchial asthma. J. Gastroenterol. 30: 667-671 (1995).

• Terasaki S, Nakanuma Y, Yamazaki M, Unoura M. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 17: 206-212 (1993).

• Terg R, Sambuelli A, Coronel E, Mazzuco J, Cartier M, Negreira S, Munoz A, Gil A, Miguez C, Huernos S, Romero G, Goncalvez S, Levi D, Abecasis R. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study. Acta Gastroenterol. Latinoam. 38: 26-33 (2008).

• Terracciano LM, Patzina RA, Lehmann FS, Tornillo L, Cathomas G, Mhawech P, Vecchione R, Bianchi L. A spectrum of histopathologic findings in autoimmune liver disease. Am. J. Clin. Pathol. 114: 705-711 (2000). *

• Tervaert JW, Van Hoek B, Koek G. Antineutrophil cytoplasmic antibodies in small-duct primary sclerosing cholangitis. Gastroenterology 136: 364 (2009). *

• Teufel A, Worns M, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J. Gastroenterol. 12: 5513-5516 (2006). *

• Theal RM, Scott K. Evaluating asymptomatic patients with abnormal liver function test results. Am. Fam. Physician 53: 2111-2119 (1996).

• Thiefin G, Morelet A, Heurgue A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75: 737-739 (2008). *

• Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am. J. Clin. Dermatol. 6: 357-363 (2005).

• Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 148-155 (2005). *

• Tobe K. Electron microscopy of liver lesions in primary biliary cirrhosis. I. Intrahepatic bile duct oncocytes. Acta Pathol. Jpn. 32: 57-70 (1982).

• Toblli JE, Findor J, Sorda J, Bruch Igartua E, Hasenclever K, Collado HD. Latent distal renal tubular acidosis (dRTA) in primary biliary cirrhosis (PBC) and chronic autoimmune hepatitis (CAH). Acta Gastroenterol. Latinoam. 23: 235-238 (1993).

• Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin. Rheumatol. 26: 578-581 (2007). *

• Tokuno T, Takahashi H, Suzuki C, Yamamoto M, Naishiro Y, Sugaya A, Sakamoto H, Imai K. Analysis of B-cell clonality in the hepatic tissue of patients with Sjogren's syndrome. Scand. J. Rheumatol. 32: 268-272 (2003).

• Tolia V, Nilsson HO, Boyer K, Wuerth A, Al-Soud WA, Rabah R, Wadstrom T. Detection of Helicobacter ganmani-like 16S rDNA in pediatric liver tissue. Helicobacter 9: 460-468 (2004). *

• Tomasevic R, Golubovic G, Kiurski M, Pavlovic A. Cholestatic syndrome in patients with systemic erythematous lupus - differential diagnostic aspects Med. Pregl. 61: 291-294 (2008).

• Toosi MN, Heathcote J. Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease? Am. J. Gastroenterol. 99: 377-382 (2004). *

• Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand. J. Gastroenterol. 42: 1095-1101 (2007). *

• Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134: 1682-1698 (2008). *

• Trautmann F, Arnold W, Manns M, Stoltenburg-Didinger G, Meyer zum Buschenfelde KH. Antimitochondrial antibodies against the M2-antigen with immune vasculitis and discoid lupus erythematosus without proof of liver disease. Z. Gastroenterol. 20: 659-666 (1982).

• Treeprasertsuk S, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Schmoll J, Hoskin T, Thapa P, Enders F, Lindor KD. The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology Nov 13 [Epub ahead of print] (2009). *

• Trewby PN, Portmann B, Brinkley DM, Williams R. Liver disease as presenting manifestation of Hodgkin's disease. Q. J. Med. 48: 137-150 (1979).

• Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 44: 440-445 (2006). *

• Tromm A, May B, Klein CG, Klein R, Fisseler-Eckhoff A, Griga T. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid. Hepatogastroenterology 52: 753-756 (2005).

• Trotter JF, Campsen J, Bak T, Wachs M, Forman L, Everson G, Kam I. Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation. Am. J. Transplant. 6: 1882-1889 (2006).

• Tsantoulas D, Perperas A, Portmann B, Eddleston AL, Williams R. Antibodies to a human liver membrane lipoprotein (LSP) in primary biliary cirrhosis. Gut 21: 557-560 (1980). *

• Tsuji K, Naoki K, Tachiyama Y, Fukumoto A, Ishida Y, Kuwabara T, Sumida T, Tatsugami M, Nagata S, Ohgoshi H, Uraki S, Hidaka T, Akagi Y, Ishine M, Saeki S, Chayama K. A case of congenital absence of the portal vein. Hepatol. Res. 31: 43-47 (2005).

• Tsukada H, Ochi H, Maekawa T, Abe H, Fujimoto Y, Tsuge M, Takahashi H, Kumada H, Kamatani N, Nakamura Y, Chayama K; Hiroshima Liver Study Group; Toranomon Hospital. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 136: 1796-1805.e6 (2009). *

• Tsukinaga S, Imazu H, Uchiyama Y, Kakutani H, Kuramoti A, Kato M, Kanazawa K, Kobayashi T, Searashi Y, Tajiri H. Diagnostic approach using endosonography guided fine needle aspiration for lymphadenopathy in primary sclerosing cholangitis. World J. Gastroenterol. 13: 3758-3759 (2007). *

• Tsuneyama K, Van De Water J, Yamazaki K, Suzuki K, Sato S, Takeda Y, Ruebner B, Yost BA, Nakanuma Y, Coppel RL, Gershwin ME. Primary biliary cirrhosis an epithelitis: evidence of abnormal salivary gland immunohistochemistry. Autoimmunity 26: 23-31 (1997).

• Turlin B, Ramm GA, Purdie DM, Laine F, Perrin M, Deugnier Y, Macdonald GA. Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies. Liver Int. 29: 530-535 (2009). *

• Twaddell WS, Lefkowitch J, Berk PD. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Semin. Liver Dis. 28: 128-134 (2008).

• Ueda Y, Takada Y, Marusawa H, Haga H, Sato T, Tanaka Y, Egawa H, Uemoto S, Chiba T. Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. J. Viral. Hepat. Oct 4 [Epub ahead of print] (2009).

• Umar RK, Rinella ME. An update on nonalcoholic fatty liver disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 94-98 (2006). *

• Uraz S, Aygun C, Sonsuz A, Ozbay G. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Dig. Dis. Sci. 50: 964-969 (2005). *

• Uribe M, Zamora-Valdes D, Moreno-Portillo M, Bermejo-Martínez L, Pichardo-Bahena R, Baptista-Gonzalez HA, Ponciano-Rodriguez G, Uribe MH, Medina-Santillan R, Mendez-Sanchez N. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 7: 67-71 (2008). *

• Usta Y, Gurakan F, Akcoren Z, Ozen S. An overlap syndrome involving autoimmune hepatitis and systemic lupus erythematosus in childhood. World J. Gastroenterol. 13: 2764-2767 (2007). *

• Usui M, Isaji S, Das BC, Kobayashi M, Osawa I, Iida T, Sakurai H, Tabata M, Yorifuji T, Egawa H, Uemoto S. Liver retransplantation with external biliary diversion for progressive familial intrahepatic cholestasis type 1: a case report. Pediatr. Transplant. 13: 611-614 (2009). *

• Utley RJ, Angus HB, Macbeth WA. Primary sclerosing cholangitis. N. Z. Med. J. 97: 324-326 (1984).

• Valente AI, Almeida A, Gouveia A, Serejo F, Ramalho F, Baptista A, Saragoca A, Moura MC. Prevalence of chronic hepatic disease in Portugal. Apropos of a review carried out in a hepatology unit. Acta Med. Port. 9: 197-202 (1996).

• Valera JM, Nei Lu C, Smok G, Fernandez M, Regonesi C, Brahm J. Hepatic veno-occlusive disease, idiopathic ulcerative colitis and portal thrombosis. Report of one case. Rev. Med. Chil. 132: 1091-1095 (2004).

• Valgimigli M, Valgimigli L, Trere D, Gaiani S, Pedulli GF, Gramantieri L, Bolondi L. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic. Res. 36: 939-948 (2002).

• Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212 (2003).

• van de Meeberg PC, Portincasa P, Wolfhagen FH, van Erpecum KJ, VanBerge-Henegouwen GP. Increased gall bladder volume in primary sclerosing cholangitis. Gut 39: 594-599 (1996). *

• Van de Water J, Gerson LB, Ferrell LD, Lake JR, Coppel RL, Batts KP, Wiesner RH, Gershwin ME. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 24: 1079-1084 (1996). *

• van den Oord JJ, Fevery J, de Groote J, Desmet VJ. Immunohistochemical characterization of inflammatory infiltrates in primary biliary cirrhosis. Liver 4: 264-274 (1984).

• van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48: 449-457 (2008). *

• van Erpecum KJ, van Berge Henegouwen GP. Hepatobiliary abnormalities in inflammatory bowel disease. Neth. J. Med. 35 Suppl. 1: S40-S49 (1989).

• van Hoek B. Non-alcoholic fatty liver disease: a brief review. Scand. J. Gastroenterol. Suppl. 241: 56-59 (2004). *

• van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MJ. A 38-year-old African-American woman with an unusually rapid progression of "Primary Biliary Cirrhosis": a missed opportunity! Semin. Liver Dis. 22: 395-406 (2002).

• Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. 90: 455-459 (1995).

• Varnholt H. Liver biopsy in advanced autoimmune hepatitis. Am. J. Med. 118: 95 (2005). *

• Varriale M, Salvio A, Giannattasio F, d'Errico T, Montone L, Borgia F, Gentile I, Reynaud L, Borgia G, Rossiello R, Visconti M. Intrahepatic cholestatic jaundice related to administration of ranitidine. A case report with histologic and ultramicroscopic study. Minerva Gastroenterol. Dietol. 50: 339-343 (2004).

• Velicia Llames MR, Gonzalez Hernandez JM, Fernandez Orcajo P, Sanz Santacruz C. Symptomatic primary biliary stenosis without cholestasis. Gastroenterol. Hepatol. 18: 330-331 (1995).

• Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, Carrieri V, Albano O. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand. J. Gastroenterol. 24: 407-415 (1989).

• Venturini I, Cosenza R, Miglioli L, Borghi A, Bagni A, Gandolfo M, Modonesi G, Zeneroli ML. Adult celiac disease and primary sclerosing cholangitis: two case reports. Hepatogastroenterology 45: 2344-2347 (1998).

• Vergani D, Ma Y, Bogdanos DP, Mieli-Vergani G. Autoreactive T cells: any evidence in autoimmune liver disease? Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 31-32 (2004). *

• Verheij J, Voortman J, van Nieuwkerk CM, Jarbandhan SV, Mulder CJ, Bloemena E. Hepatic morphopathologic findings of lead poisoning in a drug addict: a case report. J. Gastrointestin. Liver Dis. 18: 225-227 (2009). *

• Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol. 99: 1510-1516 (2004). *

• Verslype C. Evaluation of abnormal liver-enzyme results in asymptomatic patients. Acta Clin. Belg. 59: 285-289 (2004).

• Verveer C, De Knegt RJ. Non-invasive measurement of liver fibrosis: application of the FibroScan(R) in hepatology. Scand. J. Gastroenterol. Suppl. 243: 85-88 (2006). *

• Vigani AG, Macedo-de-Oliveira A, Pavan MH, Pedro MN, Goncales Jr FL. Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report. Braz. J. Med. Biol. Res. 38: 1729-1734 (2005). *

• Vignali C, Cioni R, Petruzzi P, Cicorelli A, Bargellini I, Perri M, Urbani L, Filipponi F, Bartolozzi C. Role of interventional radiology in the management of vascular complications after liver transplantation. Transplant. Proc. 36: 552-554 (2004). *

• Viguier M, Allez M, Zagdanski AM, Bertheau P, de Kerviler E, Rybojad M, Morel P, Dubertret L, Lemann M, Bachelez H. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology 40: 452-458 (2004). *

• Vilar Gomez E, Rodriguez DE Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 30: 999-1009 (2009). *

• Villari D, Rubino F, Corica F, Spinella S, Di Cesare E, Longo G, Raimondo G. Bile ductopenia following therapy with sulpiride. Virchows Arch. 427: 223-226 (1995).

• Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin. Exp. Rheumatol. 27: 1017-1025 (2009).

• Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G, Marra F, Pinzani M. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann. Hepatol. 8: 89-94 (2009). *

• Vogel W, Fagan EA, Bomford A, Portmann B, Williams R. Wash off liver cytology: a complementary diagnostic tool to liver biopsy. J. Clin. Pathol. 39: 449-452 (1986). *

• Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49: 306-317 (2009). *

• Vuppalanchi R, Chalasani N, Saxena R. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am. J. Surg. Pathol. 30: 1619-1623 (2006).

• Vyberg M, Poulsen H. Abnormal bile duct epithelium accompanying septicaemia. Virchows Arch. A. Pathol. Anat. Histopathol. 402: 451-458 (1984).

• Wang AP, Migita K, Ito M, Takii Y, Daikoku M, Yokoyama T, Komori A, Nakamura M, Yatsuhashi H, Ishibashi H. Hepatic expression of Toll-like receptor 4 in primary biliary cirrhosis. J. Autoimmun. 25: 85-91 (2005).

• Wang J, Jiang W, Gao H, He B, Liu W. Clinical and pathological characteristics of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 334-337 (2002).

• Wang JS, Wang XH, Zhu QR, Wang ZL, Hu XQ, Zheng S. Clinical and pathological characteristics of Alagille syndrome in Chinese children. World J. Pediatr. 4: 283-288 (2008). *

• Wang ZL, Wang XH, Zheng S. Management of pediatric patients who underwent liver transplantation. Zhonghua Er Ke Za Zhi 45: 428-431 (2007).

• Warren RB, Chalmers RJ, Griffiths CE, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin. Exp. Dermatol. 33: 551-554 (2008). *

• Wasmuth HE, Werth A, Mueller T, Berg T, Dietrich CG, Geier A, Schirin-Sokhan R, Gartung C, Lorenzen J, Matern S, Lammert F. CC chemokine receptor 5 Delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J. Mol. Med. 82: 64-69 (2004). *

• Watanabe H, Ohira H, Kuroda M, Takagi T, Ishikawa H, Nishimaki T, Kasukawa R, Takahashi K. Primary sclerosing cholangitis with marked eosinophilic infiltration in the liver. J. Gastroenterol. 30: 524-528 (1995).

• Weber C, Krupski G, Lorenzen J, Groteluschen R, Seitz U, Rogiers X, Adam G. MRCP in primary sclerosing cholangitis. Rofo. Fortschr. Geb. Rontgenstr. Neuen. Bildgeb. Verfahr. 175: 203-210 (2003).

• Weden M, Glaumann H, Einarsson K. Protracted cholestasis probably induced by oral contraceptive. J. Intern. Med. 231: 561-565 (1992).

• Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann. Intern. Med. 102: 581-587 (1985).

• Weiser KT, Suriawinata AA, van Leeuwen DJ. A 56-year-old man with sudden onset of portosystemic encephalopathy years after severe electrocution trauma. Semin. Liver Dis. 28: 328-336 (2008).

• Wendum D, Nachury M, Yver M, Lemann M, Flejou JF, Janin A, Bertheau P. Acute hepatitis E: a cause of lymphocytic destructive cholangitis. Hum. Pathol. 36: 436-438 (2005). *

• Wewer V, Gluud C, Schlichting P, Burcharth F, Binder V. Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol. 26: 97-102 (1991).

• Whelan G, Peters M, Desmond PV, Bhathal PS. Alcohol unrelated hepato-biliary disorders in the alcoholic: the role of liver biopsy in determining the aetiology of liver disease. Aust. N. Z. J. Med. 12: 34-38 (1982).

• Whitfield AJ, Barrett PH, Robertson K, Havlat MF, van Bockxmeer FM, Burnett JR. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin. Chem. 51: 266-269 (2005). *

• Whitt KN, Ward SC, Deniz K, Liu L, Odin JA, Qin L. Cholestatic liver injury associated with whey protein and creatine supplements. Semin. Liver Dis. 28: 226-231 (2008).

• Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103: 1372-1379 (2008). *

• Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33 (2006). *

• Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin. Liver Dis. 29: 254-261 (2009).

• Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10: 430-436 (1989).

• Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 7: 60-73 (2001). *

• Williams SG, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J. Hepatol. 22: 513-521 (1995). *

• Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St Louis P, Griffiths AM, Blendis LM, Moroz SP, Scully L, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 22: 1415-1422 (1995).

• Wirth HP, Zala G, Meyenberger C, Ammann R. Significance of subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis for prognostic parameters and response to ursodeoxycholic acid. Schweiz. Med. Wochenschr. 125: 750-754 (1995).

• Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, Milner R, Pappas SC, Rankin J, Wanless IR. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 12: 98-105 (1990).

• Wojcikiewicz TG, Gupta S. Primary biliary cirrhosis presenting with ascites and a hepatic hydrothorax: a case report. J. Med. Case Reports 3: 7371 (2009). *

• Wolfhagen FH, Vermeulen HG, de Man RA, Lesterhuis W. Initially obscure hepatotoxicity attributed to sildenafil. Eur. J. Gastroenterol. Hepatol. 20: 710-712 (2008).

• Wong GL, Hui AY, Wong VW, Chan FK, Sung JJ, Chan HL. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am. J. Gastroenterol. 100: 2205-2211 (2005). *

• Wong RK, Wai CT. Dyspnoea due to plasma transfusion-related acute lung injury. Singapore Med. J. 47: 904-906 (2006). *

• Wongsawasdi L, Ukarapol N, Visrutaratna P, Singhavejsakul J, Kattipattanapong V. Diagnostic evaluation of infantile cholestasis. J. Med. Assoc. Thai. 91: 345-349 (2008).

• Yamada G, Hyodo I, Tobe K, Mizuno M, Nishihara T, Kobayashi T, Nagashima H. Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis. Hepatology 6: 385-391 (1986).

• Yamamoto M, Taniguchi H, Ohara M, Suzuki C, Naishiro Y, Ozeki I, Yamamoto H, Takahashi H, Imai K. Beneficial effect of glucocorticosteroids for esophageal varices due to idiopathic portal hypertension following systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi 27: 40-47 (2004).

• Yan HP, Zhuang H, Liu YM, Feng X, Tan YF, Liu Y, Zhang X, Zhao CH. Immunological characteristics of primary biliary cirrhosis patients. Zhonghua Gan Zang Bing Za Zhi 13: 12-16 (2005).

• Yao H, Michitaka K, Tokumoto Y, Murata Y, Mashiba T, Abe M, Hiasa Y, Horiike N, Onji M. Recurrence of autoimmune hepatitis after liver transplantation without elevation of alanine aminotransferase. World J. Gastroenterol. 13: 1618-1621 (2007). *

• Yasoshima M, Nakanuma Y, Tsuneyama K, Van de Water J, Gershwin ME. Immunohistochemical analysis of adhesion molecules in the micro-environment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J. Pathol. 175: 319-325 (1995).

• Yasuda Y, Nakano S, Akiguchi I, Tanaka M, Kameyama M. Polymyositis associated with asymptomatic primary biliary cirrhosis. Eur. Neurol. 33: 51-53 (1993).

• Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J. Gastroenterol. 40: 1130-1138 (2005). *

• Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J. Fam. Pract. 51: 135-140 (2002). *

• Yehezkely-Schildkraut V, Munichor M, Mandel H, Berkowitz D, Hartman C, Eshach-Adiv O, Shamir R. Nonsyndromic paucity of interlobular bile ducts: report of 10 patients. J. Pediatr. Gastroenterol. Nutr. 37: 546-549 (2003). *

• Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, Gardiner G. Ramipril-associated hepatotoxicity. Arch. Pathol. Lab. Med. 127: 1493-1497 (2003). *

• Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challanges of a biomarker for chronic liver disease. Aliment. Pharmacol. Ther. 30: 1103-1109 (2009). *

• Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W, Watanabe S, Hosono K, Mawatari H, Iida H, Fujita K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Kubota K, Shimamura T, Saito S, Maeyama S, Wada K, Nakajima A. Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol. Res. 39: 963-971 (2009). *

• Yoon JY, Min SY, Park JY, Hong SG, Park SJ, Paik SY, Park YM. A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. Korean J. Hepatol. 14: 97-101 (2008).

• Yoshida EM, Singh RA, Vartanian RK, Owen DA, Erb SR, Scudamore CH. Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Can. J. Gastroenterol. 11: 229-233 (1997). *

• Yoshioka R, Sato Y, Kogure A, Ohira H, Takagi T, Kuroda M, Miyata M, Obara K, Nishimaki T, Kasukawa R. Association of primary sclerosing cholangitis, thymoma and hypogammaglobulinemia. Liver 15: 53-55 (1995).

• Young M, Dick ML, O'Rourke P. Haemochromatosis - a future focus for continuing education in general practice. Aust. Fam. Physician 33: 1041-1044 (2004). *

• Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, Vanmeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42: 665-674 (2005). *

• Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18: 1430-1437 (2008).

• Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev. Gastroenterol. Disord. 2: 11-19 (2002). *

• Yu YY, Ji J, Zhou GW, Shen BY, Chen H, Yan JQ, Peng CH, Li HW. Liver biopsy in evaluation of complications following liver transplantation. World J. Gastroenterol. 10: 1678-1681 (2004). *

• Yuce A, Kocak N, Demir H, Gurakan F, Ozen H, Saltik IN, Ozcay F. Evaluation of diagnostic parameters of Wilson's disease in childhood. Indian J. Gastroenterol. 22: 4-6 (2003).

• Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; for HIDT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 30: 430-437 (2010). *

• Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, Zappia V, Ruggiero G, Adinolfi LE. Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J. Viral Hepat. 15: 740-746 (2008).

• Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann. Hepatol. 2: 47-51 (2003). *

• Zawie DA, Garvey MS. Feline hepatic disease. Vet. Clin. North Am. Small Anim. Pract. 14: 1201-1230 (1984).

• Zech CJ, Seiderer J, Reinisch W, Ochsenkuhn T, Schima W, Diebold J, Wrba F, Reiser MF, Schoenberg SO. Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur. Radiol. 17: 1898-1905 (2007). *

• Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin. Gastroenterol. Hepatol. 1: 89-95 (2003). *

• Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum. Pathol. 38: 1669-1675 (2007).

• Zeng Z, Han YK, Zhang XF, Geng H. Clinical features of 35 cases of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Zhonghua Gan Zang Bing Za Zhi 13: 3-5 (2005).

• Zeniya M, Watanabe F, Morizane T, Shibata M, Maeyama S, Kage M, Nakanuma Y, Toda G; Study Group of Intractable Liver Diseases for Research on a Specific Disease, Health Science Research Grant, Ministry of Health, Labour, and Welfare of Japan. Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model. J. Gastroenterol. 40: 1148-1154 (2005). *

• Zetterman RK. Clinical topics in liver disease. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).

• Zhang F, Jia J, Cui R, Wang B, Wang H. Clinical features of forty patients with primary biliary cirrhosis. Chin. Med. J. (Engl.) 115: 904-908 (2002).

• Zhang F, Jia J, Wang B, Qian L, Yin S, Wang Y, Cui Y, You H, Ma H, Wang H, Zhang C. Clinical characteristics of primary biliary cirrhosis: a report of 45 cases. Zhonghua Nei Ke Za Zhi 41: 163-167 (2002).

• Zhang HF, Yang XJ, Zhu SS, Zhao JM, Zhang TH, Xu ZQ, Chen DW, Wang SS, Chen JM. Pathological changes and clinical manifestations of 1020 children with liver diseases confirmed by biopsy. Hepatobiliary Pancreat. Dis. Int. 3: 395-398 (2004). *

• Zhang J, Ji Y, Moon I, Pelleymounter LL, Ezequel Salavaggione O, Wu Y, Jenkins GD, Batzler AJ, Schaid DJ, Weinshilboum RM. Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenet. Genomics 19: 577-587 (2009).

• Zheng S, Luo Y, Wang W, Xiao X. Analysis of the pathomorphology of the intra- and extrahepatic biliary system in biliary atresia. Eur. J. Pediatr. Surg. 18: 98-102 (2008).

• Zhenglu W, Hui L, Shuying Zh, Wenjuan C, Zhongyang Sh. A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. Transplant. Proc. 39: 3287-3291 (2007).

• Zhou GD, Li MR, Zhang J, Pan D, Zhao SX, Yang JF, Yu J, Zhao JM. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand. J. Gastroenterol. 43: 1371-1377 (2008). *

• Zilkens C, Friese J, Koller M, Muhr G, Schinkel C. Hepatic failure after injury - a common pathogenesis with sclerosing cholangitis? Eur. J. Med. Res. 13: 309-313 (2008).

• Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrie N. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 135: 131-141 (2008). *

• Zizer E, Hasel C, Seufferlein T, Adler G, Dikopoulos N. A 40-year-old female patient with seronegative autoimmune hepatitis following a newly acquired hepatitis B infection. Z. Gastroenterol. 46: 201-205 (2008).

• Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50: 713-717 (2002). *

• Zuber J, Bellanne-Chantelot C, Carette C, Canaud G, Gobrecht S, Gaha K, Mallet V, Martinez F, Thervet E, Timsit J, Legendre C, Dubois-Laforgue D. HNF1B-related diabetes triggered by renal transplantation. Nat. Rev. Nephrol. 5: 480-484 (2009).

Number of references = 1356

www psc-literature.org